© 2013 and 2014 GRAHAM CREASEY, MD, & HOO-MIN TOONG, PhD. This patent document contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever. 37 CFR § 1.71(d), (e).
This invention pertains to the activation of nerves by topical stimulators to control or influence muscles, tissues, organs, or sensation, including pain, in humans and mammals.
Nerve disorders may result in loss of control of muscle and other body functions, loss of sensation, or pain. Surgical procedures and medications sometimes treat these disorders but have limitations. This invention pertains to a system for offering other options for treatment and improvement of function.
A method for electrical, mechanical, chemical and/or optical interaction with a human or mammal nervous system to stimulate and/or record body functions using small electronic devices attached to the skin and capable of being wirelessly linked to and controlled by a cellphone, activator or computer network.
The body is controlled by a chemical system and a nervous system. Nerves and muscles produce and respond to electrical voltages and currents. Electrical stimulation of these tissues can restore movement or feeling when these have been lost, or can modify the behavior of the nervous system, a process known as neuro modulation. Recording of the electrical activity of nerves and muscles is widely used for diagnosis, as in the electrocardiogram, electromyogram, electroencephalogram, etc. Electrical stimulation and recording require electrical interfaces for input and output of information. Electrical interfaces between tissues and electronic systems are usually one of three types:
a. Devices implanted surgically into the body, such as pacemakers. These are being developed for a variety of functions, such as restoring movement to paralyzed muscles or restoring hearing, and can potentially be applied to any nerve or muscle. These are typically specialized and somewhat expensive devices.
b. Devices inserted temporarily into the tissues, such as needles or catheters, connected to other equipment outside the body. Health care practitioners use these devices for diagnosis or short-term treatment.
c. Devices that record voltage from the surface of the skin for diagnosis and data collection, or apply electrical stimuli to the surface of the skin using adhesive patches connected to a stimulator. Portable battery-powered stimulators have typically been simple devices operated by a patient, for example for pain relief. Their use has been limited by;
i. The inconvenience of chronically managing wires, patches and stimulator, particularly if there are interfaces to more than one site, and
ii. The difficulty for patients to control a variety of stimulus parameters such as amplitude, frequency, pulse width, duty cycle, etc.
Nerves can also be stimulated mechanically to produce sensation or provoke or alter reflexes; this is the basis of touch sensation and tactile feedback. Nerves can also be affected chemically by medications delivered locally or systemically and sometimes targeted to particular nerves on the basis of location or chemical type. Nerves can also be stimulated or inhibited optically if they have had genes inserted to make them light sensitive like some of the nerves in the eye. The actions of nerves also produce electrical, mechanical and chemical changes that can be sensed.
The topical nerve stimulator/sensor (TNSS) is a device to stimulate nerves and sense the actions of the body that can be placed on the skin of a human or mammal to act on and respond to a nerve, muscle or tissue. One implementation of the TNSS is the Smart Band Aid™ (SBA). A system, incorporating a SBA, controls neuro modulation and neuro stimulation activities. It consists of one or more controllers or Control Units, one or more TNSS modules, software that resides in Control Units and TNSS modules, wireless communication between these components, and a data managing platform. The controller hosts software that will control the functions of the TNSS. The controller takes inputs from the TNSS of data or image data for analysis by said software, The controller provides a physical user interface for display to and recording from the user, such as activating or disabling the TNSS, logging of data and usage statistics, generating reporting data. Finally, the controller provides communications with other Controllers or the Internet cloud.
The controller communicates with the neurostim module, also called TNSS module or SBA, and also communicates with the user. In at least one example, both of these communications can go in both directions, so each set of communications is a control loop. Optionally, there may also be a control loop directly between the TNSS module and the body. So the system optionally may be a hierarchical control system with at least four control loops. One loop is between the TNSS and the body; another loop is between the TNSS and the controller; another loop is between the controller and the user; and another loop is between the controller and other users via the cloud, which may be located in the TNSS, the controller or the cloud, has several functions including: (1) sending activation or disablement signals between the controller and the TNSS via a local network such as Bluetooth; (2) driving the user interface, as when the controller receives commands from the user and provides visual, auditory or tactile feedback to the user; (3) analyzing TNSS data, as well as other feedback data such as from the user, within the TNSS, and/or the controller and/or or the cloud; (4) making decisions about the appropriate treatment; (5) system diagnostics for operational correctness; and (6) communications with other controllers or users via the Internet cloud for data transmission or exchange, or to interact with apps residing in the Internet cloud.
The control loop is closed. This is as a result of having both stimulating and sensing. The sensing provides information about the effects of stimulation, allowing the stimulation to be adjusted to a desired level or improved automatically.
Typically, stimulation will be applied. Sensing will be used to measure the effects of stimulation. The measurements sensed will be used to specify the next stimulation. This process can be repeated indefinitely with various durations of each part. For example: rapid cycling through the process (a-b-c-a-b-c-a-b-c); prolonged stimulation, occasional sensing (aaaa-b-c-aaaa-b-c-aaaa-b-c); or prolonged sensing, occasional stimulation (a-bbbb-c-a-bbbb-c-a-bbbb). The process may also start with sensing, and when an event in the body is detected this information is used to specify stimulation to treat or correct the event, for example, (bbbbbbbbb-c-a-bbbbbbbb-c-a-bbbbbbbbb). Other patterns are possible and contemplated within the scope of the application.
The same components can be used for stimulating and sensing alternately, by switching their connection between the stimulating circuits and the sensing circuits. The switching can be done by standard electronic components. In the case of electrical stimulating and sensing, the same electrodes can be used for both. An electronic switch is used to connect stimulating circuits to the electrodes and electric stimulation is applied to the tissues. Then the electronic switch disconnects the stimulating circuits from the electrodes and connects the sensing circuits to the electrodes and electrical signals from the tissues are recorded.
In the case of acoustic stimulating and sensing, the same ultrasonic transducers can be used for both (as in ultrasound imaging or radar). An electronic switch is used to connect circuits to the transducers to send acoustic signals (sound waves) into the tissues. Then the electronic switch disconnects these circuits from the transducers and connects other circuits to the transducers (to listen for reflected sound waves) and these acoustic signals from the tissues are recorded.
Other modalities of stimulation and sensing may be used (e.g. light, magnetic fields, etc) The closed loop control may be implemented autonomously by an individual TNSS or by multiple TNSS modules operating in a system such as that shown below in
Stimulators are protocol controlled initiators of electrical stimulation, where such protocol may reside in either the TNSS and/or the controller and/or the cloud. Stimulators interact with associated sensors or activators, such as electrodes or MEMS devices.
The protocol, which may be located in the TNSS, the controller or the cloud, has several functions including:
(1) Sending activation or disablement signals between the controller and the TNSS via a local network such as Bluetooth. The protocol sends a signal by Bluetooth radio waves from the smartphone to the TNSS module on the skin, telling it to start or stop stimulating or sensing. Other wireless communication types are possible.
(2) Driving the user interface, as when the controller receives commands from the user and provides visual, auditory or tactile feedback to the user. The protocol receives a command from the user when the user touches an icon on the smartphone screen, and provides feedback to the user by displaying information on the smartphone screen, or causing the smartphone to beep or buzz.
(3) Analyzing TNSS data, as well as other feedback data such as from the user, within the TNSS, and/or the controller and/or or the cloud. The protocol analyzes data sensed by the TNSS, such as the position of a muscle, and data from the user such as the user's desires as expressed when the user touches an icon on the smartphone; this analysis can be done in the TNSS, in the smartphone, and/or in the cloud.
(4) Making decisions about the appropriate treatment. The protocol uses the data it analyzes to decide what stimulation to apply.
(5) System diagnostics for operational correctness. The protocol checks that the TNSS system is operating correctly.
(6) Communications with other controllers or users via the Internet cloud for data transmission or exchange, or to interact with apps residing in the Internet cloud. The protocol communicates with other smartphones or people via the internet wirelessly; this may include sending data over the internet, or using computer programs that are operating elsewhere on the internet.
A neurological control system, method and apparatus are configured in an ecosystem or modular platform that uses potentially disposable topical devices to provide interfaces between electronic computing systems and neural systems. These interfaces may be direct electrical connections via electrodes or may be indirect via transducers (sensors and actuators). It may have the following elements in various configurations: electrodes for sensing or activating electrical events in the body; actuators of various modalities; sensors of various modalities; wireless networking; and protocol applications, e.g. for data processing, recording, control systems. These components are integrated within the disposable topical device. This integration allows the topical device to function autonomously. It also allows the topical device along with a remote control unit (communicating wirelessly via an antenna, transmitter and receiver) to function autonomously.
Referring to
Referring to
Referring to
A Topical nerve stimulator/sensor (TNSS) is used to stimulate these nerves and is convenient, unobtrusive, self-powered, controlled from a smartphone or other control device. This has the advantage of being non-invasive, controlled by consumers themselves, and potentially distributed over the counter without a prescription.
Referring to
In one or more examples, a Smart Band Aid™ incorporating a battery and electronic circuit and electrodes in the form of adhesive conductive pads may be applied to the skin, and electrical stimuli is passed from the adhesive pads into the tissues. Stimuli may typically be trains of voltage-regulated square waves at frequencies between 15 and 50 Hz with currents between 20 and 100 mA. The trains of stimuli are controlled from a smartphone operated by the user. Stimuli may be either initiated by the user when desired, or programmed according to a timed schedule, or initiated in response to an event detected by a sensor on the Smart Band Aid™ or elsewhere. Another implementation for males may be a TNSS incorporated in a ring that locates a stimulator conductively to selected nerves in a penis to be stimulated.
Referring to
Aside from the Controller, the Smart Band Aid™ Packaging Platform consists of an assembly of an adhesive patch capable of being applied to the skin and containing the TNSS Electronics, protocol, and power described above.
Referring to
Referring to
Referring to
One or more TNSSs with one or more Controllers form a System. Systems can communicate and interact with each other and with distributed virtualized processing and storage services. This enables the gathering, exchange, and analysis of data among populations of systems for medical and non-medical applications.
Referring to
Referring to
The human and mammal body is an anisotropic medium with multiple layers of tissue of varying electrical properties. Steering of an electric field may be accomplished using multiple electrodes, or multiple SBAs, using the human or mammal body as an anisotropic volume conductor. Electric field steering will discussed below with reference to
Referring to
TNSS protocol performs the functions of communications with the controller including transmitting and receiving of control and data signals, activation and control of the neural stimulation, data gathering from on board sensors, communications and coordination with other TNSSs, and data analysis. Typically the TNSS may receive commands from the controller, generate stimuli and apply these to the tissues, sense signals from the tissues, and transmit these to the controller. It may also analyze the signals sensed and use this information to modify the stimulation applied. In addition to communicating with the controller it may also communicate with other TNSSs using electrical or radio signals via a body area network.
Referring to
In this example TNSS system, most of the data gathering and analysis is performed in the Control Unit 1620. The Control Unit 1620 may be a cellular telephone or a dedicated hardware device. The Control Unit 1620 runs an app that controls the local functions of the TNSS System 1600. The protocol app also communicates via the Internet or wireless networks 1630 with other TNSS systems and/or with 3rd party software applications.
The TNSS 1610 may also be caused to operate by signals received from a Control Unit 1620 such as a cellphone, laptop, key fob, tablet, or other handheld device and may transmit information that it senses back to the Control Unit 1620. This constitutes the second level of the system 1600 in this example.
The Control Unit 1620 is caused to operate by commands from a user, who also receives information from the Control Unit 1620. The user may also receive information about actions of the body via natural senses such as vision or touch via sensory nerves and the spinal cord, and may in some cases cause actions in the body via natural pathways through the spinal cord to the muscles.
The Control Unit 1620 may also communicate information to other users, experts, or application programs via the Internet 1630, and receive information from them via the Internet 1630.
The user may choose to initiate or modify these processes, sometimes using protocol applications residing in the TNSS 1610, the Control Unit 1620, the Internet 1630, or wireless networks. This software may assist the user, for example by processing the stimulation to be delivered to the body to render it more selective or effective for the user, and/or by processing and displaying data received from the body or from the Internet 1630 or wireless networks to make it more intelligible or useful to the user.
An example 10×10 matrix of electrical contacts 1860 is shown. By varying the pattern of electrical contacts 1860 employed to cause an electric field 1820 to form and by time varying the applied electrical power to this pattern of contacts 1860, it is possible to steer the field 1820 across different parts of the body, which may include muscle 1870, bone, fat, and other tissue, in three dimensions. This electric field 1820 can activate specific nerves or nerve bundles 1880 while sensing the electrical and mechanical actions produced 1890, and thereby enabling the TNSS to discover more effective or the most effective pattern of stimulation for producing the desired action.
The SBA's ability to stimulate and collect organic data has multiple applications including bladder control, reflex incontinence, sexual stimulations, pain control and wound healing among others. Examples of SBA's application for medical and other uses follow.
Medical Uses
Bladder Management
1) Overactive bladder: When the user feels a sensation of needing to empty the bladder urgently, he or she presses a button on the Controller to initiate stimulation via a Smart Band Aid™ applied over the dorsal nerve of the penis or clitoris. Activation of this nerve would inhibit the sensation of needing to empty the bladder urgently, and allow it to be emptied at a convenient time.
2) Incontinence: A person prone to incontinence of urine because of unwanted contraction of the bladder uses the SBA to activate the dorsal nerve of the penis or clitoris to inhibit contraction of the bladder and reduce incontinence of urine. The nerve could be activated continuously, or intermittently when the user became aware of the risk of incontinence, or in response to a sensor indicating the volume or pressure in the bladder.
Erection, ejaculation and orgasm: Stimulation of the nerves on the underside of the penis by a Smart Band Aid™ (electrical stimulation or mechanical vibration) can cause sexual arousal and might be used to produce or prolong erection and to produce orgasm and ejaculation.
Pain control: A person suffering from chronic pain from a particular region of the body applies a Smart Band Aid™ over that region and activates electrically the nerves conveying the sensation of touch, thereby reducing the sensation of pain from that region. This is based on the gate theory of pain.
Wound care: A person suffering from a chronic wound or ulcer applies a Smart Band Aid™ over the wound and applies electrical stimuli continuously to the tissues surrounding the wound to accelerate healing and reduce infection.
Essential tremor: A sensor on a Smart Band Aid™ detects the tremor and triggers neuro stimulation to the muscles and sensory nerves involved in the tremor with an appropriate frequency and phase relationship to the tremor. The stimulation frequency would typically be at the same frequency as the tremor but shifted in phase in order to cancel the tremor or reset the neural control system for hand position.
Reduction of spasticity: Electrical stimulation of peripheral nerves can reduce spasticity for several hours after stimulation. A Smart Band Aid™ operated by the patient when desired from a smartphone could provide this stimulation.
Restoration of sensation and sensory feedback: People who lack sensation, for example as a result of diabetes or stroke use a Smart Band Aid™ to sense movement or contact, for example of the foot striking the floor, and the SBA provides mechanical or electrical stimulation to another part of the body where the user has sensation, to improve safety or function. Mechanical stimulation is provided by the use of acoustic transducers in the SBA such as small vibrators. Applying a Smart Band Aid™ to the limb or other assistive device provides sensory feedback from artificial limbs. Sensory feedback can also be used to substitute one sense for another, e.g. touch in place of sight.
Recording of mechanical activity of the body: Sensors in a Smart Band Aid™ record position, location and orientation of a person or of body parts and transmit this data to a smartphone for the user and/or to other computer networks for safety monitoring, analysis of function and coordination of stimulation.
Recording of sound from the body or reflections of ultrasound waves generated by a transducer in a Smart Band Aid™ could provide information about body structure, e.g. bladder volume for persons unable to feel their bladder. Acoustic transducers may be piezoelectric devices or MEMS devices that transmit and receive the appropriate acoustic frequencies. Acoustic data may be processed to allow imaging of the interior of the body.
Recording of Electrical Activity of the Body
Electrocardiogram: Recording the electrical activity of the heart is widely used for diagnosing heart attacks and abnormal rhythms. It is sometimes necessary to record this activity for 24 hours or more to detect uncommon rhythms. A Smart Band Aid™ communicating wirelessly with a smartphone or computer network achieves this more simply than present systems.
Electromyogram: Recording the electrical activity of muscles is widely used for diagnosis in neurology and also used for movement analysis. Currently this requires the use of many needles or adhesive pads on the surface of the skin connected to recording equipment by many wires. Multiple Smart Band Aids™ record the electrical activity of many muscles and transmit this information wirelessly to a smartphone.
Recording of optical information from the body: A Smart Band Aid™ incorporating a light source (LED, laser) illuminates tissues and senses the characteristics of the reflected light to measure characteristics of value, e.g. oxygenation of the blood, and transmit this to a cellphone or other computer network.
Recording of chemical information from the body: The levels of chemicals or drugs in the body or body fluids is monitored continuously by a Smart Band Aid™ sensor and transmitted to other computer networks and appropriate feedback provided to the user or to medical staff. Levels of chemicals may be measured by optical methods (reflection of light at particular wavelengths) or by chemical sensors.
Special Populations of Disabled Users
There are many potential applications of electrical stimulation for therapy and restoration of function. However, few of these have been commercialized because of the lack of affordable convenient and easily controllable stimulation systems. Some applications are shown in the
Limb Muscle stimulation: Lower limb muscles can be exercised by stimulating them electrically, even if they are paralyzed by stroke or spinal cord injury. This is often combined with the use of a stationary exercise cycle for stability. Smart Band Aid™ devices could be applied to the quadriceps muscle of the thigh to stimulate these, extending the knee for cycling, or to other muscles such as those of the calf. Sensors in the Smart Band Aid™ could trigger stimulation at the appropriate time during cycling, using an application on a smartphone, tablet, handheld hardware device such as a key fob, wearable computing device, laptop, or desktop computer, among other possible devices. Upper limb muscles can be exercised by stimulating them electrically, even if they are paralyzed by stroke of spinal cord injury. This is often combined with the use of an arm crank exercise machine for stability. Smart Band Aid™ devices are applied to multiple muscles in the upper limb and triggered by sensors in the Smart Band Aids™ at the appropriate times, using an application on a smartphone.
Prevention of osteoporosis: Exercise can prevent osteoporosis and pathological fractures of bones. This is applied using Smart Band Aids™ in conjunction with exercise machines such as rowing simulators, even for people with paralysis who are particularly prone to osteoporosis.
Prevention of deep vein thrombosis: Electric stimulation of the muscles of the calf can reduce the risk of deep vein thrombosis and potentially fatal pulmonary embolus. Electric stimulation of the calf muscles is applied by a Smart Band Aid™ with stimulation programmed from a smartphone, e.g. during a surgical operation, or on a preset schedule during a long plane flight.
Restoration of Function (Functional Electrical Stimulation)
Lower Limb
1) Foot drop: People with stroke often cannot lift their forefoot and drag their toes on the ground. A Smart Band Aid™ is be applied just below the knee over the common peroneal nerve to stimulate the muscles that lift the forefoot at the appropriate time in the gait cycle, triggered by a sensor in the Smart Band Aid™
2) Standing: People with spinal cord injury or some other paralyses can be aided to stand by electrical stimulation of the quadriceps muscles of their thigh. These muscles are stimulated by Smart Band Aids™ applied to the front of the thigh and triggered by sensors or buttons operated by the patient using an application on a smartphone. This may also assist patients to use lower limb muscles when transferring from a bed to a chair or other surface.
3) Walking: Patients with paralysis from spinal cord injury are aided to take simple steps using electrical stimulation of the lower limb muscles and nerves. Stimulation of the sensory nerves in the common peroneal nerve below the knee can cause a triple reflex withdrawal, flexing the ankle, knee and hip to lift the leg, and then stimulation of the quadriceps can extend the knee to bear weight. The process is then repeated on the other leg. Smart Band Aids™ coordinated by an application in a smartphone produce these actions.
Upper Limb
1) Hand grasp: People with paralysis from stroke or spinal cord injury have simple hand grasp restored by electrical stimulation of the muscles to open or close the hand. This is produced by Smart Band Aids™ applied to the back and front of the forearm and coordinated by sensors in the Smart Band Aids™ and an application in a smartphone.
2) Reaching: Patients with paralysis from spinal cord injury sometimes cannot extend their elbow to reach above the head. Application of a Smart Band Aid™ to the triceps muscle stimulates this muscle to extend the elbow. This is triggered by a sensor in the Smart Band Aid™ detecting arm movements and coordinating it with an application on a smartphone.
Posture: People whose trunk muscles are paralyzed may have difficulty maintaining their posture even in a wheelchair. They may fall forward unless they wear a seatbelt, and if they lean forward they may be unable to regain upright posture. Electrical stimulation of the muscles of the lower back using a Smart Band Aid™ allows them to maintain and regain upright posture. Sensors in the Smart Band Aid™ trigger this stimulation when a change in posture was detected.
Coughing: People whose abdominal muscles are paralyzed cannot produce a strong cough and are at risk for pneumonia. Stimulation of the muscles of the abdominal wall using a Smart Band Aid™ could produce a more forceful cough and prevent chest infections. The patient using a sensor in a Smart Band Aid™ triggers the stimulation.
Essential Tremor: It has been demonstrated that neuro stimulation can reduce or eliminate the signs of ET. ET may be controlled using a TNSS. A sensor on a Smart Band Aid™ detects the tremor and trigger neuro stimulation to the muscles and sensory nerves involved in the tremor with an appropriate frequency and phase relationship to the tremor. The stimulation frequency is typically be at the same frequency as the tremor but shifted in phase in order to cancel the tremor or reset the neural control system for hand position.
Non-Medical Applications
Sports Training
Sensing the position and orientation of multiple limb segments is used to provide visual feedback on a smartphone of, for example, a golf swing, and also mechanical or electrical feedback to the user at particular times during the swing to show them how to change their actions. The electromyogram of muscles could also be recorded from one or many Smart Band Aids™ and used for more detailed analysis.
Gaming
Sensing the position and orientation of arms, legs and the rest of the body produces a picture of an onscreen player that can interact with other players anywhere on the Internet. Tactile feedback would be provided to players by actuators in Smart Band Aids on various parts of the body to give the sensation of striking a ball, etc.
Motion Capture for Film and Animation
Wireless TNSS capture position, acceleration, and orientation of multiple parts of the body. This data may be used for animation of a human or mammal and has application for human factor analysis and design.
Sample Modes of Operation
A SBA system consists of at least a single Controller and a single SBA. Following application of the SBA to the user's skin, the user controls it via the Controller's app using Near Field Communications. The app appears on a smartphone screen and can be touch controlled by the user; for ‘key fob’ type Controllers, the SBA is controlled by pressing buttons on the key fob.
When the user feels the need to activate the SBA s/he presses the “go” button two or more times to prevent false triggering, thus delivering the neuro stimulation. The neuro stimulation may be delivered in a variety of patterns of frequency, duration, and strength and may continue until a button is pressed by the user or may be delivered for a length of time set in the application.
Sensor capabilities in the TNSS, are enabled to start collecting/analyzing data and communicating with the controller when activated.
The level of functionality in the protocol app, and the protocol embedded in the TNSS, will depend upon the neuro modulation or neuro stimulation regimen being employed.
In some cases there will be multiple TNSSs employed for the neuro modulation or neuro stimulation regimen. The basic activation will be the same for each TNSS.
However, once activated multiple TNSSs will automatically form a network of neuro modulation/stimulation points with communications enabled with the controller.
The need for multiple TNSSs arises from the fact that treatment regimens may need several points of access to be effective.
While illustrative systems and methods as described herein embodying various aspects of the present disclosure are shown, it will be understood by those skilled in the art, that the invention is not limited to these embodiments. Modifications may be made by those skilled in the art, particularly in light of the foregoing teachings. For example, each of the elements of the aforementioned embodiments may be utilized alone or in combination or subcombination with elements of the other embodiments. It will also be appreciated and understood that modifications may be made without departing from the true spirit and scope of the present disclosure. The description is thus to be regarded as illustrative instead of restrictive on the present invention.
This application claims priority to and the benefit of the filing date of PCT application PCT/US2014/040240 filed on May 30, 2014, and U.S. provisional patent application U.S. Ser. No. 61/828,981 filed on May 30, 2013, and incorporates that application in its entirety herein.
Number | Name | Date | Kind |
---|---|---|---|
4277980 | Coats et al. | Jul 1981 | A |
4532930 | Crosby et al. | Aug 1985 | A |
4542753 | Brenman et al. | Sep 1985 | A |
4549556 | Tarjan et al. | Oct 1985 | A |
4553549 | Pope et al. | Nov 1985 | A |
4590949 | Pohndorf | May 1986 | A |
4614395 | Peers-Trevarton | Sep 1986 | A |
4658835 | Pohndorf | Apr 1987 | A |
4677989 | Robblee | Jul 1987 | A |
4690144 | Rise et al. | Sep 1987 | A |
4702254 | Zabara | Oct 1987 | A |
4706682 | Stypulkowski et al. | Nov 1987 | A |
4717581 | Robblee | Jan 1988 | A |
4759228 | Butler et al. | Jul 1988 | A |
4800898 | Hess et al. | Jan 1989 | A |
4817628 | Zealear et al. | Apr 1989 | A |
4881526 | Johnson et al. | Nov 1989 | A |
4883666 | Sabel et al. | Nov 1989 | A |
4919148 | Muccio | Apr 1990 | A |
4940453 | Cadwell | Jul 1990 | A |
4959532 | Owechko | Sep 1990 | A |
5031621 | Grandjean et al. | Jul 1991 | A |
5035242 | Franklin et al. | Jul 1991 | A |
5047005 | Cadwell | Sep 1991 | A |
5092332 | Lee et al. | Mar 1992 | A |
5092835 | Schurig et al. | Mar 1992 | A |
5095905 | Klepinski | Mar 1992 | A |
5211657 | Yamada et al. | May 1993 | A |
5265608 | Lee et al. | Nov 1993 | A |
5381801 | McShane et al. | Jan 1995 | A |
5476494 | Edell et al. | Dec 1995 | A |
5501703 | Holsheimer et al. | Mar 1996 | A |
5569307 | Schulman et al. | Oct 1996 | A |
5575813 | Edell et al. | Nov 1996 | A |
5584869 | Heck et al. | Dec 1996 | A |
5597381 | Rizzo, III | Jan 1997 | A |
5603726 | Schulman et al. | Feb 1997 | A |
5609616 | Schulman et al. | Mar 1997 | A |
5628769 | Saringer | May 1997 | A |
5643330 | Holsheimer et al. | Jul 1997 | A |
5679340 | Chappel | Oct 1997 | A |
5713922 | King | Feb 1998 | A |
5738625 | Gluck | Apr 1998 | A |
5741314 | Daly et al. | Apr 1998 | A |
5795790 | Schinstine et al. | Aug 1998 | A |
5824022 | Zilberman et al. | Oct 1998 | A |
5830651 | Cauley et al. | Nov 1998 | A |
5837236 | Dinsmore | Nov 1998 | A |
5853370 | Chance et al. | Dec 1998 | A |
5871534 | Messick et al. | Feb 1999 | A |
5876425 | Gord et al. | Mar 1999 | A |
5891437 | Pietropaolo et al. | Apr 1999 | A |
5916870 | Lee et al. | Jun 1999 | A |
5921245 | O'Donnell, Jr. | Jul 1999 | A |
5922012 | Sakano | Jul 1999 | A |
5937318 | Warner, Jr. et al. | Aug 1999 | A |
5938691 | Schulman et al. | Aug 1999 | A |
5948428 | Lee et al. | Sep 1999 | A |
5987361 | Mortimer | Nov 1999 | A |
5989445 | Wise et al. | Nov 1999 | A |
5992769 | Wise et al. | Nov 1999 | A |
6002960 | Sternberger et al. | Dec 1999 | A |
6011018 | Crabtree et al. | Jan 2000 | A |
6016449 | Fischell et al. | Jan 2000 | A |
6058331 | King | May 2000 | A |
6060048 | Cherksey | May 2000 | A |
6060054 | Staerz | May 2000 | A |
6066084 | Edrich et al. | May 2000 | A |
6067474 | Schulman et al. | May 2000 | A |
6085115 | Weaver et al. | Jul 2000 | A |
6096537 | Chappel | Aug 2000 | A |
6119071 | Gorenflo et al. | Sep 2000 | A |
6120538 | Rizzo, III et al. | Sep 2000 | A |
6140116 | Dinsmore | Oct 2000 | A |
6178349 | Kieval | Jan 2001 | B1 |
6203792 | Filbin | Mar 2001 | B1 |
6204053 | Dinsmore | Mar 2001 | B1 |
6258353 | Isacson et al. | Jul 2001 | B1 |
6264950 | Staerz | Jul 2001 | B1 |
6265175 | Gage et al. | Jul 2001 | B1 |
6270831 | Kumar et al. | Aug 2001 | B2 |
6277372 | Fraser et al. | Aug 2001 | B1 |
6284245 | Edge | Sep 2001 | B1 |
6288527 | Sugihara et al. | Sep 2001 | B1 |
6294383 | Isacson et al. | Sep 2001 | B1 |
6304784 | Allee et al. | Oct 2001 | B1 |
6304787 | Kuzma et al. | Oct 2001 | B1 |
6359550 | Brisebois et al. | Mar 2002 | B1 |
6374140 | Rise | Apr 2002 | B1 |
6379393 | Mavroidis et al. | Apr 2002 | B1 |
6392118 | Hammang et al. | May 2002 | B1 |
6392550 | Najor | May 2002 | B1 |
6393327 | Scribner | May 2002 | B1 |
6415186 | Chim et al. | Jul 2002 | B1 |
6421232 | Sallam | Jul 2002 | B2 |
6427083 | Owen et al. | Jul 2002 | B1 |
6444205 | Dinsmore et al. | Sep 2002 | B2 |
6472181 | Mineau-Hanschke | Oct 2002 | B1 |
6510347 | Borkan | Jan 2003 | B2 |
6517833 | Edge | Feb 2003 | B2 |
6533732 | Urmey | Mar 2003 | B1 |
6537200 | Leysieffer et al. | Mar 2003 | B2 |
6546291 | Merfeld et al. | Apr 2003 | B2 |
6561975 | Pool et al. | May 2003 | B1 |
6565503 | Leysieffer et al. | May 2003 | B2 |
6575894 | Leysieffer et al. | Jun 2003 | B2 |
6599695 | Gage et al. | Jul 2003 | B2 |
6640118 | Van Heerden et al. | Oct 2003 | B2 |
6640121 | Telischi et al. | Oct 2003 | B1 |
RE38323 | Sugihara et al. | Nov 2003 | E |
6647297 | Scribner | Nov 2003 | B2 |
6690974 | Archer et al. | Feb 2004 | B2 |
6697674 | Leysieffer | Feb 2004 | B2 |
6727696 | Kruspe et al. | Apr 2004 | B2 |
6744367 | Forster | Jun 2004 | B1 |
6788976 | Gesotti | Sep 2004 | B2 |
6795737 | Gielen et al. | Sep 2004 | B2 |
6807445 | Baumann et al. | Oct 2004 | B2 |
6839596 | Nelson et al. | Jan 2005 | B2 |
6850802 | Holsheimer | Feb 2005 | B2 |
6879855 | Schulman et al. | Apr 2005 | B2 |
6884122 | Robinson et al. | Apr 2005 | B2 |
6892097 | Holsheimer | May 2005 | B2 |
6893812 | Woltering et al. | May 2005 | B2 |
6894616 | Forster | May 2005 | B1 |
6902547 | Aves et al. | Jun 2005 | B2 |
6931273 | Groenewegen et al. | Aug 2005 | B2 |
6949251 | Dalal et al. | Sep 2005 | B2 |
6970745 | Scribner | Nov 2005 | B2 |
6976998 | Rizzo et al. | Dec 2005 | B2 |
7001608 | Fishman et al. | Feb 2006 | B2 |
7003335 | Briancon | Feb 2006 | B2 |
7010351 | Firlik et al. | Mar 2006 | B2 |
7027873 | Pajunk et al. | Apr 2006 | B2 |
7030411 | Krulevitch et al. | Apr 2006 | B2 |
7037603 | Lasater | May 2006 | B2 |
7047080 | Palanker et al. | May 2006 | B2 |
7058455 | Huie, Jr. et al. | Jun 2006 | B2 |
7079882 | Schmidt | Jul 2006 | B1 |
7101542 | Vallera et al. | Sep 2006 | B1 |
7106190 | Owens | Sep 2006 | B1 |
7107104 | Keravel et al. | Sep 2006 | B2 |
7115071 | Sunbeck | Oct 2006 | B1 |
7117034 | Kronberg | Oct 2006 | B2 |
7120499 | Thrope et al. | Oct 2006 | B2 |
7127301 | Okandan et al. | Oct 2006 | B1 |
7155278 | King et al. | Dec 2006 | B2 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7174223 | Dalton et al. | Feb 2007 | B2 |
7181288 | Rezai et al. | Feb 2007 | B1 |
7191018 | Gielen et al. | Mar 2007 | B2 |
7193414 | Kruspe et al. | Mar 2007 | B2 |
7206632 | King | Apr 2007 | B2 |
7209787 | DiLorenzo | Apr 2007 | B2 |
7218216 | Uehran | May 2007 | B1 |
7218964 | Hill et al. | May 2007 | B2 |
7228178 | Carroll et al. | Jun 2007 | B2 |
7228727 | Discenzo | Jun 2007 | B2 |
7239918 | Strother et al. | Jul 2007 | B2 |
7249998 | van Esbroeck et al. | Jul 2007 | B2 |
7283867 | Strother et al. | Oct 2007 | B2 |
7297420 | Jiang | Nov 2007 | B2 |
7299034 | Kates | Nov 2007 | B2 |
7308303 | Whitehurst et al. | Dec 2007 | B2 |
7308317 | Okandan et al. | Dec 2007 | B1 |
7333851 | Echauz et al. | Feb 2008 | B2 |
7337004 | Classen et al. | Feb 2008 | B2 |
7349169 | Lee et al. | Mar 2008 | B2 |
RE40209 | Sugihara et al. | Apr 2008 | E |
7376467 | Thrope et al. | May 2008 | B2 |
7384145 | Hetling et al. | Jun 2008 | B2 |
7392093 | Khan | Jun 2008 | B2 |
7398255 | Lauer et al. | Jul 2008 | B2 |
7415309 | McIntyre | Aug 2008 | B2 |
7420760 | Zhang et al. | Sep 2008 | B2 |
7422564 | Parsons et al. | Sep 2008 | B2 |
7435443 | Jiang | Oct 2008 | B2 |
7435585 | Tykocinski et al. | Oct 2008 | B2 |
7437193 | Parramon et al. | Oct 2008 | B2 |
7437196 | Wyler et al. | Oct 2008 | B2 |
7483747 | Gliner et al. | Jan 2009 | B2 |
7499745 | Littrup et al. | Mar 2009 | B2 |
7499748 | Moffitt et al. | Mar 2009 | B2 |
7502652 | Gaunt et al. | Mar 2009 | B2 |
7519419 | Jiang et al. | Apr 2009 | B2 |
7529582 | DiLorenzo | May 2009 | B1 |
7553307 | Bleich et al. | Jun 2009 | B2 |
7555343 | Bleich | Jun 2009 | B2 |
7561919 | Shalev et al. | Jul 2009 | B2 |
7565199 | Sheffield et al. | Jul 2009 | B2 |
7565200 | Wyler et al. | Jul 2009 | B2 |
7571002 | Thrope et al. | Aug 2009 | B2 |
7571006 | Gordon et al. | Aug 2009 | B2 |
7578819 | Bleich et al. | Aug 2009 | B2 |
7584004 | Caparso et al. | Sep 2009 | B2 |
7587238 | Moffitt et al. | Sep 2009 | B2 |
7598031 | Liew | Oct 2009 | B2 |
7599737 | Yomtov et al. | Oct 2009 | B2 |
7620456 | Gliner et al. | Nov 2009 | B2 |
7622303 | Soykan et al. | Nov 2009 | B2 |
7636597 | Gross et al. | Dec 2009 | B2 |
7657308 | Miles et al. | Feb 2010 | B2 |
7658707 | Topolev | Feb 2010 | B2 |
7662558 | Liew | Feb 2010 | B2 |
7676274 | Hung et al. | Mar 2010 | B2 |
7680526 | McIntyre et al. | Mar 2010 | B2 |
7684866 | Fowler et al. | Mar 2010 | B2 |
D613868 | Lhuillery et al. | Apr 2010 | S |
7699768 | Kishawi et al. | Apr 2010 | B2 |
7704740 | Schindler et al. | Apr 2010 | B2 |
7706888 | Jolly | Apr 2010 | B2 |
7706893 | Hung et al. | Apr 2010 | B2 |
7711416 | Akkin et al. | May 2010 | B1 |
7715919 | Osorio et al. | May 2010 | B2 |
7715924 | Rezai et al. | May 2010 | B2 |
7725196 | Machado et al. | May 2010 | B2 |
7732407 | Hunter | Jun 2010 | B2 |
7738968 | Bleich | Jun 2010 | B2 |
7738969 | Bleich | Jun 2010 | B2 |
7740631 | Bleich et al. | Jun 2010 | B2 |
7747318 | John et al. | Jun 2010 | B2 |
7756583 | Demarais et al. | Jul 2010 | B2 |
7756584 | Sheffield et al. | Jul 2010 | B2 |
7769462 | Meadows et al. | Aug 2010 | B2 |
7769470 | Rezai et al. | Aug 2010 | B1 |
7798982 | Zets et al. | Sep 2010 | B2 |
7799021 | Leung et al. | Sep 2010 | B2 |
7801603 | Westlund et al. | Sep 2010 | B2 |
7813809 | Strother et al. | Oct 2010 | B2 |
7819801 | Miles et al. | Oct 2010 | B2 |
7819869 | Godara et al. | Oct 2010 | B2 |
7831305 | Gliner | Nov 2010 | B2 |
7844340 | Pawlowicz, III | Nov 2010 | B2 |
7877136 | Moffitt et al. | Jan 2011 | B1 |
7892180 | Epley | Feb 2011 | B2 |
7894911 | Greenberg et al. | Feb 2011 | B2 |
7894914 | Stahmann et al. | Feb 2011 | B2 |
7899542 | Cowan et al. | Mar 2011 | B2 |
7914842 | Greenberg et al. | Mar 2011 | B1 |
7917231 | Farah et al. | Mar 2011 | B2 |
7918802 | Urmey | Apr 2011 | B2 |
7943632 | Katzman et al. | May 2011 | B2 |
7945330 | Gliner et al. | May 2011 | B2 |
7947448 | Couillard-Despres et al. | May 2011 | B2 |
RE42449 | Forster | Jun 2011 | E |
7959577 | Schmitz et al. | Jun 2011 | B2 |
7963915 | Bleich | Jun 2011 | B2 |
7967751 | Goscha et al. | Jun 2011 | B2 |
7974689 | Volpe et al. | Jul 2011 | B2 |
7981144 | Geist et al. | Jul 2011 | B2 |
7988688 | Webb et al. | Aug 2011 | B2 |
7991475 | Tang et al. | Aug 2011 | B1 |
7991480 | Stahmann et al. | Aug 2011 | B2 |
7992521 | Bocquier | Aug 2011 | B2 |
8000782 | Gharib et al. | Aug 2011 | B2 |
8000796 | Tass et al. | Aug 2011 | B2 |
8000804 | Wessendorf et al. | Aug 2011 | B1 |
8010202 | Shah et al. | Aug 2011 | B2 |
8014868 | Greenberg et al. | Sep 2011 | B2 |
8014878 | Greenberg et al. | Sep 2011 | B2 |
8025632 | Einarsson | Sep 2011 | B2 |
8027716 | Gharib et al. | Sep 2011 | B2 |
8033996 | Behar | Oct 2011 | B2 |
8060210 | Carroll | Nov 2011 | B1 |
8065012 | Firlik et al. | Nov 2011 | B2 |
8067173 | Liew | Nov 2011 | B2 |
8073526 | Graham et al. | Dec 2011 | B2 |
8073546 | Sheffield et al. | Dec 2011 | B2 |
8075556 | Betts | Dec 2011 | B2 |
8078252 | Kipke et al. | Dec 2011 | B2 |
8090446 | Fowler et al. | Jan 2012 | B2 |
8092398 | Weinberg et al. | Jan 2012 | B2 |
8095209 | Flaherty | Jan 2012 | B2 |
8101358 | Liew | Jan 2012 | B2 |
8110358 | Liew | Feb 2012 | B2 |
8114019 | Miles et al. | Feb 2012 | B2 |
8114597 | Liew | Feb 2012 | B2 |
8116875 | Osypka et al. | Feb 2012 | B2 |
8126562 | Fowler et al. | Feb 2012 | B2 |
8131376 | Faraji et al. | Mar 2012 | B1 |
8133674 | Liew | Mar 2012 | B2 |
8133675 | Liew | Mar 2012 | B2 |
8135472 | Fowler et al. | Mar 2012 | B2 |
8137258 | Dennis et al. | Mar 2012 | B1 |
8137284 | Miles et al. | Mar 2012 | B2 |
8140152 | John et al. | Mar 2012 | B2 |
8140162 | Jiang et al. | Mar 2012 | B1 |
8140170 | Rezai et al. | Mar 2012 | B2 |
8148072 | Liew | Apr 2012 | B2 |
8155757 | Neisz et al. | Apr 2012 | B1 |
8160713 | Greenberg et al. | Apr 2012 | B2 |
8162846 | Epley | Apr 2012 | B2 |
8165685 | Knutson et al. | Apr 2012 | B1 |
8170676 | Greenberg et al. | May 2012 | B2 |
8174371 | Schwieger | May 2012 | B2 |
8180453 | Greenberg et al. | May 2012 | B2 |
8180460 | Nevsmith et al. | May 2012 | B2 |
8192357 | Miles et al. | Jun 2012 | B2 |
8195300 | Gliner et al. | Jun 2012 | B2 |
8195307 | Vilims | Jun 2012 | B2 |
8200338 | Grennberg et al. | Jun 2012 | B2 |
8215773 | Gibson-Horn et al. | Jul 2012 | B2 |
8216135 | Goscha et al. | Jul 2012 | B2 |
8226661 | Balling et al. | Jul 2012 | B2 |
8228202 | Buchner et al. | Jul 2012 | B2 |
8239036 | Shah et al. | Aug 2012 | B2 |
8255044 | Miles et al. | Aug 2012 | B2 |
8257922 | Liew | Sep 2012 | B2 |
8260428 | Fink et al. | Sep 2012 | B2 |
8260439 | DiUbaldi et al. | Sep 2012 | B2 |
8280516 | Graupe | Oct 2012 | B2 |
8301266 | Zilberman et al. | Oct 2012 | B1 |
8303516 | Schmitz et al. | Nov 2012 | B2 |
8308665 | Harry et al. | Nov 2012 | B2 |
8313443 | Tom | Nov 2012 | B2 |
8323320 | Lowry et al. | Dec 2012 | B2 |
8328354 | Li et al. | Dec 2012 | B2 |
8332037 | Imran | Dec 2012 | B2 |
8332044 | McIntyre | Dec 2012 | B2 |
8346367 | Carroll | Jan 2013 | B2 |
8352022 | Akkin et al. | Jan 2013 | B2 |
8359083 | Clark et al. | Jan 2013 | B2 |
8364257 | Van Den Eerenbeemd et al. | Jan 2013 | B2 |
8364258 | Della Rocca et al. | Jan 2013 | B2 |
8374698 | Ok et al. | Feb 2013 | B2 |
8374701 | Hyde et al. | Feb 2013 | B2 |
8382656 | Brown | Feb 2013 | B1 |
8386032 | Bachinski et al. | Feb 2013 | B2 |
8386053 | Kornet | Feb 2013 | B2 |
8388678 | Singhal et al. | Mar 2013 | B2 |
8391970 | Tracey et al. | Mar 2013 | B2 |
8391986 | Graupe et al. | Mar 2013 | B2 |
8391987 | Faraji et al. | Mar 2013 | B2 |
8396556 | Libbus et al. | Mar 2013 | B2 |
8403841 | Miles et al. | Mar 2013 | B2 |
8406886 | Gaunt et al. | Mar 2013 | B2 |
8412328 | Whelan et al. | Apr 2013 | B2 |
8412335 | Gliner et al. | Apr 2013 | B2 |
8417345 | Machado et al. | Apr 2013 | B2 |
8419653 | Bleich et al. | Apr 2013 | B2 |
8428732 | Nishida et al. | Apr 2013 | B2 |
8428738 | Valencia | Apr 2013 | B2 |
8428739 | Ahuja et al. | Apr 2013 | B2 |
8430882 | Lowry et al. | Apr 2013 | B2 |
8444640 | Demarais et al. | May 2013 | B2 |
8457764 | Ramachandran et al. | Jun 2013 | B2 |
8460167 | Chornenky et al. | Jun 2013 | B2 |
8463383 | Sakai et al. | Jun 2013 | B2 |
8473048 | Greenberg et al. | Jun 2013 | B2 |
8494640 | Peterson et al. | Jul 2013 | B2 |
8494642 | Cowan et al. | Jul 2013 | B2 |
8498717 | Lee et al. | Jul 2013 | B2 |
8498720 | Pellinen et al. | Jul 2013 | B2 |
8506613 | Webb et al. | Aug 2013 | B2 |
8509903 | York et al. | Aug 2013 | B2 |
8512235 | Miles et al. | Aug 2013 | B2 |
8515533 | Rofougaran et al. | Aug 2013 | B2 |
8515543 | Greenberg et al. | Aug 2013 | B2 |
8517961 | Imran et al. | Aug 2013 | B2 |
8524311 | Greenberg et al. | Sep 2013 | B1 |
8532776 | Greenberg et al. | Sep 2013 | B2 |
8538537 | Hulvershorn et al. | Sep 2013 | B2 |
8543210 | Sharma | Sep 2013 | B2 |
8548600 | Deem et al. | Oct 2013 | B2 |
8554328 | Faraji et al. | Oct 2013 | B2 |
8554337 | Barolat | Oct 2013 | B2 |
8556838 | Moutray | Oct 2013 | B2 |
8560041 | Flaherty et al. | Oct 2013 | B2 |
8562521 | Miles et al. | Oct 2013 | B2 |
8565894 | Vetter et al. | Oct 2013 | B2 |
8568331 | Bertagnoli et al. | Oct 2013 | B2 |
8571665 | Moffitt et al. | Oct 2013 | B2 |
8579837 | Makower et al. | Nov 2013 | B1 |
8583238 | Heldman et al. | Nov 2013 | B1 |
8588918 | Bighetti | Nov 2013 | B2 |
8594798 | Osorio et al. | Nov 2013 | B2 |
8600514 | Carroll | Dec 2013 | B1 |
8608664 | Kunitake et al. | Dec 2013 | B2 |
8612002 | Faltys et al. | Dec 2013 | B2 |
8615308 | Hung et al. | Dec 2013 | B2 |
8617808 | Braesch-Andersen et al. | Dec 2013 | B2 |
8626265 | Hempel et al. | Jan 2014 | B2 |
8626305 | Nielsen et al. | Jan 2014 | B2 |
8628469 | Miles et al. | Jan 2014 | B2 |
8634930 | Dalal et al. | Jan 2014 | B2 |
8634932 | Ye et al. | Jan 2014 | B1 |
8639344 | Greenberg et al. | Jan 2014 | B2 |
8644900 | Balberg et al. | Feb 2014 | B2 |
8644937 | Greenberg et al. | Feb 2014 | B2 |
8644938 | Craggs | Feb 2014 | B2 |
8647346 | Bleich et al. | Feb 2014 | B2 |
8649845 | McIntyre et al. | Feb 2014 | B2 |
8649868 | Greenberg et al. | Feb 2014 | B2 |
8652129 | Wu et al. | Feb 2014 | B2 |
8652187 | Wells et al. | Feb 2014 | B2 |
8655455 | Mann et al. | Feb 2014 | B2 |
8660655 | Peterson et al. | Feb 2014 | B2 |
8666500 | Greenberg et al. | Mar 2014 | B2 |
8667971 | Makkar et al. | Mar 2014 | B2 |
8667972 | Makkar et al. | Mar 2014 | B2 |
8669058 | Liew | Mar 2014 | B2 |
8670837 | Daneshvar et al. | Mar 2014 | B2 |
8674838 | Konishi et al. | Mar 2014 | B2 |
8676274 | Li | Mar 2014 | B2 |
8682443 | Faraji et al. | Mar 2014 | B2 |
8698637 | Raichman | Apr 2014 | B2 |
8702685 | Schwartz et al. | Apr 2014 | B2 |
8706241 | Firlik et al. | Apr 2014 | B2 |
8708899 | Miles et al. | Apr 2014 | B2 |
8712517 | Jolly | Apr 2014 | B2 |
8712538 | Greenberg et al. | Apr 2014 | B2 |
8712549 | Zdeblick et al. | Apr 2014 | B2 |
8721637 | Zarins et al. | May 2014 | B2 |
8725251 | Della Rocca et al. | May 2014 | B2 |
8734339 | Rao et al. | May 2014 | B2 |
8740783 | Gharib et al. | Jun 2014 | B2 |
8740896 | Zarins et al. | Jun 2014 | B2 |
8744570 | Lee et al. | Jun 2014 | B2 |
8750957 | Tang et al. | Jun 2014 | B2 |
8753271 | Miles et al. | Jun 2014 | B1 |
8755896 | Humayun et al. | Jun 2014 | B2 |
8761889 | Wingeier et al. | Jun 2014 | B2 |
8774922 | Zarins et al. | Jul 2014 | B2 |
8774937 | Mercanzini et al. | Jul 2014 | B2 |
8777942 | Wu et al. | Jul 2014 | B2 |
8781603 | Ye et al. | Jul 2014 | B2 |
8784461 | Webb et al. | Jul 2014 | B2 |
8788064 | Mercanzini et al. | Jul 2014 | B2 |
8788065 | Rezai et al. | Jul 2014 | B2 |
8790338 | Asirvatham et al. | Jul 2014 | B2 |
8798756 | McClure et al. | Aug 2014 | B2 |
8801589 | Peterchev et al. | Aug 2014 | B2 |
8805467 | Yobas et al. | Aug 2014 | B2 |
8805517 | Radivojevic et al. | Aug 2014 | B2 |
8805521 | Carroll | Aug 2014 | B2 |
8821396 | Miles et al. | Sep 2014 | B1 |
8831750 | Ramachandran et al. | Sep 2014 | B2 |
8834545 | Stafford et al. | Sep 2014 | B2 |
8835163 | Zhao et al. | Sep 2014 | B2 |
8843201 | Heldman et al. | Sep 2014 | B1 |
8843204 | Garnham et al. | Sep 2014 | B2 |
8843210 | Simon et al. | Sep 2014 | B2 |
8849412 | Perryman et al. | Sep 2014 | B2 |
8855767 | Faltys et al. | Oct 2014 | B2 |
8862236 | Wolpaw et al. | Oct 2014 | B2 |
8864665 | Rotondo et al. | Oct 2014 | B2 |
8864759 | Godara et al. | Oct 2014 | B2 |
8866621 | Wolfe et al. | Oct 2014 | B2 |
8868164 | Kabakov et al. | Oct 2014 | B2 |
8868172 | Leyde et al. | Oct 2014 | B2 |
8868216 | Dunagan | Oct 2014 | B2 |
8870857 | Seymour et al. | Oct 2014 | B2 |
8874216 | Kim et al. | Oct 2014 | B2 |
8874239 | Greenberg et al. | Oct 2014 | B2 |
8880189 | Lipani | Nov 2014 | B2 |
8886324 | Beuter et al. | Nov 2014 | B2 |
8888773 | Chang et al. | Nov 2014 | B2 |
8892215 | Lipani | Nov 2014 | B2 |
8903494 | Goldwasser et al. | Dec 2014 | B2 |
8903501 | Perryman | Dec 2014 | B2 |
8909343 | Towe | Dec 2014 | B2 |
8909344 | Arle et al. | Dec 2014 | B2 |
8909345 | Danilov et al. | Dec 2014 | B1 |
8912149 | Rawat et al. | Dec 2014 | B1 |
8915846 | Miles et al. | Dec 2014 | B2 |
8915867 | Imran et al. | Dec 2014 | B2 |
8918178 | Simon et al. | Dec 2014 | B2 |
8921473 | Hyman | Dec 2014 | B1 |
8926959 | Deisseroth et al. | Jan 2015 | B2 |
8929990 | Moffitt et al. | Jan 2015 | B2 |
8932196 | Chornenky et al. | Jan 2015 | B2 |
8942797 | Bartol et al. | Jan 2015 | B2 |
8942812 | MacHado et al. | Jan 2015 | B2 |
8942821 | Barolat | Jan 2015 | B2 |
8945004 | Miles et al. | Feb 2015 | B2 |
8945216 | Parker et al. | Feb 2015 | B2 |
8948884 | Ramachandran et al. | Feb 2015 | B2 |
8951193 | Ong et al. | Feb 2015 | B2 |
8954144 | Anderson et al. | Feb 2015 | B2 |
8954150 | Swanson et al. | Feb 2015 | B2 |
8954157 | Faraji et al. | Feb 2015 | B2 |
8954167 | Zarembo et al. | Feb 2015 | B2 |
8956387 | Naghavi et al. | Feb 2015 | B2 |
8958862 | Hetke et al. | Feb 2015 | B2 |
8958883 | Mueller et al. | Feb 2015 | B2 |
8958890 | Kipke et al. | Feb 2015 | B2 |
8965513 | Wingeier et al. | Feb 2015 | B2 |
8969532 | DeFrees et al. | Mar 2015 | B2 |
8972026 | Kipke et al. | Mar 2015 | B2 |
8974402 | Oddsson et al. | Mar 2015 | B2 |
8983593 | Bartol et al. | Mar 2015 | B2 |
8983601 | Fukamachi et al. | Mar 2015 | B2 |
8983628 | Simon et al. | Mar 2015 | B2 |
8983629 | Simon et al. | Mar 2015 | B2 |
8985057 | Woodward | Mar 2015 | B2 |
8986294 | Demarais et al. | Mar 2015 | B2 |
8992522 | Pellegrino et al. | Mar 2015 | B2 |
8996131 | Owen et al. | Mar 2015 | B1 |
8998894 | Mauch et al. | Apr 2015 | B2 |
9002458 | Pal et al. | Apr 2015 | B2 |
9002477 | Burnett | Apr 2015 | B2 |
9005191 | Azamian et al. | Apr 2015 | B2 |
9008784 | Chan et al. | Apr 2015 | B2 |
9014810 | Sauter-Starace et al. | Apr 2015 | B2 |
9014811 | Pal et al. | Apr 2015 | B2 |
9014823 | Simon et al. | Apr 2015 | B2 |
9019106 | Alameh et al. | Apr 2015 | B2 |
9020598 | Simon et al. | Apr 2015 | B2 |
9020612 | Danilov et al. | Apr 2015 | B1 |
9023037 | Zarins et al. | May 2015 | B2 |
9034640 | Matos et al. | May 2015 | B2 |
9037268 | Knight | May 2015 | B2 |
9042958 | Karmarkar et al. | May 2015 | B2 |
9043001 | Simon et al. | May 2015 | B2 |
9044596 | Mahadevan-Jansen et al. | Jun 2015 | B2 |
9044611 | Zhao et al. | Jun 2015 | B2 |
9056197 | Kishawi et al. | Jun 2015 | B2 |
9061097 | Holt et al. | Jun 2015 | B2 |
9061134 | Askin, III et al. | Jun 2015 | B2 |
9061135 | Keller et al. | Jun 2015 | B1 |
9072886 | Gaunt et al. | Jul 2015 | B2 |
9072889 | Guarraia et al. | Jul 2015 | B1 |
9072891 | Rao | Jul 2015 | B1 |
9084550 | Bartol et al. | Jul 2015 | B1 |
9084610 | Goshgarian et al. | Jul 2015 | B2 |
9084895 | Greenberg et al. | Jul 2015 | B2 |
9084900 | Hershey et al. | Jul 2015 | B2 |
9089341 | Chomas et al. | Jul 2015 | B2 |
9089687 | Lee, II et al. | Jul 2015 | B2 |
9089691 | Libbus et al. | Jul 2015 | B2 |
9095267 | Halpern et al. | Aug 2015 | B2 |
9095320 | Littrup et al. | Aug 2015 | B2 |
9095538 | Yu et al. | Aug 2015 | B2 |
9101279 | Ritchey et al. | Aug 2015 | B2 |
9113912 | Mehta et al. | Aug 2015 | B1 |
9114261 | Yonce | Aug 2015 | B2 |
9119628 | Mehta et al. | Sep 2015 | B1 |
9119964 | Marnfeldt | Sep 2015 | B2 |
9126197 | Orwar et al. | Sep 2015 | B2 |
9132058 | Imboden et al. | Sep 2015 | B2 |
9138579 | Wolpaw et al. | Sep 2015 | B2 |
9144677 | Garnham et al. | Sep 2015 | B2 |
9155887 | Miller, III et al. | Oct 2015 | B2 |
9158890 | Meredith et al. | Oct 2015 | B2 |
9162010 | Lenarz et al. | Oct 2015 | B2 |
9162064 | Faltys et al. | Oct 2015 | B2 |
9173585 | Tsampazis et al. | Nov 2015 | B2 |
9179850 | Wingeier et al. | Nov 2015 | B2 |
9179875 | Hua | Nov 2015 | B2 |
9189613 | Tuthill et al. | Nov 2015 | B1 |
9192757 | Seymour | Nov 2015 | B2 |
9192767 | Mercanzini et al. | Nov 2015 | B2 |
9199089 | Perryman et al. | Dec 2015 | B2 |
9205275 | Pan et al. | Dec 2015 | B2 |
9220897 | Perryman et al. | Dec 2015 | B2 |
9220899 | Cattaneo et al. | Dec 2015 | B2 |
9220900 | Libbus et al. | Dec 2015 | B2 |
9221177 | Herr et al. | Dec 2015 | B2 |
9227051 | Fisk et al. | Jan 2016 | B1 |
9227056 | Heldman et al. | Jan 2016 | B1 |
9254382 | Ahmad et al. | Feb 2016 | B2 |
9895546 | Jiang et al. | Feb 2018 | B2 |
20010034477 | Mansfield et al. | Oct 2001 | A1 |
20010055776 | Greenwalt | Dec 2001 | A1 |
20020009461 | Isacson et al. | Jan 2002 | A1 |
20020031497 | Fraser et al. | Mar 2002 | A1 |
20020034819 | Smith et al. | Mar 2002 | A1 |
20020055779 | Andrews | May 2002 | A1 |
20020090722 | Dominko et al. | Jul 2002 | A1 |
20020136705 | Dinsmore | Sep 2002 | A1 |
20020176849 | Slepian | Nov 2002 | A1 |
20030002297 | Nemtsev | Jan 2003 | A1 |
20030004547 | Owen et al. | Jan 2003 | A1 |
20030049328 | Dalal et al. | Mar 2003 | A1 |
20030088274 | Gliner et al. | May 2003 | A1 |
20030097161 | Firlik et al. | May 2003 | A1 |
20030100367 | Cooke | May 2003 | A1 |
20030104993 | Rueger et al. | Jun 2003 | A1 |
20030109901 | Greatbatch | Jun 2003 | A1 |
20030125786 | Gliner et al. | Jul 2003 | A1 |
20030149450 | Mayberg | Aug 2003 | A1 |
20030157712 | Daniel et al. | Aug 2003 | A1 |
20030195441 | Firouzgar | Oct 2003 | A1 |
20030198664 | Sullivan et al. | Oct 2003 | A1 |
20030232055 | Medzhitov | Dec 2003 | A1 |
20040005291 | Rogers et al. | Jan 2004 | A1 |
20040014662 | Lindquist et al. | Jan 2004 | A1 |
20040028613 | Quay | Feb 2004 | A1 |
20040030365 | Rubin | Feb 2004 | A1 |
20040038888 | Mercer et al. | Feb 2004 | A1 |
20040048279 | Olek et al. | Mar 2004 | A1 |
20040048373 | Gage et al. | Mar 2004 | A1 |
20040049134 | Tosaya et al. | Mar 2004 | A1 |
20040054300 | Hung et al. | Mar 2004 | A1 |
20040062755 | Smith et al. | Apr 2004 | A1 |
20040064052 | Chance et al. | Apr 2004 | A1 |
20040081652 | Zack et al. | Apr 2004 | A1 |
20040093093 | Andrews | May 2004 | A1 |
20040097401 | Datta | May 2004 | A1 |
20040097839 | Epley | May 2004 | A1 |
20040102525 | Kozachuk | May 2004 | A1 |
20040106966 | Scribner et al. | Jun 2004 | A1 |
20040121464 | Rathjen et al. | Jun 2004 | A1 |
20040143170 | DuRousseau | Jul 2004 | A1 |
20040147975 | Popovic et al. | Jul 2004 | A1 |
20040156826 | Dangond et al. | Aug 2004 | A1 |
20040162583 | Bingham et al. | Aug 2004 | A1 |
20040172100 | Humayun et al. | Sep 2004 | A1 |
20040172102 | Leysieffer | Sep 2004 | A1 |
20040185557 | Smith et al. | Sep 2004 | A1 |
20040199235 | Younis | Oct 2004 | A1 |
20040212504 | Forcier et al. | Oct 2004 | A1 |
20040219184 | Brown et al. | Nov 2004 | A1 |
20040228831 | Belinka et al. | Nov 2004 | A1 |
20040229702 | Cooke | Nov 2004 | A1 |
20040230226 | Bingham et al. | Nov 2004 | A1 |
20040243021 | Murphy et al. | Dec 2004 | A1 |
20050003998 | Bertilsson et al. | Jan 2005 | A1 |
20050015133 | Ibrahim et al. | Jan 2005 | A1 |
20050020519 | Albiston et al. | Jan 2005 | A1 |
20050020945 | Tosaya et al. | Jan 2005 | A1 |
20050038473 | Tamarkin et al. | Feb 2005 | A1 |
20050054096 | Piniella | Mar 2005 | A1 |
20050054907 | Page et al. | Mar 2005 | A1 |
20050070819 | Poux et al. | Mar 2005 | A1 |
20050073649 | Spector | Apr 2005 | A1 |
20050107859 | Daglow et al. | May 2005 | A1 |
20050125044 | Tracey | Jun 2005 | A1 |
20050165323 | Montgomery et al. | Jul 2005 | A1 |
20050203366 | Donoghue et al. | Sep 2005 | A1 |
20050203601 | Palanker et al. | Sep 2005 | A1 |
20050222631 | Dalal et al. | Oct 2005 | A1 |
20050226852 | Toda et al. | Oct 2005 | A1 |
20050234370 | Beal et al. | Oct 2005 | A1 |
20050267552 | Conquergood et al. | Dec 2005 | A1 |
20050272097 | Calenoff | Dec 2005 | A1 |
20050273890 | Flaherty et al. | Dec 2005 | A1 |
20050277918 | Shah et al. | Dec 2005 | A1 |
20060034767 | Lum et al. | Feb 2006 | A1 |
20060047326 | Wheeler | Mar 2006 | A1 |
20060049950 | Lockhart | Mar 2006 | A1 |
20060049957 | Surgenor et al. | Mar 2006 | A1 |
20060058627 | Flaherty et al. | Mar 2006 | A1 |
20060118035 | Lasater | Jun 2006 | A1 |
20060122458 | Bleich | Jun 2006 | A1 |
20060122529 | Tsau | Jun 2006 | A1 |
20060122864 | Gottesman et al. | Jun 2006 | A1 |
20060140930 | Rodriguez et al. | Jun 2006 | A1 |
20060149345 | Boggs et al. | Jul 2006 | A1 |
20060161225 | Sormann et al. | Jul 2006 | A1 |
20060167498 | DiLorenzo | Jul 2006 | A1 |
20060167564 | Flaherty et al. | Jul 2006 | A1 |
20060171933 | Short | Aug 2006 | A1 |
20060184219 | Pajunk et al. | Aug 2006 | A1 |
20060190056 | Fowler et al. | Aug 2006 | A1 |
20060195146 | Tracey et al. | Aug 2006 | A1 |
20060195153 | Diubaldi et al. | Aug 2006 | A1 |
20060206167 | Flaherty et al. | Sep 2006 | A1 |
20060206178 | Kim | Sep 2006 | A1 |
20060234376 | Mistry et al. | Oct 2006 | A1 |
20060263336 | Caplan | Nov 2006 | A1 |
20060265037 | Kuzma | Nov 2006 | A1 |
20060281130 | Bock et al. | Dec 2006 | A1 |
20070005106 | Adducci | Jan 2007 | A1 |
20070021803 | Deem et al. | Jan 2007 | A1 |
20070043591 | Meretei et al. | Feb 2007 | A1 |
20070049814 | Muccio | Mar 2007 | A1 |
20070049842 | Hill et al. | Mar 2007 | A1 |
20070067004 | Boveja et al. | Mar 2007 | A1 |
20070073361 | Goren et al. | Mar 2007 | A1 |
20070088335 | Jolly | Apr 2007 | A1 |
20070100393 | Whitehurst et al. | May 2007 | A1 |
20070102009 | Wong et al. | May 2007 | A1 |
20070107071 | Couillard-Despres | May 2007 | A1 |
20070123778 | Kantorovich | May 2007 | A1 |
20070129769 | Bourget et al. | Jun 2007 | A1 |
20070134657 | Poznansky et al. | Jun 2007 | A1 |
20070135846 | Knudson et al. | Jun 2007 | A1 |
20070165322 | Strom et al. | Jul 2007 | A1 |
20070173893 | Pitts | Jul 2007 | A1 |
20070173903 | Goren et al. | Jul 2007 | A1 |
20070179558 | Gliner et al. | Aug 2007 | A1 |
20070180542 | Brinster et al. | Aug 2007 | A1 |
20070192881 | Brinster et al. | Aug 2007 | A1 |
20070203533 | Goren et al. | Aug 2007 | A1 |
20070208385 | Carroll et al. | Sep 2007 | A1 |
20070219074 | Pride | Sep 2007 | A1 |
20070239211 | Lorincz et al. | Oct 2007 | A1 |
20070249952 | Rubin et al. | Oct 2007 | A1 |
20070276449 | Gunter et al. | Nov 2007 | A1 |
20070282396 | Overstreet et al. | Dec 2007 | A1 |
20070287613 | Adducci | Dec 2007 | A1 |
20070293893 | Stolen et al. | Dec 2007 | A1 |
20070299483 | Strother et al. | Dec 2007 | A1 |
20080002276 | Strom et al. | Jan 2008 | A1 |
20080033520 | Jolly | Feb 2008 | A1 |
20080040951 | Kates | Feb 2008 | A1 |
20080057028 | Alitalo et al. | Mar 2008 | A1 |
20080064946 | Greenberg et al. | Mar 2008 | A1 |
20080071321 | Boggs et al. | Mar 2008 | A1 |
20080074794 | Lee et al. | Mar 2008 | A1 |
20080077192 | Harry et al. | Mar 2008 | A1 |
20080095747 | Rutishauser et al. | Apr 2008 | A1 |
20080097530 | Muccio et al. | Apr 2008 | A1 |
20080120029 | Zelek et al. | May 2008 | A1 |
20080125870 | Carmichael et al. | May 2008 | A1 |
20080133016 | Heinz | Jun 2008 | A1 |
20080139907 | Rao et al. | Jun 2008 | A1 |
20080154335 | Thrope et al. | Jun 2008 | A1 |
20080161879 | Firlik et al. | Jul 2008 | A1 |
20080161882 | Firlik et al. | Jul 2008 | A1 |
20080161887 | Hagen | Jul 2008 | A1 |
20080170234 | Kim | Jul 2008 | A1 |
20080170316 | Kim | Jul 2008 | A1 |
20080195163 | Scharmer | Aug 2008 | A1 |
20080200967 | Ponomarev et al. | Aug 2008 | A1 |
20080208280 | Lindenthaler et al. | Aug 2008 | A1 |
20080215112 | Firlik et al. | Sep 2008 | A1 |
20080221653 | Agrawal et al. | Sep 2008 | A1 |
20080241208 | Shanley et al. | Oct 2008 | A1 |
20080242607 | DeFrees | Oct 2008 | A1 |
20080243218 | Bottomley et al. | Oct 2008 | A1 |
20080248959 | DeFrees | Oct 2008 | A1 |
20080249439 | Tracey et al. | Oct 2008 | A1 |
20080253992 | DeFrees et al. | Oct 2008 | A1 |
20080255582 | Harris | Oct 2008 | A1 |
20080262557 | Brown | Oct 2008 | A1 |
20080262584 | Bottomley et al. | Oct 2008 | A1 |
20080274958 | DeFrees | Nov 2008 | A1 |
20080275546 | Storey et al. | Nov 2008 | A1 |
20080280818 | DeFrees | Nov 2008 | A1 |
20080312538 | Shahar et al. | Dec 2008 | A1 |
20080318314 | Fulga et al. | Dec 2008 | A1 |
20090012586 | Kepecs | Jan 2009 | A1 |
20090012590 | Inman et al. | Jan 2009 | A1 |
20090029912 | Gronthos et al. | Jan 2009 | A1 |
20090036938 | Shipley et al. | Feb 2009 | A1 |
20090054800 | Martinerie et al. | Feb 2009 | A1 |
20090054950 | Stephens | Feb 2009 | A1 |
20090076421 | Grant | Mar 2009 | A1 |
20090076444 | Machado et al. | Mar 2009 | A1 |
20090086015 | Larsen et al. | Apr 2009 | A1 |
20090105149 | Albrechtsen et al. | Apr 2009 | A1 |
20090112278 | Wingeier et al. | Apr 2009 | A1 |
20090112279 | Wingeier et al. | Apr 2009 | A1 |
20090118788 | Firlik et al. | May 2009 | A1 |
20090124965 | Greenberg et al. | May 2009 | A1 |
20090131995 | Sloan et al. | May 2009 | A1 |
20090132018 | DiUbaldi et al. | May 2009 | A1 |
20090149782 | Cohen | Jun 2009 | A1 |
20090149900 | Moffitt et al. | Jun 2009 | A1 |
20090157091 | Buysman | Jun 2009 | A1 |
20090171381 | Schmitz et al. | Jul 2009 | A1 |
20090182393 | Bachinski | Jul 2009 | A1 |
20090201671 | Huntley | Aug 2009 | A1 |
20090214474 | Jennings | Aug 2009 | A1 |
20090215896 | Morseman et al. | Aug 2009 | A1 |
20090220466 | Ratajczak et al. | Sep 2009 | A1 |
20090226598 | Feng et al. | Sep 2009 | A1 |
20090227025 | Nichols et al. | Sep 2009 | A1 |
20090227965 | Wijesiriwardana | Sep 2009 | A1 |
20090234265 | Reid et al. | Sep 2009 | A1 |
20090258048 | Ward et al. | Oct 2009 | A1 |
20090270958 | Greenberg et al. | Oct 2009 | A1 |
20090292338 | Gordon et al. | Nov 2009 | A1 |
20090299439 | Mire et al. | Dec 2009 | A1 |
20090306728 | Wright et al. | Dec 2009 | A1 |
20090306745 | Parker et al. | Dec 2009 | A1 |
20090326612 | Distler | Dec 2009 | A1 |
20100004654 | Schmitz et al. | Jan 2010 | A1 |
20100010550 | Ponomarev et al. | Jan 2010 | A1 |
20100016732 | Wells et al. | Jan 2010 | A1 |
20100035299 | DeFrees et al. | Feb 2010 | A1 |
20100037755 | McMillen et al. | Feb 2010 | A1 |
20100042180 | Mueller et al. | Feb 2010 | A1 |
20100042185 | Curtis | Feb 2010 | A1 |
20100045595 | Bakke | Feb 2010 | A1 |
20100047915 | Soykan et al. | Feb 2010 | A1 |
20100092983 | Liew | Apr 2010 | A1 |
20100092984 | Liew | Apr 2010 | A1 |
20100094311 | Jolly et al. | Apr 2010 | A1 |
20100099786 | Dias et al. | Apr 2010 | A1 |
20100112026 | Karp et al. | May 2010 | A1 |
20100114195 | Burnes et al. | May 2010 | A1 |
20100124745 | Liew | May 2010 | A1 |
20100124746 | Liew | May 2010 | A1 |
20100145427 | Gliner et al. | Jun 2010 | A1 |
20100168739 | Wu et al. | Jul 2010 | A1 |
20100179284 | Ward et al. | Jul 2010 | A1 |
20100185042 | Schneider et al. | Jul 2010 | A1 |
20100189712 | Heureux et al. | Jul 2010 | A1 |
20100203520 | Liew | Aug 2010 | A1 |
20100204538 | Burnett et al. | Aug 2010 | A1 |
20100204777 | Storey et al. | Aug 2010 | A1 |
20100211172 | Bellamkonda et al. | Aug 2010 | A1 |
20100222630 | Mangrum et al. | Sep 2010 | A1 |
20100222844 | Troosters et al. | Sep 2010 | A1 |
20100241195 | Meadows et al. | Sep 2010 | A1 |
20100268055 | Jung et al. | Oct 2010 | A1 |
20100268125 | Epley | Oct 2010 | A9 |
20100280570 | Sturm et al. | Nov 2010 | A1 |
20100280571 | Sloan | Nov 2010 | A1 |
20100286067 | DeFrees | Nov 2010 | A1 |
20100292759 | Hahn et al. | Nov 2010 | A1 |
20100298916 | Rabischong et al. | Nov 2010 | A1 |
20100304864 | Johnson et al. | Dec 2010 | A1 |
20100305674 | Zarembo et al. | Dec 2010 | A1 |
20100310529 | Aizman | Dec 2010 | A1 |
20100324355 | Spitaels et al. | Dec 2010 | A1 |
20100324626 | Lefkovitz | Dec 2010 | A1 |
20110009959 | Tiedtke | Jan 2011 | A1 |
20110014189 | Soula et al. | Jan 2011 | A1 |
20110022105 | Owen et al. | Jan 2011 | A9 |
20110022131 | Giuliano | Jan 2011 | A1 |
20110028345 | Fang et al. | Feb 2011 | A1 |
20110040204 | Ivorra et al. | Feb 2011 | A1 |
20110040349 | Graupe | Feb 2011 | A1 |
20110059447 | Liew | Mar 2011 | A1 |
20110060266 | Streeter et al. | Mar 2011 | A1 |
20110082531 | Swanson et al. | Apr 2011 | A1 |
20110092863 | Kim et al. | Apr 2011 | A1 |
20110098777 | Silverstone | Apr 2011 | A1 |
20110106207 | Cauller et al. | May 2011 | A1 |
20110106219 | Cauller et al. | May 2011 | A1 |
20110112352 | Pilla et al. | May 2011 | A1 |
20110118556 | Siegel et al. | May 2011 | A1 |
20110124959 | Murison | May 2011 | A1 |
20110137189 | Kuo et al. | Jun 2011 | A1 |
20110158444 | Waldmann | Jun 2011 | A1 |
20110177029 | DeFrees | Jul 2011 | A1 |
20110184269 | Sauter-Starace et al. | Jul 2011 | A1 |
20110190882 | Parker et al. | Aug 2011 | A1 |
20110195106 | McMurtrey | Aug 2011 | A1 |
20110196454 | Strand et al. | Aug 2011 | A1 |
20110202120 | Ball et al. | Aug 2011 | A1 |
20110208226 | Fatone et al. | Aug 2011 | A1 |
20110218593 | Rubinstein et al. | Sep 2011 | A1 |
20110224565 | Ong et al. | Sep 2011 | A1 |
20110224754 | Wei | Sep 2011 | A1 |
20110257501 | Huys et al. | Oct 2011 | A1 |
20110257504 | Hendricks et al. | Oct 2011 | A1 |
20110262501 | Webster et al. | Oct 2011 | A1 |
20110264178 | Mehregany et al. | Oct 2011 | A1 |
20110268776 | Schapira et al. | Nov 2011 | A1 |
20110270345 | Johnston et al. | Nov 2011 | A1 |
20110270361 | Borsody | Nov 2011 | A1 |
20110295156 | Arturi | Dec 2011 | A1 |
20110301662 | Bar-Yoseph et al. | Dec 2011 | A1 |
20110313270 | Neves et al. | Dec 2011 | A1 |
20110319703 | Wiskerke et al. | Dec 2011 | A1 |
20120016431 | Paul et al. | Jan 2012 | A1 |
20120016440 | Muccio | Jan 2012 | A1 |
20120022616 | Garnham et al. | Jan 2012 | A1 |
20120035684 | Thompson et al. | Feb 2012 | A1 |
20120045487 | Lahann et al. | Feb 2012 | A1 |
20120046702 | Gibson | Feb 2012 | A1 |
20120059389 | Larson et al. | Mar 2012 | A1 |
20120064628 | Blick et al. | Mar 2012 | A1 |
20120076830 | Sitharaman et al. | Mar 2012 | A1 |
20120078327 | Sloan et al. | Mar 2012 | A1 |
20120089047 | Ryba et al. | Apr 2012 | A1 |
20120095166 | Ward et al. | Apr 2012 | A1 |
20120095524 | Nelson et al. | Apr 2012 | A1 |
20120101326 | Simon et al. | Apr 2012 | A1 |
20120101413 | Beetel et al. | Apr 2012 | A1 |
20120109233 | Lee et al. | May 2012 | A1 |
20120123508 | Wentz et al. | May 2012 | A1 |
20120124470 | West et al. | May 2012 | A1 |
20120130360 | Buckley et al. | May 2012 | A1 |
20120134965 | Kim et al. | May 2012 | A1 |
20120136232 | Jeong et al. | May 2012 | A1 |
20120143293 | Mauch et al. | Jun 2012 | A1 |
20120158095 | Jolly | Jun 2012 | A1 |
20120158104 | Huynh et al. | Jun 2012 | A1 |
20120158113 | Jolly et al. | Jun 2012 | A1 |
20120158114 | Debruyne et al. | Jun 2012 | A1 |
20120179076 | Bavelier et al. | Jul 2012 | A1 |
20120185173 | Yamamoto et al. | Jul 2012 | A1 |
20120191052 | Rao | Jul 2012 | A1 |
20120191086 | Moll et al. | Jul 2012 | A1 |
20120197092 | Luo et al. | Aug 2012 | A1 |
20120197252 | Deem et al. | Aug 2012 | A1 |
20120197374 | Vogt et al. | Aug 2012 | A1 |
20120214737 | Marchionni | Aug 2012 | A1 |
20120221072 | Fukamachi et al. | Aug 2012 | A1 |
20120226331 | Banna et al. | Sep 2012 | A1 |
20120237557 | Lewitus et al. | Sep 2012 | A1 |
20120238924 | Avni | Sep 2012 | A1 |
20120239363 | Durrani et al. | Sep 2012 | A1 |
20120244503 | Neveldine | Sep 2012 | A1 |
20120245534 | Jolly | Sep 2012 | A1 |
20120253236 | Snow et al. | Oct 2012 | A1 |
20120259255 | Tomlinson et al. | Oct 2012 | A1 |
20120259390 | Canion | Oct 2012 | A1 |
20120277825 | Mawson et al. | Nov 2012 | A1 |
20120277842 | Kunis | Nov 2012 | A1 |
20120282228 | Bhasin | Nov 2012 | A1 |
20120283800 | Perryman et al. | Nov 2012 | A1 |
20120296191 | McGrath et al. | Nov 2012 | A1 |
20120296230 | Davis et al. | Nov 2012 | A1 |
20120296444 | Greenberg et al. | Nov 2012 | A1 |
20120302856 | Chang et al. | Nov 2012 | A1 |
20120310140 | Kramer et al. | Dec 2012 | A1 |
20120323288 | Anderson et al. | Dec 2012 | A1 |
20130012831 | Schmitz et al. | Jan 2013 | A1 |
20130018240 | McCoy | Jan 2013 | A1 |
20130018444 | Glenn et al. | Jan 2013 | A1 |
20130035745 | Ahmed et al. | Feb 2013 | A1 |
20130041432 | Tucker et al. | Feb 2013 | A1 |
20130052712 | Cha et al. | Feb 2013 | A1 |
20130053853 | Schmitz et al. | Feb 2013 | A1 |
20130053934 | Gluckman et al. | Feb 2013 | A1 |
20130066147 | Brown | Mar 2013 | A1 |
20130066216 | Park | Mar 2013 | A1 |
20130066391 | Hulvershorn et al. | Mar 2013 | A1 |
20130066392 | Simon et al. | Mar 2013 | A1 |
20130066395 | Simon et al. | Mar 2013 | A1 |
20130072808 | Neves et al. | Mar 2013 | A1 |
20130072835 | Harry et al. | Mar 2013 | A1 |
20130090542 | Kipke et al. | Apr 2013 | A1 |
20130090711 | Ramachandran et al. | Apr 2013 | A1 |
20130101635 | Park et al. | Apr 2013 | A1 |
20130116685 | Deem et al. | May 2013 | A1 |
20130116744 | Blum et al. | May 2013 | A1 |
20130122528 | Tyrell et al. | May 2013 | A1 |
20130123568 | Hamilton et al. | May 2013 | A1 |
20130123570 | Ly et al. | May 2013 | A1 |
20130131743 | Yamasaki et al. | May 2013 | A1 |
20130131753 | Simon et al. | May 2013 | A1 |
20130137955 | Kong et al. | May 2013 | A1 |
20130144143 | Kim et al. | Jun 2013 | A1 |
20130144369 | Elias et al. | Jun 2013 | A1 |
20130144370 | Debruyne et al. | Jun 2013 | A1 |
20130150653 | Borsody | Jun 2013 | A1 |
20130154838 | Alameh et al. | Jun 2013 | A1 |
20130157229 | Lauritzen et al. | Jun 2013 | A1 |
20130178765 | Mishelevich | Jul 2013 | A1 |
20130184792 | Simon et al. | Jul 2013 | A1 |
20130184795 | Kipke et al. | Jul 2013 | A1 |
20130184799 | Kipke et al. | Jul 2013 | A1 |
20130204122 | Hendler et al. | Aug 2013 | A1 |
20130204317 | Sauter-Starace et al. | Aug 2013 | A1 |
20130210041 | Anderberg et al. | Aug 2013 | A1 |
20130218456 | Zelek et al. | Aug 2013 | A1 |
20130231725 | Williams et al. | Sep 2013 | A1 |
20130238066 | Joseph et al. | Sep 2013 | A1 |
20130238074 | Zimmerling | Sep 2013 | A1 |
20130245480 | Crockford | Sep 2013 | A1 |
20130245486 | Simon et al. | Sep 2013 | A1 |
20130245711 | Simon et al. | Sep 2013 | A1 |
20130245712 | Simon et al. | Sep 2013 | A1 |
20130245717 | Stohl et al. | Sep 2013 | A1 |
20130245765 | Lowry et al. | Sep 2013 | A1 |
20130248226 | Sime et al. | Sep 2013 | A1 |
20130253299 | Weber et al. | Sep 2013 | A1 |
20130274540 | Pilla et al. | Oct 2013 | A1 |
20130274658 | Steinke et al. | Oct 2013 | A1 |
20130274842 | Gaunt et al. | Oct 2013 | A1 |
20130280233 | Kahn et al. | Oct 2013 | A1 |
20130282001 | Hezi-Yamit et al. | Oct 2013 | A1 |
20130282090 | Decré et al. | Oct 2013 | A1 |
20130288233 | Murray | Oct 2013 | A1 |
20130289678 | Clark et al. | Oct 2013 | A1 |
20130289686 | Masson et al. | Oct 2013 | A1 |
20130296767 | Zarins et al. | Nov 2013 | A1 |
20130309278 | Peyman | Nov 2013 | A1 |
20130310909 | Simon et al. | Nov 2013 | A1 |
20130317400 | Ferezy | Nov 2013 | A1 |
20130317580 | Simon et al. | Nov 2013 | A1 |
20130324994 | Pellegrino et al. | Dec 2013 | A1 |
20130331869 | Runge et al. | Dec 2013 | A1 |
20130338729 | Spector | Dec 2013 | A1 |
20130341185 | Collaert et al. | Dec 2013 | A1 |
20140003696 | Taghva | Jan 2014 | A1 |
20140018792 | Gang et al. | Jan 2014 | A1 |
20140022162 | Yu et al. | Jan 2014 | A1 |
20140023999 | Greder | Jan 2014 | A1 |
20140024981 | Chun et al. | Jan 2014 | A1 |
20140025301 | Storm et al. | Jan 2014 | A1 |
20140030735 | Merali et al. | Jan 2014 | A1 |
20140046423 | Rajguru et al. | Feb 2014 | A1 |
20140051938 | Goldstein et al. | Feb 2014 | A1 |
20140058481 | Perryman et al. | Feb 2014 | A1 |
20140058483 | Zao et al. | Feb 2014 | A1 |
20140066924 | Azamian et al. | Mar 2014 | A1 |
20140073883 | Rao et al. | Mar 2014 | A1 |
20140074186 | Faltys et al. | Mar 2014 | A1 |
20140081682 | Perlmuter | Mar 2014 | A1 |
20140094674 | Nurmikko et al. | Apr 2014 | A1 |
20140099352 | Matheny | Apr 2014 | A1 |
20140107397 | Simon et al. | Apr 2014 | A1 |
20140107398 | Simon et al. | Apr 2014 | A1 |
20140114168 | Block et al. | Apr 2014 | A1 |
20140127171 | Nocera et al. | May 2014 | A1 |
20140128939 | Embrey et al. | May 2014 | A1 |
20140135607 | Lee et al. | May 2014 | A1 |
20140135680 | Peyman | May 2014 | A1 |
20140142374 | Makower et al. | May 2014 | A1 |
20140148649 | Miles et al. | May 2014 | A1 |
20140148871 | Southwell et al. | May 2014 | A1 |
20140148872 | Goldwasser et al. | May 2014 | A1 |
20140155811 | Gibson | Jun 2014 | A1 |
20140155973 | Grigsby et al. | Jun 2014 | A1 |
20140163580 | Tischendorf et al. | Jun 2014 | A1 |
20140163641 | Yao et al. | Jun 2014 | A1 |
20140163658 | Faraji et al. | Jun 2014 | A1 |
20140171807 | Akkin et al. | Jun 2014 | A1 |
20140180036 | Bukkapatnam et al. | Jun 2014 | A1 |
20140180196 | Stone et al. | Jun 2014 | A1 |
20140180365 | Perryman et al. | Jun 2014 | A1 |
20140187872 | Stivoric et al. | Jul 2014 | A1 |
20140197937 | Huang et al. | Jul 2014 | A1 |
20140200432 | Banerji et al. | Jul 2014 | A1 |
20140200466 | Sereno et al. | Jul 2014 | A1 |
20140200496 | Hyde et al. | Jul 2014 | A1 |
20140200681 | Kennedy et al. | Jul 2014 | A1 |
20140206947 | Isserow et al. | Jul 2014 | A1 |
20140207292 | Ramagem et al. | Jul 2014 | A1 |
20140213842 | Simon et al. | Jul 2014 | A1 |
20140213971 | Dolan et al. | Jul 2014 | A1 |
20140220555 | Chen et al. | Aug 2014 | A1 |
20140222125 | Glenn et al. | Aug 2014 | A1 |
20140225763 | Kavaler et al. | Aug 2014 | A1 |
20140228901 | Vogt | Aug 2014 | A1 |
20140228926 | Santina et al. | Aug 2014 | A1 |
20140235950 | Miles et al. | Aug 2014 | A1 |
20140236249 | Rao et al. | Aug 2014 | A1 |
20140236847 | Hamilton | Aug 2014 | A1 |
20140243616 | Johnson | Aug 2014 | A1 |
20140243932 | Libbus et al. | Aug 2014 | A1 |
20140249395 | Zhou et al. | Sep 2014 | A1 |
20140255461 | McMurtrey | Sep 2014 | A9 |
20140257063 | Ong et al. | Sep 2014 | A1 |
20140257437 | Simon et al. | Sep 2014 | A1 |
20140267123 | Ludwig | Sep 2014 | A1 |
20140275737 | Shore et al. | Sep 2014 | A1 |
20140276718 | Turovskiy et al. | Sep 2014 | A1 |
20140276760 | Bonyak et al. | Sep 2014 | A1 |
20140277031 | Ballakur et al. | Sep 2014 | A1 |
20140277033 | Taylor et al. | Sep 2014 | A1 |
20140277220 | Brennan et al. | Sep 2014 | A1 |
20140277237 | Maskara et al. | Sep 2014 | A1 |
20140277271 | Chan et al. | Sep 2014 | A1 |
20140277310 | Beetel et al. | Sep 2014 | A1 |
20140277582 | Leuthardt et al. | Sep 2014 | A1 |
20140288379 | Miles et al. | Sep 2014 | A1 |
20140296646 | Wingeier et al. | Oct 2014 | A1 |
20140300490 | Kotz et al. | Oct 2014 | A1 |
20140303525 | Sitharaman | Oct 2014 | A1 |
20140303548 | Jolly et al. | Oct 2014 | A1 |
20140304773 | Woods et al. | Oct 2014 | A1 |
20140309548 | Merz et al. | Oct 2014 | A1 |
20140316398 | Kelly et al. | Oct 2014 | A1 |
20140320289 | Raichman | Oct 2014 | A1 |
20140330337 | Linke et al. | Nov 2014 | A1 |
20140336631 | Wu et al. | Nov 2014 | A1 |
20140336722 | Lima et al. | Nov 2014 | A1 |
20140350041 | Yun et al. | Nov 2014 | A1 |
20140350633 | Gustafson et al. | Nov 2014 | A1 |
20140357453 | Tamanaha | Dec 2014 | A1 |
20140357933 | Lee et al. | Dec 2014 | A1 |
20140360511 | Mohler | Dec 2014 | A1 |
20140371547 | Gartenberg et al. | Dec 2014 | A1 |
20140371564 | Anikeeva et al. | Dec 2014 | A1 |
20140371622 | Hausman et al. | Dec 2014 | A1 |
20140375457 | Diaz | Dec 2014 | A1 |
20140378779 | Freeman et al. | Dec 2014 | A1 |
20140378789 | McKinley et al. | Dec 2014 | A1 |
20140378946 | Thompson et al. | Dec 2014 | A1 |
20140379045 | Rahimi et al. | Dec 2014 | A1 |
20140379049 | Mashiach et al. | Dec 2014 | A1 |
20150005607 | Cui et al. | Jan 2015 | A1 |
20150005680 | Lipani | Jan 2015 | A1 |
20150005840 | Pal et al. | Jan 2015 | A1 |
20150005841 | Pal et al. | Jan 2015 | A1 |
20150005851 | Bradley | Jan 2015 | A1 |
20150010607 | Francis et al. | Jan 2015 | A1 |
20150012079 | Goroszeniuk et al. | Jan 2015 | A1 |
20150016647 | Martinez et al. | Jan 2015 | A1 |
20150017140 | Bhatia et al. | Jan 2015 | A1 |
20150018659 | Ware et al. | Jan 2015 | A1 |
20150032044 | Peyman | Jan 2015 | A9 |
20150032178 | Simon et al. | Jan 2015 | A1 |
20150032184 | Muccio | Jan 2015 | A1 |
20150038886 | Snow | Feb 2015 | A1 |
20150039055 | Wagner et al. | Feb 2015 | A1 |
20150049325 | Curtis | Feb 2015 | A1 |
20150051439 | Hillbratt et al. | Feb 2015 | A1 |
20150051684 | Greenberg et al. | Feb 2015 | A1 |
20150057736 | Zachar | Feb 2015 | A1 |
20150059390 | Hayes | Mar 2015 | A1 |
20150062018 | Naidu et al. | Mar 2015 | A1 |
20150066126 | Marx et al. | Mar 2015 | A1 |
20150067422 | Hamilton | Mar 2015 | A1 |
20150073232 | Ahmad et al. | Mar 2015 | A1 |
20150073520 | Strahl et al. | Mar 2015 | A1 |
20150080709 | Chaturvedi | Mar 2015 | A1 |
20150080926 | Emery | Mar 2015 | A1 |
20150088030 | Taylor | Mar 2015 | A1 |
20150088223 | Blum et al. | Mar 2015 | A1 |
20150088224 | Goldwasser et al. | Mar 2015 | A1 |
20150088225 | Noble et al. | Mar 2015 | A1 |
20150102925 | Foldyna et al. | Apr 2015 | A1 |
20150105794 | Dhanasingh et al. | Apr 2015 | A1 |
20150105795 | Lenarz et al. | Apr 2015 | A1 |
20150112234 | McCaffrey et al. | Apr 2015 | A1 |
20150112321 | Cadouri | Apr 2015 | A1 |
20150112359 | Gillbe | Apr 2015 | A1 |
20150112360 | Pellinen et al. | Apr 2015 | A1 |
20150112404 | Holding et al. | Apr 2015 | A1 |
20150112405 | Brown et al. | Apr 2015 | A1 |
20150112408 | Kals | Apr 2015 | A1 |
20150119673 | Pellinen et al. | Apr 2015 | A1 |
20150119790 | Moffitt et al. | Apr 2015 | A1 |
20150119954 | Bhadra et al. | Apr 2015 | A2 |
20150119989 | Pimenta et al. | Apr 2015 | A1 |
20150126997 | Beetel et al. | May 2015 | A1 |
20150133761 | Vetter et al. | May 2015 | A1 |
20150133956 | Dayan et al. | May 2015 | A1 |
20150135840 | Sato et al. | May 2015 | A1 |
20150148643 | Small et al. | May 2015 | A1 |
20150148644 | Vaidyanathan et al. | May 2015 | A1 |
20150148736 | Jolly et al. | May 2015 | A1 |
20150148869 | Alan et al. | May 2015 | A1 |
20150148878 | Yoo et al. | May 2015 | A1 |
20150150508 | Glenn et al. | Jun 2015 | A1 |
20150157398 | Zarins et al. | Jun 2015 | A1 |
20150157851 | Sefkow et al. | Jun 2015 | A1 |
20150157854 | Hetke et al. | Jun 2015 | A1 |
20150157862 | Greenberg et al. | Jun 2015 | A1 |
20150164360 | Kipke et al. | Jun 2015 | A1 |
20150164401 | Toth et al. | Jun 2015 | A1 |
20150173673 | Toth et al. | Jun 2015 | A1 |
20150173918 | Herr et al. | Jun 2015 | A1 |
20150174403 | Pal et al. | Jun 2015 | A1 |
20150174418 | Tyler et al. | Jun 2015 | A1 |
20150182753 | Harris et al. | Jul 2015 | A1 |
20150190635 | Neuvonen et al. | Jul 2015 | A1 |
20150190636 | Simon et al. | Jul 2015 | A1 |
20150190637 | Simon et al. | Jul 2015 | A1 |
20150196767 | Ahmed | Jul 2015 | A1 |
20150201855 | Pellinen et al. | Jul 2015 | A1 |
20150202331 | Blumenfeld et al. | Jul 2015 | A1 |
20150202437 | Franke et al. | Jul 2015 | A1 |
20150209104 | Tran et al. | Jul 2015 | A1 |
20150209577 | Golestanirad et al. | Jul 2015 | A1 |
20150209586 | Silva et al. | Jul 2015 | A1 |
20150217125 | Chornenky et al. | Aug 2015 | A1 |
20150223731 | Sahin | Aug 2015 | A1 |
20150224300 | Hagr et al. | Aug 2015 | A1 |
20150224330 | Kaib et al. | Aug 2015 | A1 |
20150230749 | Gharib et al. | Aug 2015 | A1 |
20150231396 | Burdick et al. | Aug 2015 | A1 |
20150235529 | Deschamps | Aug 2015 | A1 |
20150238104 | Tass | Aug 2015 | A1 |
20150238253 | Wu et al. | Aug 2015 | A1 |
20150238764 | Franke | Aug 2015 | A1 |
20150246072 | Bhatia et al. | Sep 2015 | A1 |
20150248470 | Coleman et al. | Sep 2015 | A1 |
20150251004 | Imran et al. | Sep 2015 | A1 |
20150254992 | Sethi | Sep 2015 | A1 |
20150257824 | Mauch | Sep 2015 | A1 |
20150272805 | Burnett et al. | Oct 2015 | A1 |
20150273206 | Monteiro | Oct 2015 | A1 |
20150283365 | Dacey et al. | Oct 2015 | A1 |
20150284416 | Zhao | Oct 2015 | A1 |
20150290439 | Eldredge et al. | Oct 2015 | A1 |
20150290450 | Kolb et al. | Oct 2015 | A1 |
20150290464 | Monteiro | Oct 2015 | A1 |
20150290472 | Maguire et al. | Oct 2015 | A1 |
20150297104 | Chen et al. | Oct 2015 | A1 |
20150297444 | Tass | Oct 2015 | A1 |
20150297914 | Hamid et al. | Oct 2015 | A1 |
20150305667 | Durand | Oct 2015 | A1 |
20150305686 | Coleman et al. | Oct 2015 | A1 |
20150310762 | Seim et al. | Oct 2015 | A1 |
20150313498 | Coleman et al. | Nov 2015 | A1 |
20150313512 | Hausman et al. | Nov 2015 | A1 |
20150314017 | Zhao | Nov 2015 | A1 |
20150320560 | Mulliken et al. | Nov 2015 | A1 |
20150320588 | Connor | Nov 2015 | A1 |
20150321000 | Rosenbluth et al. | Nov 2015 | A1 |
20150321010 | Marnfeldt | Nov 2015 | A1 |
20150321017 | Perryman et al. | Nov 2015 | A1 |
20150322155 | Zhao | Nov 2015 | A1 |
20150328454 | Lambert | Nov 2015 | A1 |
20150328455 | Meadows et al. | Nov 2015 | A1 |
20150335288 | Toth et al. | Nov 2015 | A1 |
20150335876 | Jeffery et al. | Nov 2015 | A1 |
20150335877 | Jeffery et al. | Nov 2015 | A1 |
20150335883 | Halpern et al. | Nov 2015 | A1 |
20150343196 | Vasapollo | Dec 2015 | A1 |
20150343215 | Ridder | Dec 2015 | A1 |
20150343242 | Tyler et al. | Dec 2015 | A1 |
20150354922 | Carriere | Dec 2015 | A1 |
20150359704 | Imboden et al. | Dec 2015 | A1 |
20150364018 | Mirov et al. | Dec 2015 | A1 |
20150374515 | Meijer et al. | Dec 2015 | A1 |
20150379880 | Sethi | Dec 2015 | A1 |
20170080216 | Pham | Mar 2017 | A1 |
20170209693 | An et al. | Jul 2017 | A1 |
Number | Date | Country |
---|---|---|
101868279 | Oct 2010 | CN |
107362447 | Nov 2017 | CN |
2646779 | Jul 1993 | FR |
2011502707 | Jan 2011 | JP |
2013500080 | Jan 2013 | JP |
2011011748 | Jan 2011 | WO |
2011053607 | May 2011 | WO |
2012129574 | Sep 2012 | WO |
Entry |
---|
US 8,398,630 B2, 03/2013, Demarais et al. (withdrawn) |
US 8,613,701 B2, 12/2013, Rao et al. (withdrawn) |
US 8,652,133 B2, 02/2014, Zarins et al. (withdrawn) |
Nijman, RJ; Role of antimuscarinics in the treatment of nonneurogenic daytime urinary incontinence in children; Urology; 2004; 45-50; 63. |
Nilsson, KF, et al.; Estimation of endogenous adenosine activity at adenosine receptors in guinea-pig ileum using a new pharmacolofical method; Acta Physiol (Oxf); 2010; 231-241; 199. |
Nitti, VW; Urodynamics, Incontinence, and Neurourology: Highlights from the Society for Urodynamics and Female Urology Annual Winter Meeting, Feb. 28-Mar. 2, 2008, Miami, FL; Rev Urol; 2008; 229-231; 10. |
Noblett, K. et al.; Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder; Neurourol Urodyn; 2016; 246-251; 35. |
Noblett, KL., et al.; Sacral nerve stimulation for the treatment of refractory voiding and bowel dysfunction: Am J Obstet Gynecol; 2014, 99-106; 210. |
Nordling, J: Surgical treatment of painful bladder syndrome/interstitial cystitis: Womens Health (Lond Engl): 2006: 233-238: 2. |
Nyarangi-Dix, JN, et al.; [Overactive bladder syndrome. Are there indications for surgical therapy?]: Urologe A; 2006; 1289-1290, 1292: 45. |
Occhino, JA, et al.; Sacral nerve modulation in overactive bladder; Curr Urol Rep: 2010: 348-352: 11. |
Oerlemans, DJ, et al.: Is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime?: Neurourol Urodyn: 2011: 1493-1496; 30. |
Oerlemans, DJ. et al.: Sacral nerve stimulation for neuromodulation of the lower urinary tract: Neurourol Urodyn: 2008; 28-33; 27. |
Offiah, I, et al.; Interstitial cystitis/bladder pain syndrome: diagnosis and management: Int Urogynecol J; 2013: 1243-1256: 24. |
Oliver. S, et al.: Measuring the sensations of urge and bladder filling during cystometry in urge incontinence and the effects of neuromodulation; Neurourol Urodyn: 2003; 42567: 22. |
Olivera, CK, et al.; Non-antimuscarinic treatment for overactive bladder: a systemactic review; Am J Obstet Gynecol: 2016:Abstract. |
Olujide. LO, et al.: Female voiding dysfunction; Best Pract Res Clin Obstet Gynaecol: 2005; 807-828: 19. |
Oom, DM. et al.; Anterior sphincteroplasty for fecal incontinence: a single center experience in the era of sacral neuomodulation; Dis Colon Rectum: 2009; 1681-1687: 52. |
Oom, DM, et al; Is sacral neuromodulation for fecal incontinence worthwhile in patients with associated pelvic floor injury?; Dis Colon Rectum: 2010; 422-427: 53. |
Ordia, JI, et al.; Continuous intrathecal baclofen infusion delivered by a programmable pump for the treatment of severe spasticity following traumatic brain injury: Neuromodulation; 2002: 103-107; 5. |
O'Reilly, BA, et al.; A prospective randomised double-blind controlled trial evaluating the effect of trans-sacral magnetic stimulation in women with overactive bladder: Int Urogynecol J Pelvic Floor Dysfunct; 2008; 497-502; 19. |
Osman, NI, et al.: Fowler's syndrome—a cause of unexplained orinary retention in young women?; Nat Rev Urol; 2014; 87-98: 11;Abstract. |
Osman, NI, et al.: Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches; Arab J Urol; 2013; 313-318; 11. |
Otto, W, et al.; [Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a German high-volume clinic]: Aktuelle Urol: 2012; 162-166; 43;Abstract. |
Ozyalcin, NS, et al.; [Sacral nerve stimulation in fecal incontinence: efficacy and safety]; Agri: 2004; 35-44; 16;Abstract. |
Panicker, JN, et al.; Lower urinary tract dysfuntion in the neurological patient; clinical assessment and management; Lancet Neurol; 2015: 720-732; 14. |
Pannek, J, et al.; [Initial results of Stoller peripheral neuromodulation in disorders of bladder function]; Urologe A; 2003; 1470-1476; 42. |
Parija, SC, et al.; Adenosine- and alpha,beta-methylene ATP-induced differential inhibition of cholinergic and non-cholinergic neurogenic responses in a rat urinary bladder; Br J Pharmacol; 1991; 396-400; 102. |
Park, SH, et al.; Overactive bladder; treatment options for the aging woman; Int J Fertil Womens Med; 2005; 37-44; 50;Abstract. |
Parnell, BA, et al.; The effect of sacral neuromodulation on pudendal nerve function and female sexual function; Neurourol Urodyn; 2015; 456-460; 34. |
Pascual, I, et al.; Sacral nerve stimulation for fecal incontinence; Rev Esp Enferm Dig; 2011; 355-359; 103. |
Patidar, N. et al.; Transcutaneous posterior tibial nerve stimulation in pediatric overactive bladder; A preliminary report; J Pediatr Urol; 2015; 351.e351-356; 11. |
Pauls, RN, et al.; Effects of sacral neuromodulation on female sexual function; Int Urogynecol J Pelvic Floor Dysfunct; 2007; 391-395; 18. |
Peeters, K, et al.; Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction; BJU Int; 2014; 789-794; 113. |
Peirce, C, et al.; Central representation of the inferior rectal nerve of the rat; Dis Colon Rectum; 2010; 315-320; 53. |
Pelaez, E. et al.; [Epidural spinal cord stimulation for interstitial cystitis]; Rev Esp Anestesiol Reanim; 2004; 549-552; 51;Abstract. |
Pelliccioni, G, et al.; External and sphincter responses after S3 spinal root electrical stimulation; Neurourol Urodyn; 2006; 788-791; 25. |
Pena, G, et al.; Cholinergic regulatory lymphocyles re-establish neuromodulation of innate immune responses in sepsis; J Immunol. 2011; 718-725; 187. |
Peng, CW, et al.; Pudendal neuromodulation with a closed-loop control strategy to improve bladder functions in the animal study; Conf Proc IEEE Eng Med Biol Soc; 2013; 3626-3629; 2013. |
Penson, DF; Re: Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin a treatment for patients with idiopathis overactive bladder; J Urol; 2012; 2157-2158; 187. |
Penson, DF; Re: Physician Use of Sacral Neuromodulation among Medicare Beneficiaries with Overactive Bladder and Urinary Retention; J Urol; 2016; 689; 195. |
Perissinotto et al.; Transcutaneous Tibial Nerve Stimulation in the Treatment of Lower UrinaryTract Symptoms and its Impact on Health-Related Quality of Life in Patients With ParkinsonDisease; J Wound, Ostomy and Continence Nurses Society; 2015; 94-89: 42. |
Perrigot, M. et al.; [Perineal electrical stimulation and rehabilitation in urinary incontinence and other symptoms of non-neurologic origin]; Ann Readapt Med Phys; 2008: 479-480; 51;Abstract. |
Pescatori, LC, et al.; Sphincteroplasty for anal incontinence; Gastroenterol Rep (Oxf); 2014; 92-97; 2. |
Peters, KM, et al.; Characterization of a clinical cohort of 87 women with interstitial cystitis/painful bladder syndrome; Urology: 2008; 634-640; 71. |
Peters, KM, et al.; Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptons; Neurourol Urodyn; 2010; 1267-1271; 29. |
Peters, KM, et al.; Clinical outcomes of sacral neuromodulation in patients with neurologic conditions; Urology, 2013; 738-743; 81. |
Peters, KM, et al.; Does patient age impact outcomes of neuromodulation?; Neurourol Urodyn; 2013; 30-36; 32. |
Peters, KM, et al.; Effect of Sacral neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients: Low Urin Tract Symptoms; 2015: 77-83: 7. |
Peters, KM, et al.; Effect of Sacral Neuromodulation Rate on Overactive Bladder Symptoms; A Randomized Crossover Feasibility Study; Low Urin Tract Symptoms; 2013; 129-133; 5. |
Peters, KM, et al.; Is sensory testing during lead placement crucial for achieving positive outcomes after sacral neuromodulation?; Neurourol Urodyn; 2011; 1489-1492; 30. |
Peters, KM, et at.; Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder; 3-year results of the STEP study; J Urol; 2013; 2194-2201; 189. |
Peters, KM, et al.; Predictors of reoperation after sacral neuromodulation: A single institution evaluation of over 400 patients; Neurourol Urodyn; 2015;Abstract. |
Van Wunnik, BP, et al.; Patient experience and satisfaction with sacral neuromodulation; results of a single-center sample survey; Dis Colon Rectum; 2011; 95-100; 54. |
Van Wunnik, BP, et al.; Sacral neuromodulation therapy; a promising treatment for adolescents with refractory functional constipation; Dis Colon Rectum; 2012; 278-285; 5. |
Vasavada, SP, et al.; Neuromodulation techniques; a comparison of available and new therapies; Curr Urol Rep; 2007; 455-460; 8. |
Vasdev, N, et al.; The surgical management of the refractory overactive bladder; Indian J Urol; 2010; 263-269; 26. |
Veeratterapillay, R, et al.; Augmentation cystoplasty; Contemporary indications, techniques and complications; Indian J Urol; 2013; 322-327; 29. |
Veit-Rubin, N, et al.; [Overactive bladder syndrome—a public health challenge]; Rev Med Suisse; 2015; 2016-2021; 11;Abstract. |
Vigil, HR, et al.; Urinary tract infection in the neurogenic bladder; Transl Androl Urol; 2016; 72-87; 5. |
Vignes, JR, et al.; Animal models of sacral neuromodulcation for detrusor overactivity; Neurourol Urodyn; 2009; 42594; 28. |
Vignes, JR, et al.; Sacral neuromodulation as a functional treatment of bladder overactivity; Acta Neurochir Suppl; 2007; 315-322; 97;Abstract. |
Vignes, JR, et al.; Sacral neuromodulation in lower urinary tract dysfunction; Adv Tech Stand Neurosurg; 2005; 177-224; 30;Abstract. |
Wallace, JL, et al.; Lack of beneficial effect of a tachykinin receptor antagonist in experimental colitis; Regul Pept; 1998; 95-101; 73. |
Walsh, IK, et al.; Non-invasive antidromic neurostimulation; a simple effective method for improving bladder storage; Neurourol Urodyn; 2001; 73-84; 20. |
Walter, S; [Duloxetine. A new preparation for patients with urinary incontinence]; Ugeskr Laeger; 2005; 4553-4555; 167;Abstract. |
Wang, Y, et al.; Neuromodulation reduces c-fos gene expression in spinalized rats; a double-blind randomized study; J Urol; 2000; 1966-1970; 163. |
Wang, Y, et al.; Neuromodulation reduces uriniary frequency in rats with hydrochloric acid-induced cystitis; BJU Int; 2000; 726-730; 86. |
Wark, HA, et al.; Restoration from acute urinary dysfunction using Utah electrode arrays implanted into the feline pudendal nerve: Neuromodulation; 2015: 317-323; 18. |
Watanabe, JH, et al.; Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder; Urology; 2010; 835-840; 76. |
Wehbe, SA, et al.; Minimally invasive therapies for chronic pelvic pain syndrome; Curr Urol Rep; 2010; 276-265; 11. |
Wehbe, SA, et al.; Sacral neuromodulations for female lower urinary tract, pelvic floor, and bowel disorders; Curr Opin Obstet Gynecol; 2010; 414-419; 22. |
Weil, EH, et al.; Sacral root neuromodulation in the treatment of refractory urinary urge incontinence; a prospective randomized clinical trial; Eur Urol; 2000; 161-171; 37;Abstract. |
Wein, AJ, et al.; Overactive bladder; a better understanding of pathophysiology, diagnosis and management; J Urol; 2006; S5-10; 175. |
Wein, AJ; Diagnosis and treatment of the overactive bladder; Urology; 2003; 20-27; 62. |
Wein, AJ; Re; inhibition of bladder overactivity by a combination of tibial neuromodulation and tramadol treatment in cats; J Urol; 2014; 868-869; 191. |
Wein, AJ; Re; is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime?; J Urol; 2013; 610-611; 189. |
Wein, AJ; Re; Results of a Prospective, Randomized, Multicenter Study Evaluating Sacral Neuromodulation with InterStim Therapy Compared to Standard Medical Therapy at 6-Months in Subjects with Mild Symptoms of Overactive Bladder; J Urol; 2015; 1051-1052; 194. |
Wenzler, DL, et al.; Proof of concept trial on changes in current perception threshold after sacral neuromodulation; Neuromodulation; 2015; 228-231; discussion 232; 18. |
Wexner, SD. et al.; Current surgical strategies to treat fecal incontinence; Expert Rev Gastroenterol Hepatol; 2015; 1577-1589; 9;Abstract. |
White, N, et al.; Overactive Bladder; Obstet Gynecol Clin North Am; 2016; 59-68; 43. |
Whitmore, KE; Complementary and alternative therapies as treatment approaches for interstitial cystitis; Rev Urol; 2002; S28-35; 4 Suppl 1. |
Wiklund CU, et al.; Modulation of cholinergic and substance P-like neurotransmission by nitric oxide in the guinea-pig ileum; Br J Pharmacol; 1993: 833-839: 110. |
Wiklund, NP, et al.; Cholinergic neuromodulation by endothelin in guinea pig ileum; Neurosci Lett; 1989; 342-346; 101. |
Wiklund, NP, et al.; Neuromodulation by adenine nucleotides, as indicated by experiments with inhibitors of nucleotide inactivation; Acta Physiol Scand; 1988; 217-223; 126:Abstract. |
Williams, MJ, et al.; Self-Reported Medication Costs in Patients Receiving Sacral Neuromodulation for Overactive Bladder; Value Health; 2015; A352; 18. |
Withington, J, et al.; The changing face of urinary continence surgery in England: a perspective from the Hospital Episode Statistics database; BJU Int; 2014; 268-277; 114. |
Wolff, K, et al.; Function outcome and quality of life after stapled transanal rectal resection for obstructed defecation syndrome: Dis Colon Rectum; 2010; 881-888; 53. |
Wood, LN, et al.; Urinary incontinence in women; Brnj; 2014; g4531; 349. |
Wooldridge, LS; Percutaneous tibial nerve stimulation for the treatment of urinary frequency, urinary urgency, and urge incontinence; results from a community-based clinic; Urol Nurs; 2009; 177-185; 29. |
Worsoe, J, et al., Turning off sacral nerve stimulation does not affect gastric and small intestinal motility in patients treated for faecal incontinence; Colorectal Dis; 2012; e713-720; 14. |
Wosnitzer, MS, et al.; The use of sacral neuromodulation for the treatment of non-obstructive urinary retention secondary to Guillain-Barre syndrome; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 1145-1147; 20. |
Wu, JM, et al.; Patient preferences for different severities of and treatments for overactive bladder; Female Pelvic Med Reconstr Surg; 2011; 184-189; 17;Abstract. |
Wyndaele, JJ, et al,; Conservative treatment of the neuropathic bladder in spinal cord injured patients; Spinal Cord; 2001; 294-300; 39. |
Wyndaele, JJ, et al.; Influence of sacral neuromodulation on electrosensation of the lower urinary tract; J Urol; 2000; 221-224; 163. |
Wyndaele, JJ; Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms; Spinal Cord; 2009; 427; 47. |
Xiao, Z. et al.; Role of spinal GABAA receptors in pudendal inhibition of nociceptive and nonnociceptive bladder reflexes in cats; Am J Physiol Renal Physiol; 2014; F781-789, 306. |
Xiao, Z, et al.; Somatic modulation of spinal reflex bladder activity mediated by nociceptive bladder afferent nerve fibers in cats; Am J Physiol Renal Physiol; 2014; F673-679; 307. |
Yamanishi, T, et al.; Neuromodulation for the Treatment of Lower Urinary Tract Symptoms; Low Urin Tract Symptoms; 2015; 121-132; 7. |
Yamanouchi, M. et el.; Integrative control of rectoanal reflex in guinea pigs through lumbar colonic nerves; Am J Physiol Gastrointest Liver Physiol; 2002; G148-156; 283. |
Yang, G, et al.; Pudendal nerve stimulation and block by a wireless-controlled implantable stimulator in cats; Neuromodulation; 2014; 490-496; discussion 496; 17. |
Yazdany, T, et al., Determing outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women; Int Urogynecol J; 2011; 1549-1554; 22. |
Yih, JM, et al.; Changes in sexual functioning in women after neuromodulation for voiding dysfunction; J Sex Med; 2013; 2477-2483; 10. |
Yoong, W, et al.; Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability; outcomes following a shortened 6-week protocol; BJU Int; 2010; 1673-1676; 106. |
Yun, AJ, et al.; Opening the floodgates: benign prostatic hyperplasia may represent another disease in the compendium of ailments caused by the global sympathetic bias that emerges with aging; Med Hypotheses; 2006; 392-394; 67. |
Zabihi, N, el al.; Short-term results of bilateral S2-S4 sacral neuromodulation for the treatment of refractory interstitial cystitis, painful bladder syndrome, and chronic pelvic pain; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 553-557; 19. |
Zariffa, J, et al.; A Phase-Based Electrical Plethysmography Approach to Bladder Volume Measurement; Ann Biomed Eng; 2015. |
Zecca, C, et al., Motor and sesensory responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract symptoms treated in daily practice: Eur J Neurol; 2014; 506-511; 21. |
Zecca, C, et al.; Posterior tibial nerve stimulation in the management of lower urinary tract symptoms in patients with multiple sclerosis; Int Urogynecol J; 2015. |
Zempleni, MZ, et al.; Cortical substrate of bladder control in SCI and the effect of peripheral pudendal stimulation; Neuroimage; 2010; 2983-2994; 49. |
Zhang, F, et al.; Inhibition of bladder overactivity by a combination of tibial neuromodulation and tramadol treatment in cats; Am J Physiol Renal Physiol; 2012; F1576-1582; 302. |
Zhang, F, et al,; Neural pathways involved in sacral neuromodulation of reflex bladder activity in cats; Am J Physiol Renal Physiol; 2013; F710-717; 304. |
Zhang, N, et al,; Transcutaneous Neuromodulation at Posterior Tibial Nerve and ST36 for Chronic Constipation; Evid Based Complement Alternat Med; 2014; 560802; 2014. |
Zhao, X. et al.; Diffused and sustained inhibitory effects of intestinal electrical stimulation on intestinal motility mediated via sympathetic pathway: Neuromodulation; 2014; 373-379; discussion 380; 17. |
Zheng, J, et al.; [Sacral neuromodulation in the treatment of intractable constipation]; Zhonghua Wei Chang Wai Ke Za Zhi; 2014; 1175-1178; 17;Abstract. |
Zhou, Y, et al.; Change of vanilloid receptor 1 following neuromodulation in rats with spinal cord injury; J Surg Res; 2002; 140-144; 107. |
Zullo, MA, et al.; Sacral neuromodulation after stabilization of L2-S1 vertebrae with metallic fixation devices; is it feasible?; Int Urogynecol J; 2011; 373-375; 22. |
Zvara, P, et al.; An animal model for the neuromodulation of neurogenic bladder dysfunction; Br J Urol. 1998; 267-271; 82. |
Jezernik, S. et al.; Electrical stimulation for the treatment of bladder dysfunction: current status and future possibilities; Neurol Res; 2002; 413-430; 24;Abstract. |
Jiang, CH; Modulation of the micturition reflex pathway by intravesical electrical stimulation: an experimental study in the rat; Neurourol Urodyn; 1998; 543-553; 17. |
Jimenez-Toscano, M, et al.; Efficacy and quality of life after transcutaneous posterior tibial neuromodulation for faecal incontinence; Colorectal Dis; 2015; 718-723; 17. |
Jin, H. et al.; Electrical neuromodulation at acupoint ST36 normalizes impaired colonic motility induced by rectal distenseion in dogs; Am J Physiol Gastrointest Liver Physiol; 2015; G368-376; 309. |
Johnsen, NV, et al.; The role of electrical stimulation techniques in the management of the male patient with urgency incontinence; Curr Opin Urol; 2014; 560-565; 24. |
Johnston, TE, et al.; Implantable FES system for upright mobility and bladder and bowel function for individuals with spinal cord injury; Spinal Cord; 2005; 713-723; 43. |
Joussain, C, et al.; Electrical management of neurogenic lower urinary tract disorders; Ann Phys Rehabil Med; 2015; 245-250; 58. |
Julius. F. et al.; Catheter tip granuloma associate with sacral region intrathecal drug administration; Neuromodulation; 2003; 225-228; 6. |
Kachur, JF, et al.; Neuromodulation of guinea pig intestinal electrolyte transport by cholecystokinin octapeptide; Gastroenterology; 1991; 344-349; 100;Abstract. |
Kacker, R, et al.; Electrical and mechanical office-based neuromodulation; Urol Clin North Am; 2013; 581-589; 40. |
Kacker, R, et al.; Selection of ideal candidates for neuromodulation in refractory overactive bladder; Curr Urol Rep; 2010; 372-378; 11. |
Kantartzis, K, et al.; Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder; Curr Opin Obstet Gynecol; 2012; 331-336; 24. |
Kantartzis, KL, et al.; Cost-effectiveness of test phase implantation strategies for InterSlim(R) sacral neuromodulation; Female Pelvice Med Reconstr Surg; 2013; 322-327; 19;Abstract. |
Kapoor, DS, et al.; Combined urinary and faecal incontinence; Int Urogynecol J Pelvic Floor Dysfunct; 2005; 321-328; 16. |
Karademir, K, et al.; A peripheric neuromodulation technique for curing detrusor overactivity; Stoller afferent neurostimulation; Scand J Urol Nephrol; 2005; 230-233; 39. |
Karam, R, et al.; Real-Time Classification of Bladder Events for Effective Diagnosis and Treatment of Urinary Incontinence; IEEE Trans Biomed Eng; 2015. |
Karmarkar, R, et al.; Emerging drugs for overactive bladder; Expert Opin Emerg Drugs; 2015; 613-624; 20;Abstract. |
Karram, MM; Sacral neuromodulation: emerging technology with expanding indications; Int Urogynecol J; 2010; 1443;21. |
Karsenty, G, et al.; Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux; J Urol; 2007; 1011-1014; 177. |
Karsenty, G, et al.; Understanding detrusor sphincter dyssynergia—significance of chronology; Urology; 2005; 763-768; 66. |
Katsuragi, T, et al.; Cholinergic neuromodulation by ATP, adenosine and its N6-substituted analogues in guinea-pig ileum; Clin Exp Pharmacol Physiol; 1985; 73-78; 12;Abstract. |
Katsuragi, T. et al.; Involvement of dihydropyridine-sensitive Ca2+ channels in adenosine-evoked inhibition of acetylcholine release from guinea pig ileal preparation; J Neurochem; 1990; 363-369; 55. |
Katsuragi, T, et al.; Possible transsynaptic cholinergic neuromodulation by ATP released from ileal longitudinal muscles of guinea pigs; Life Sci; 1993; 911-918; 53. |
Kaufmann, S. et al.; Unilateral vs bilateral sacral neuromodulation in pigs with formalin-induced detrusor hyperactivity; BJU Int; 2009; 260-263; 103. |
Kavia, R, et al.; A functional magnetic resonance imaging study of the effect of sacral neuromodulation on brain responses in women with Fowler's syndrome; BJU Int; 2010; 366-372; 105. |
Kavia, R, et al.; Overactive bladder; J R Soc Promot Health; 2005; 176-179; 125;Abstract. |
Kenefick, NJ; Sacral nerve neuromodulation for the treatment of lower bowel motility disorders; Ann R Coll Surg Engl; 2006; 617-623; 86. |
Keppene, V, et al.; [Neuromodulation in the management of neurogenic lower urinary tract dysfunction]; Prog Urol; 2007; 609-615; 17;Abstract. |
Kessler, TM, et al.; [Sacral neuromodulation for neurogenic bladder dysfunction]; Urologe A; 2012; 179-183; 51. |
Kessler, TM, et al.; [Urodynamic phenomena in the aging bladder]; Urologe A; 2004; 542-546; 43. |
Kessler, TM, et al.; Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection methods?; Eur Urol; 2005; 660-665; 47. |
Kessler, TM, et al.; Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland; Eur Urol; 2007; 1357-1363; 51. |
Kessler. TM, et al.; Urologists' referral attitude for sacral neuromodulation for treating refractory idiopathic overactive bladder syndrome: discrete choice experiment; Neurourol Urodyn; 2014; 1240-1246; 33. |
Killinger, KA, et al.; Secondary changes in bowel function after successful treatment of voiding symptoms with neuromodulation; Neurourol Urodyn; 2011; 133-137; 30. |
Kim, JH, et al.; Sacral nerve stimulation for treatment of intractable pain associated with cauda equina syndrome; J Korean Neurosurg Soc; 2010; 473-476; 47. |
Kinder, MV, et al.; Neuronal circuitry of the lower urinary tract; central and peripheral neuronal control of the micturition cycle; Anat Embryol (Berl); 1995; 195-209; 192. |
Kirkham, AP, et al.; Neuromodulation through sacral nerve roots 2 to 4 with a Finetech-Brindley sacral posterior and anterior root stimulator; Spinal Cord; 2002; 272-281; 40. |
Kirkham, AP, et al.; The acute effects of continuous and conditional neuromodulation on the bladder in spinal cord injury; Spinal Cord; 2001; 420-428; 39. |
Klingler, HC, et al.; Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study; Urology; 2000; 766-771; 56. |
Knowles; CH, et al.; Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial, Lancet: 2015; 1640-1648; 386. |
Knupfer, S, et al.; [Therapy-refractory overactive bladder: alternative treatment approaches]; Urologe A; 2011; 806-809; 50. |
Knupfer, SC, et al.; Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction; BMC Urol; 2014; 65; 14. |
Kocjancic, E, et al.; Sacral neuromodulation for urinary retention in a kidney-transplant patient; Urol Int; 2005; 187-188; 75. |
Kohli, N, et al.; InterStim Therapy: A Contemporary Approach to Overactive Bladder; Rev Obstet Gynecol. 2009; 18-27; 2. |
Kohli, N, et al.; Neuromodulation techniques for the treatment of the overactive bladder; Clin Obstet Gynecol; 2002; 218-232; 45. |
Koldewijn, EL; [What to do if pills do not work fo urge incontinence—still many questions and ambiguities]; Ned Tijdschr Geneeskd; 2012; A5099; 156;Abstract. |
Kosan, M, et al.; Alteration in contractile responses in human detrusor smooth muscle from obstructed bladders with overactivity; Urol Int: 2008; 193-200; 80. |
Kovacevic, M, et al.; Reflex neuromodulation of bladder function elicited by posterior tibial nerve stimulation in anesthetized rats; Am J Physiol Renal Physiol; 2015; F320-329; 308. |
Krames, E, et al.; Spinal cord stimulation reverses pain and diarrheal episodes of irritable bowel syndrome: a case report; Neuromodulation; 2004; 82-88; 7. |
Krivoborodov, GG, et al.; [Afferent stimulation of the tibial nerve in patients with hyperactive bladder]; Urologiia; 2002; 36-39; ;Abstract. |
Peters, KM, et al.; Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial; J Urol; 2010; 1438-1443; 183. |
Peters, KM; Alternative approaches to sacral nerve stimulation; Int Urogynecol J; 2010; 1559-1563; 21. |
Peters, KM; Sacral neuromodulation is an effective treatment for interstitial cystitis/bladder pain syndrome: pro; J Urol; 2012; 2043-2044; 188. |
Pettit, PD, et al.; Sacral neuromodulation: new applications in the treatment of female pelvic floor dysfunction; Curr Opin Obstet Gynecol; 2002; 521-525; 14. |
Peyronnet, B, et al.; [Management of overactive bladder in women]; Prog Urol; 2015; 877-883; 25;Abstract. |
Phe, V, et al.; How to define a refractory idiopathic overactive bladder?; Neurourol Urodyn; 2015; 42411; 34. |
Possover, M, et al.; Neuromodulation of the Superior hypogastric plexus: a new option to treat bladder atonia secondary to radical pelvic surgery?; Surg Neurol; 2009; 573-576; 72. |
Possover, M, et al.; Risks. symptoms, and management of pelvic nerve damage secondary to surgery for pelvic organ prolapse: a report of 95 cases; Int Urogynecol J; 2011; 1485-1490; 22. |
Possover, M; A novel implantation technique for pudendal nerve stimulation for treatment of overactive bladder and urgency incontinence; J Minim Invasive Gynecol; 2014; 888-892; 21. |
Possover M; Laparoscopic management of endopelvic etiologies of pudendal pain in 134 consecutive patients; J Urol; 2009; 1732-1736; 181. |
Possover, M; The laparoscopic implantation of neuroprothesis to the sacral plexus for therapy of neurogenic bladder dysfunctions after failure of percutaneous sacral nerve stimulation; Neuromodulation; 2010; 141-144; 13. |
Possover, M; The sacral LION procedure for recovery of bladder/rectum/sexual functions in paraplegic patients after explantation of a previous Finetech-Brindley controller; J Minim Invasive Gynecol; 2009; 98-101; 16. |
Powell, CR, et al.; Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures; J Urol; 2010; 173-176; 183. |
Pucciani, F; A review on functional results of sphincter-saving surgery for rectal cancer: the anterior resection syndrome; Updates Surg; 2013; 257-263; 65. |
Puccini, F, et al.; Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis, Int Urogynecol J; 2016; 347-354; 27. |
Qin, C, et al.; Is constant current or constant voltage spinal cord stimulation superior for the suppression of nociceptive visceral and somatic stimuli? A rat model; Neuromodulation; 2012: 132-142; discussion 143; 15. |
Rahnama'i, MS, et al.; Evidence for prostaglandin E2 receptor expression in the intramural ganglia of the guinea pig urinary bladder; J Chem Neuroanat; 2015; 43-47; 64-65. |
Rai, BP, et al.; Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults: Cochrane Database Syst Rev; 2012; Cd003193; 12;Abstract. |
Ramage, L, et al.; A systematic review of sacral nerve stimulation for low anterior resection syndrome; Colorectal Dis; 2015; 762-771: 17. |
Ramundo, JM, et al.; State of the science: pathology and management of the patient with overactive bladder; Ostomy Wound Manage; 2002; 22-27; 48. |
Rana, MV, et al.; Tripolar spinal cord stimulation for the treatment of abdominal pain associated with irritable bowel syndrome; Neuromodulation; 2013; 73-77; discussion 77; 16. |
Rashid, TG, et al.; Male incontinence: onabotulinum toxin A and sacral nerve stimulation; Curr Opin Urol; 2013; 545-551; 23. |
Rasmussen, NT, et al.; Successful use of sacral neuromodulation after failed bladder augmentation: Can Urol Assoc J: 2009; E49-50; 3. |
Ratto, C, et al.; Minimally invasive sacral neuromodulation implant technique: modifications to the conventional procedure; Dis Colon Rectum; 2003; 414-417; 46. |
Ratto, C, et al.; Sacral neuromodulation in the treatment of defecation disorders; Acta Neurochir Suppl; 2007; 341-350; 97;Abstract. |
Rawashdeh, YF, et al.; International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children; Neurourol Urodyn; 2012; 615-620; 31. |
Reese, JN, et al.; Role of spinal metabotropic glutamate receptor 5 in pudendal inhibition of the nociceptive bladder reflex in cats; Am J Physiol Renal Physiol; 2015; F832-838; 308. |
Reitz, A, et al.; Topographic anatomy of a new posterior approach to the pudendal nerve for stimulation; Eur Urol; 2007; 1350-1355; discussion 1355-1356; 51. |
Reyblat, P. et al.; Augmentation enterocystoplasty in overactive bladder; is there still a role?; Curr Urol Rep; 2010; 432-439; 11. |
Riazimand, SH, et al.; A rat model for studying effects of sacral neuromodulation on the contractile activity of a chronically inflamed bladder; BJU Int; 2004; 158-163; 94. |
Riazimand, SH, et al.; Interaction between neurotransmitter antagonists and effects of sacral neuromodulation in rats with chronically hyperactive bladder; BJU Int; 2005; 900-908; 96. |
Richter, EO, et al.; Percutaneous cephalocaudal implantation of epidural stimulation electrodes over sacral nerve roots—a technical note on the importance of the lateral approach; Neuromodulation; 2011; 62-67; discussion 67; 14. |
Ridout, AE, et al.; Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy; J Obstet Gynaecol; 2010; 111-114; 30. |
Rigaud, J, et al.; [Specific treatments for painful bladder syndrome]; Prog Urol; 2010; 1044-1053; 20;Abstract. |
Rimmer, CJ, et al.; Short-term Outcomes of a Randomized Pilot Trial of 2 Treatment Regimens of Transcutaneous Tibial Nerve Stimulation for Fecal Incontinence; Dis Colon Rectum; 2015; 974-985; 58. |
Ripetti, V, et al.; Sacral nerve neuromodulation improves physical, psychological and social quality of life in patients with fecal incontinence; Tech Coloproctol; 2002; 147-152; 6. |
Rittenmeyer. H; Sacral nerve neuromodulation (InterStim). Part 1. Review of the InterStim system; Urol Nurs; 2008; 15-20; 28. |
Robaina Padron, FJ; [Surgical neuromodulation; new frontiers in neurosurgery]; Neurocirugia (Astur); 2008; 143-155; 19;Abstract. |
Robinson, D, et al.; Overactive bladder: diagnosis and management; Maturitas; 2012; 188-193; 71. |
Robinson, D, et al.; The management of overactive bladder refractory to medical therapy; Maturitas; 2013; 101-104; 75. |
Robinson, D, et al.; The medical management of refractory overactive bladder; Maturitas; 2013; 386-390; 74. |
Rogers, MJ, et al.; Propranolol, but not naloxone, enhances spinal reflex bladder activity and reduces pudendal inhibition in cats; Am J Physiol Regul Integr Comp Physiol; 2015; R42-49; 308. |
Rogers, MJ, et al.; Role of glycine in nociceptive and non-nociceptive bladder reflexes and pudendal afferent inhibition of these reflexes in cats; Neurourol Urodyn; 2015;Abstract. |
Romero Maroto, J, et al.; [Techniques and current practice of urodynamics, Problems and traps]; Acias Urol Esp; 2003; 75-91; 27;Abstract. |
Roth, TM; Blunt trauma leafding to delayed extrusion of sacral nerve implant; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 735-737; 20. |
Roth, TM; Sacral neuromodulation and cardiac pacemakers; Int Urogynecol J; 2010; 1035-1037; 21. |
Roth, TM; Safe Simultaneous Use of Sacral Neuromodulation and Vagal Nerve Stimulation; Female Pelvic Med Reconstr Surg; 2016; e1-2; 22;Abstract. |
Roth, TM; Subcapsular relocation for sacral neuromodulation pulse generator implant revision; Neuromodulation; 2010; 145-146; 13. |
Roupret, M, et al.; Sacral neuromodulation for refractory detrusor overactivity in women with an artificial urinary sphincter; J Urol; 2004; 236-239; 172. |
Rovner, ES; Treatment of urinary incontinence; Curr Urol Rep; 2000; 235-244; 1. |
Ruffion, A, et al.; [Sacral root neuromodulation for the treatment of urinary incontinence reported to detrusor hyperactivity]; Neurochirurgie; 2003; 377-382; 49;Abstract. |
Ruffion, A. et al., [Two indications for bilateral neuromodulation]; Prog Urol; 2003; 1394-1396; 13;Abstract. |
Saber-Khalaf, M, et al.; Sacral neuromodulation outcomes in male patients with chronic urinary retention; Neuromodulation; 2015; 329-334; discussion 334; 18. |
Sadiq, A, et al.; Management of neurogenic lower urinary tract dysfuntion in multiple sclerosis patients; Curr Urol Rep; 2015; 44; 16. |
Sahai, A, et al.; Neurogenic detrusor overactivity in patients with spinal cord injury; evaluation and management; Curr Urol Rep; 2011; 404-412; 12. |
Sajadi, KP, et al.; Bladder augmentation and urinary diversion for neurogenic LUTS: current indications; Curr Urol Rep; 2012; 389-393; 13. |
Sajadi, KP, et al.; Overactive bladder after sling surgery; Curr Urol Rep; 2010; 366-371; 11. |
Sakas, DE, et al., An introduction to operative neuromodulation and functional neuroprosthetics, the new frontiers of clinical neuroscience and biotechnology; Acta Neurochir Suppl; 2007; 42439; 97;Abstract. |
Sancaktar, M. et .; The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder; Gynecol Endocrinol; 2010; 729-732; 26. |
Sanford, MT, et al.; Neuromodulation in neurogenic bladder; Transl Androl Urol; 2016; 117-126; 5. |
Scaglia, M, et al.; Fecal incontinence treated with acupuncture—a pilot study; Auton Neurosci; 2009; 89-92; 145. |
Scheepens, WA, et al.; [Neuromodulation and neurostimulation in urology]; Ned Tijdschr Geneeskd; 2001; 1730-1734; 145;Abstract. |
Scheepens, WA, et al.; Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction; Urology; 2002; 598-602; 60. |
Scheepens, WA, et al.; Unilateral versus bilateral sacral neuromodulation in patients with chronic voiding dysfunction; J Urol; 2002; 2046-2050; 168. |
Scheepens, WA, et al.; Urodynamic results of sacral neuromodulation correlate with subjective improvement in patients with an overactive bladder; Eur Urol; 2003; 282-287; 43. |
Scheiner, DA, et al.; [Interstitial cystitis/bladder pain syndrome (IC/BPS)]; Praxis (Bern 1994); 2015; 909-918; 104. |
Schijns, O. et al.; Development and characterization of [123l]iodotiagabine for in-vivo GABA-transporter imaging; Nucl Med Commun; 2013; 175-179; 34;Abstract. |
Schmidt, RA, et al.; Neurostimulation and neuromodulation: a guide to selecting the right urologic patient; Eur Urol; 1998; 23-26; 34 Suppl 1;Abstract. |
Schneider, MP, et al.; Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review: Eur Urol; 2015; 859-887; 68. |
Schonberger, B; [Bladder dysfunction and surgery in the small pelvis. Therapeutic possibilities]; Urologe A; 2003; 1569-1575; 42. |
Schreiber, KL, et al.; Evidence for neuromodulation of enteropathogen invasion in the intestinal mucosa; J Neuroimmune Pharmacol; 2007; 329-337; 2. |
Schultz-Lampel, D, et al.; Experimental results on mechanisms of action of electrical neuromodulation in chronic urinary retention; World J Urol; 1983; 301-304; 16. |
Schurch, B, et al.; Dysfunction of lower urinary tract in patients with spinal cord injury; Handb Clin Neurol; 2015; 247-267; 130. |
Schurch, B, et al.; Electrophysiological recordings during the peripheral nerve evaluation (PNE) test in complete spinal cord injury patients; World J Urol; 2003; 319-322; 20. |
Schwalenberg, T, et al.; [Sacral neuromodulation in urology—development and current status]; Aktuelle Urol; 2012; 39-48; 43;Abstract. |
Schwen, Z, et al.; Combination of foot stimulation and tolterodine treatment eliminates bladder overactivity in cats; Neurourol Urodyn; 2014; 1266-1271; 33. |
Schwen, Z, et al.; Inhibition of bladder overactivity by duloxetine in combination with foot stimulation of WAY-100635 treatment in cats: Am J Physiol Renal Physiol; 2013; F1663-1668; 305. |
Schwen, Z, et al.; Involvement of 5-HT3 receptors in pudendal inhibition of bladder overactivity in cats; Am J Physiol Renal Physiol; 2013; F663-671; 305. |
Seif, C, et al.; [Pudendal nerve stimulation therapy of the overactive bladder—an alternative to sacral neuromodulation?]; Aktuelle Urol; 2005; 234-238; 36;Abstract. |
Seif, C, et al.; [Use of permanent electrodes in the peripheral nerve evaluation test (PNE-Test) in comparison to conventional wire electrodes]; Aktuelle Urol; 2006; 277-280; 37;Abstract. |
Seif, C, et al.; Findings with Bilateral Sacral Neurostimulation: Sixty-two PNE-Tests in Patients with Neurogenic and Idiopathic Bladder Dysfunctions; Neuromodulation; 2004; 141-145; 7. |
Seif, C, et al.; Improved sacral neuromodulation in the treatment of the hyperactive detrusor: signal modification in an animal model; BJU Int; 2003; 711-715; 91. |
Seth, A, et al.; What's new in the diagnosis and management of painful bladder syndrome/interstitial cystitis?; Curr Urol Rep; 2008; 349-357; 9. |
Sevcencu, C; A review of electrical stimulation to treat motility dysfunctions in the digestive tract: effects and stimulation patterns; Neuromodulation; 2007; 85-99; 10. |
Sevcencu, C; Gastrointestinal mechanisms activated by electrical stimulation to treat motility dysfunctions in the digestive tract: a review; Neuromodulation; 2007; 100-112; 10. |
Shafik, A, et al.; Percutaneous peripheral neuromodulation in the treatment of fecal incontinence: Eur Surg Res; 2003; 103-107; 35. |
Shah, P, et al.; Unique spatiotemporal neuromodulation of the lumbosacral circuitry shapes locomotor success after spinal cord injury; J Neurotrauma; 2016;Abstract. |
Shaker, H, et al.; Role of C-afferent fibres in the machanism of action of sacral nerve root neuromodulation in chronic spinal cord injury; BJU Int: 2000; 905-910; 85. |
Shaker, H, et ai.; Sacral root neuromodulation in the treatment of various voiding and storage problems; Int Urogynecol J Pelvic Floor Dysfunct; 1999; 336-343; 10;Abstract. |
Shaker, HS, et al.; Sacral nerve root neuromodulation: an effective treatment for refractory urge incontinence J Urol; 1998; 1516-1519; 159. |
Shaker, HS, et al.; Sacral root neuromodulation in idiopathic nonobstructive chronic urinary retention: J Urol; 1998; 1476-1478; 159. |
Shalmon, DF, et al.; Sacral nerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity; Am J Obstet Gynecol: 20014; 561,e561-565; 211. |
Shamliyan, T, et al.; Prevention of urinary and fecal incontinence in adults; Evid Rep Technol Assess (Full Rep); 2007; 1-379; ;Abstract. |
Sharma, A, et al.; Review of sacral neuromodulation for management of constipation; Surg Innov; 2013; 614-624; 20. |
Sharma, A, et al.; Sacral neuromodulation for the management of severe constipation; development of a constipation treatment protocol; Int J Colorectal Dis; 2011; 1583-1587; 26. |
Shen, B, et al.; Neuromodulation of bladder activity by stimulation of feline pudendal nerve using a transdermal amplitude modulated signal (TAMS); Neurourol Urodyn; 2011; 1686-1694; 30. |
Shepherd, JP, et al.; InterStim Sacral Neuromodulation and Botox Botulinum-A Toxin Intradetrusor Injections for Refractory Urge Urinary Incontinence: A Decision Analysis Comparing Outcomes Including Efficacy and Complications; Female Pelvic Med Reconstr Surg; 2011; 199-203; 17;Abstract. |
Sherif, H, et al.; Posterior tibial nerve stimulation as treatment for the overactive bladder; Arab J Urol; 2013; 131-135; 11. |
Sheriff, MK, et al.; Neuromodulation of detrusor hyper-reflexia by functional magnetic stimulation of the sacral roots; Br J Urol; 1996; 39-46; 78;Abstract. |
Sherman, ND, et al.; Current and future techniques of neuromodulation by bladder dysfunction; Curr Urol Rep; 2007; 448-454; 8. |
Tai, C, et al.; Irritation induced bladder overactivity is suppressed by tibial nerve stimulation in cats; J Urol; 2011; 326-330; 186. |
Tai, C, et al.; Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats; Am J Physiol Renal Physiol; 2011; F385-392; 300. |
Takahashi, S, et al.; Overactive bladder: magnetic versus electrical stimulation: Curr Opin Obstet Gynecol; 2003; 429-433; 15. |
Tanagho, EA; Concepts of neuromodulation: Neurourol Urodyn; 1993; 487-488; 12. |
Tanagho, EA; Neuromodulation in the management of voiding dysfunction in children; J Urol; 1992; 655-657; 148;Abstract. |
Tang, H, et al.; Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women; a clinical trial; Urol J; 2014; 1800-1805; 11. |
Taweel, WA, et al.; Neurogenic bladder in spinal cord injury patients; Res Rep Urol; 2015; 85-99; 7. |
Thin, NN, et al.; Randomized clinical trial of sacral versus percutaneous tibial nerve stimulation in patients with faecal incontinence; Br J Surg; 2015; 349-358; 102. |
Thin, NN, et al.; Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence; Br J Surg: 2013; 1430-1447; 100. |
Thomas, GP, et al.; A pilot study of transcutaneous sacral nerve stimulation for faecal incontinence; Colorectal Dis; 2013; 1406-1409; 15. |
Thomas, GP, et al.; Sacral nerve stimulation for faecal incontinence secondary to congenital imperforate anus; Tech Coloproctol; 2013; 227-229; 17. |
Thompson, JH, et al.; Sacral neuromodulation: Therapy evolution; Indian J Urol; 2010; 379-384; 26. |
Thoua, NM, et al.; Internal anal sphincter atrophy in patients with systemic sclerosis; Rheumatology (Oxford); 2011; 1596-1602; 50. |
Tian, Y, et al.; Inhibitory Effect and Possible Mechanism of Intraurethral Stimulation on Overactive Bladder in Female Rats; Int Neurourol J; 2015; 151-157; 19. |
Tirlapus, SA, et al.; Nerve stimulation for chronic pelvic pain and bladder pain syndrome: a systematic review; Acta Obstet Gynecol Scand; 2013; 881-887; 92. |
Tjandra, JJ, et al.; Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized. controlled study; Dis Colon Retum; 2008; 494-502; 51. |
Tomonori Yamanishi et al.; Neuromodulation for the Treatment of Lower Urinary TractSymptoms; Low Urin Tract Symptoms; 2015; 121-132; 7. |
Traynor, TR, et al.; Neuromodulation of ion transport in porcine distal colon: NPY reduces secretory actions of leukotrienes; Am J Physiol. 1995; R426-431; 269;Abstract. |
Trevizol, AP, et al.; Trigeminal Nerve Stimulation (TNS) for the Treatment of Irritable Bowel Syndrome in an Elderly Patient with Major Depressive Disorder: A Case Study; Brain Stimul; 2015; 1235-1236; 8. |
Turner, WH, et al.; Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment; Pharmacol. Ther; 1997; 77-110; 75. |
Ullah, S, et al.; Temporary gastric neuromodulation for intractable nausea and vomiting; Ann R Coll Surg Engl; 2011; 624-628; 93. |
Uludag, O, et al.; [Sacral neuromodulation is effective in the treatment of fecal incontinence with intact sphincter muscles: a prospective study]; Ned Tijdschr Geneeskd; 2002; 989-993; 146;Abstract. |
Uludag, O, et al.; Sacral neuromodulation in patients with fecal incontinence: a single-center study; Dis Colon Rectum; 2004; 1350-1357; 47. |
Uludag, O, et al.; Sacral neuromodulation: does it affect the rectoanal angle in patients with fecal incontinence?; World J Surg; 2010; 1109-1114; 34. |
Uludag, O, et al.; Sacral neuromodulation: long-term outcome and quality of life in patients with faecal incontinence; Colorectal Dis; 2011; 1162-1166; 13. |
Uludag, O, et al.; Sacral neuromodulation; does it affect colonic transit time in patients with faecal incontinence?; Colorectal Dis; 2006; 318-322; 8. |
Unger, CA, et al.; Fecal incontinence: the role of the urologist; Curr Urol Rep; 2014; 388; 15. |
Unwala, DJ, et al.; Repeated botulinum toxin injection for idiopathic overactive bladder: will chemodenervation become a long-term solution?: Curr Urol Rep; 2007; 419-424; 8. |
Uranga, A, et al.; An integrated implantable electrical sacral root stimulator for bladder control; Neuromodulation; 2002; 238-247; 5. |
Vaarala, MH, et al.; Sacral neuromodulation in urological indications: the Finnish experience; Scand J Urol Nephrol; 2011; 46-51; 45. |
Vaizey, CJ, et al.; Effects of short term sacral nerve stimulation on anal and rectal function in patients with anal incontinence; Gut; 1999; 407-412; 44. |
Vallet, C, et al.; Sacral nerve stimulation for faecal incontinence: response rate, satisfaction and the value of preoperative investigation in patient selection; Colorectal Dis; 2010; 247-253; 12. |
Van Balken, MR, et al.; Prognostic factors for successful percutaneous tibial nerve stimulation; Eur Urol; 2006; 360-365; 49. |
Van Balken, MR, et al.; Sexual functioning in patients with lower urinary tract dysfunction improves after percutaneous tibial nerve stimulation; Int J Impot Res: 2006; 470-475; discussion 476; 18. |
Van Balken, MR, et al.; The use of electrical devices for the treatment of bladder dysfunction: a review of methods; J Urol; 2004; 846-851; 172. |
Van Balken, MR; Percutaneous tibial nerve stimulation: the Urgent PC device; Expert Rev Med Devices; 2007; 693-698; 4. |
Van Der AA, HE, et al.; Sacral anterior root stimulation for bladder control: clinical results; Arch Physiol Biochem; 1999; 248-256; 107. |
Van Der Pal, F, et al.; Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction; Curr Opin Urol, 2006; 261-267; 16. |
Van Der Pal, F, et al.; Implant-Driven Tibial Nerve Stimulation in the Treatment of Refractory Overactive Bladder Syndrome; 12-Month Follow-up; Neuromodulation; 2006; 163-171; 9. |
Van Kerrebroeck, P; Editorial comment re: Killinger et al. “Secondary changes in bowel function after successful treatment of voiding symptoms with neuromodulation”; Neurourol urodyn; 2011; 1403; 30. |
Van Kerrebroeck, PE. et al.; Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study; J Urol; 2007; 2029-2034; 178. |
Van Kerrebroeck, PE; Advances in the role of sacral nerve neuromodulation in lower urinary tract symptoms; Int Urogynecol J: 2020; S467-474; 21 Suppl 2. |
Van Kerrebroeck, PE; Neuromodulation and other electrostimulatory techniques; Scand J Urol Nephrol Suppl; 2002; 82-86. |
Van Kerrebroeck, PE; The role of electrical stimulation in voiding dysfunction; Eur Urol. 1998; 27-30; 34 Suppl 1;Abstract. |
Van Koeveringe, GA, et al.; Detrusor underactivity: a plea for new approaches to a common bladder dysfunction; Neurourol Urodyn; 2011; 723-728; 30. |
Van Ophoven, A, et al.; [The future of invasive neuromodulation: new techniques and expanded indications]; Urologe A; 2012; 212-216; 51. |
Van Voskuilen, AC, et al.; Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study; Eur Urol; 2006; 366-372; 49. |
Van Voskuilen, AC, et al.; Medium-term experience of sacral neuromodulation by tined lead implantation; BJU Int; 2007; 107-110; 99. |
Van Wunnik, BP, et al.; Cost-effectiveness analysis of sacral neuromodulation for faecal incontinence in The Netherlands, Colorectal Dis; 2012; e807-814; 14. |
Van Wunnik, BP, et al.; Neuromodulation for constipation: sacral and transcutaneous stimulation; Best Pract Res Clin Gastroenterol; 2011; 181-191; 25. |
Desrosiers, L, et al.; Urogynecologic conditions: interstitial cystitis/painful bladder syndrome; FP Essent; 2015; 17-22; 430;Abstract. |
Devane, LA, et al.; Acute lumbosacral nerve stimulation does not affect anorectal motor function in a rodent model; Neurogastroenterol Motil; 2016; 358-363; 28. |
Devroede, G, et al.; Quality of life is markedly improved in patients with fecal incontinence after sacral nerve stimulation; Female Pelvic Med Reconstr Surg; 2012; 103-112; 18;Abstract. |
Di Giovangiulio, M, et al.; The Neuromodulation of the Intestinal Immune System and Its Relevance in Inflammatory Bowel Disease; Front Immunol; 2015; 590; 6. |
Dijkema, HE, et al.; [Initial experiences with neuromodulation as treatment for incontinence and micturition disorders in The Netherlands]; Ned Tijdschr Geneeskd; 1992; 88-90; 136;Abstract. |
Dijkema, HE, et al.; Neuromodulation of sacral nerves for incontinence and voiding dysfunctions. Clinical results and complications; Eur Urol; 1993; 72-76; 24;Abstract. |
Dmochowski, R; Neuromodulation and the urinary tract—are we over the rainbow or have we simply stepped through the looking glass?; J Urol; 2007; 1844-1845; 178. |
Donon, L, et al.; [Sacral neuromodulation: results of a monocentric study of 93 patients]; Prog Urol; 2014; 1120-1131; 24;Abstract. |
Dorflinger, A, et al.; Voiding dysfunction; Curr Opin Obstet Gynecol; 2001; 507-512; 13. |
Doumouchtsis, SK, et al.; Female voiding dysfunction; Obstet Gynecol Surv; 2008; 519-526; 63. |
Drake, MJ; Management and rehabilitation of neurologic patients with lower urinary tract dysfunction; Handb Clin Neurol; 2015; 451-468; 130. |
Drossaerts, J, et al.; Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation; Neurourol Urodyn; 2015;Abstract. |
Drossaerts, J, et al.; The value of urodynamic tools to guide patient selection in sacral neuromodulation; World J Urol; 2015; 1889-1895; 33. |
Dudding, TC, et al.; Sacral nerve stimulation for faecal incontinence: optimizing outcome and managing complications; Colorectal Dis; 2011; e196-202; 13. |
Dudding, TC, et al.; Sacral nerve stimulation for faecal incontinence: patient selection, service provision and operative technique; Colorectal Dis; 2011; e187-195; 13. |
Dudding, TC, et al.; Sacral nerve stimulation: an effective treatment for chronic functional anal pain?; Colorectal Dis; 2013; 1140-1144; 15. |
Dudding, TC; Future indications for sacral nerve stimulation; Colorectal Dis; 2011; 23-28; 13 Suppl 2. |
Duelund-Jakobsen, J, et al.; Baseline factors predictive of patient satisfaction with sacral neuromodulation for diopathic fecal incontinence; Int J Colorectal Dis; 2014; 793-798; 29. |
Duthie, J, et al.; Botulinum toxin injections for adults with overactive bladder syndrome; Cochrane Database Syst Rev; 2007; Cd005493; ;Abstract. |
Duthie, JB, et al.; Botulinum toxin injections for adults with overactive bladder syndrome; Cochrane Database Syst Rev; 2011; Cd005493. |
Duve H, et al.; Distribution and functional significance of Leu-callatostatins in the blowfly Calliphora vomitoria; Cell Tissue Res; 1994; 367-379; 276. |
Dwyer, ME, et al.; The dysfunctional elimination syndrome in children—is sacral neuromodulation worth the trouble?; J Urol; 2012; 1076-1077; 188. |
Elkelini, MS, et al.; Mechanism of action of sacral nerve stimulation using a transdermal amplitude-modulated signal in a spinal cord injury rodent model; Can Urol Assoc J; 2012; 227-230; 6. |
Elkelini, MS, et al.; Safety of MRI at 1.5Tesla in patients with implanted sacral nerve neurostimulator; Eur Urol; 2006; 311-316; 50. |
Ellsworth, P, et al.; Neurogenic detrusor overactivity: an update on management options; R I Med J (2013); 2013; 38-40; 96. |
Ellsworth, P, et al.; Update on the pharmacologic management of overactive bladder: the present and the future; Urol Nurs; 2010; 29-38, 53; 30. |
Elneil, S, et al.; Optimizing the duration of assessment of stage-1 sacral neuromodulation in nonobstructive chronic urinary retention; Neuromodulation; 2014; 66-70; discussion 70-61; 17. |
Elneil, S; Urinary retention in women and sacral neuromodulation; Int Urogynecol J; 2010; S475-483; 21 Suppl 2. |
Elser, DM; Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management; Postgrad Med; 2012; 42-49; 124;Abstract. |
Evans, RJ; Sacral neuromodulation is an effective treatment for interstitial cystitis/bladder pain syndrome: con; J Urol; 2012; 2044-2045; 188. |
Everaert, K, et al.; Sacral nerve stimulation for pelvic floor and bladder dysfunction in adults and children; Neuromodulation; 2005; 186-187; 8. |
Everaert, K, et al.; The urodynamic evaluation of neuromodulation in patients with voiding dysfunction; Br J Urol; 1997; 702-707; 79. |
Evers, J, et al.; Effects of stimulation frequency and intensity in sacral neuromodulation on anorectal inputs to the somatosensory cortex in an experimental model; Br J Surg; 2014; 1317-1328; 101. |
Evers, J, et al.; Reversal of sensory deficit through sacral neuromodulation in an animal model of fecal incontinence; Neurogastroenterol Motil; 2016;Abstract. |
Fall, M, et al.; EAU guidelines on chronic pelvic pain; Eur Urol; 2004; 681-689; 46. |
Fall, M, et al.; EAU guidelines on chronic pelvic pain; Eur Urol; 2010; 35-48; 57. |
Falletto, E, et al.; Is sacral nerve stimulation an effective treatment for chronic idiopathic anal pain?; Dis Colon Rectum; 2009; 456-462; 52. |
Falletto, E, et al.; Sacral neuromodulation for bowel dysfunction: a consensus statement from the Italian group; Tech Coloproctol; 2014; 53-64; 18. |
Fang, Q, et al.; [Morphological study on the role of ICC-like cells in detrusor neuro-modulation of rat urinary bladder]; Zhonghua Wai Ke Za Zhi; 2008; 1542-1545; 46. |
Fariello, JY, et al.; Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction; Int Urogynecol J; 2010; 1553-1558; 21. |
Faucheron, JL, et al.; Sacral neuromodulation for bowel dysfunction; Tech Coloproctol; 2014; 42433; 18. |
Faucheron, JL; [Anal incontinence]; Presse Med; 2008; 1447-1462; 37;Abstract. |
Feler, CA, et al.; Sacral neuromodulation for chronic pain conditions; Anesthesiol Clin North America; 2003; 785-795; 21. |
Felt-Bersma, RJ, et al.; Temperature-controlled radiofrequency energy (SECCA) to the anal canal for the treatment of faecal incontinence offers moderate improvement; Eur J Gastroenterol Hepatol; 2007; 575-580; 19;Abstract. |
Ferhi, K, et al.; [Results of sacral posterior neuromodulation on voiding disorders and impact on sexuality based on a single-center study]; Prog Urol; 2008; 160-166; 18;Abstract. |
Ferroni, MC, et al.; Role of the brain stem in tibial inhibition of the micturition reflex in cats; Am J Physiol Renal Physiol; 2015; F242-250; 309. |
Ferulano, GP, et al.; [Sacral neuromodulation in fecal continence disorders]; Recenti Prog Med; 2002; 403-409; 93; Abstract. |
Finazzi-Agro, E, et al.; Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials; Neurourol Urodyn; 2009; 320-324; 28. |
Findlay, JM, et al.; Peripheral neuromodulation via posterior tibial nerve stimulation—a potential treatment for faecal incontinence?; Ann R Coll Surg Engl; 2010; 385-390; 92. |
Firoozi, F, et al.; Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged; J Urol; 2013; 594-597; 190. |
Fjorback, MV, et al.; A portable device for experimental treatment of neurogenic detrusor overactivity; Neuromodulation; 2003; 158-165; 6. |
Foditsch, EE, et al.; Laparoscopic placement of a tined lead electrode on the pudendal nerve with urodynamic monitoring of bladder function during electrical stimulation: an acute experimental study in healthy female pigs; Springerplus; 2014; 309; 3. |
Foon, R, et al.; The overactive bladder; Ther Adv Urol; 2010; 147-155; 2. |
Ford, AP, et al.; P2X3 receptors and sensitization of autonomic reflexes; Auton Neurosci; 2015; 16-24; 191. |
Fowler, CJ; The perspective of a neurologist on treatment-related research in fecal and urinary incontinence; Gastroenterology; 2004; S172-174; 126. |
Franzen, K, et al.; Surgery for urinary incontinence in women 65 years and older: a systematic review; Int Urogynecol J; 2015; 1095-1102; 26. |
Fraser, MO, et al.; Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence; BJU Int; 2003; 743-748; 91. |
Freeman, RM, et al.; Overactive bladder; Best Pract Res Clin Obstet Gynaecol; 2005; 829-841; 19. |
French, JS, et al.; What do spinal cord injury consumers want? A review of spinal cord injury consumer priorities and neuroprosthesis from the 2008 neural interfaces conference; Neuromodulation; 2010; 229-231; 13. |
Frokjaer, JB, et al.; Modulation of vagal tone enhances gastroduodenal motility and reduces somatic pain sensitivity; Neurogastroenterol Motil; 2016. |
Fu, G, et al.; [Neuromodulation for treatment for neurogenic bowel dysfunction]; Zhonghua Wai Ke Za Zhi; 2009; 128-131; 47. |
Gaj, F, et al.; [Chronic pelvic pain treatment with posterior tibial nerve stimulation]; Clin Ter; 2011; e111-114; 162; Abstract. |
Gajewski, JB, et al.; The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre; BJU Int; 2011; 1258-1264; 107. |
Game, X, et al.; [Alternative treatments for interstitial cystitis]; Prog Urol; 2009; 357-363; 19;Abstract. |
Game, X, et al.; Outcome after treatment of detrusor-sphincter dyssynergia by temporary stent; Spinal Cord; 2008; 74-77; 46. |
Game, X; [Sacral neuromodulation and sexuality]; Prog Urol; 2008; 167; 18;Abstract. |
Ganio, E, et al.; Neuromodulation for fecal incontinence: outcome in 16 patients with definitive implant. The initial Italian Sacral Neurostimulation Group (GINS) experience; Dis Colon Rectum; 2001; 965-970; 44. |
George, E, et al.; Use of combined anticholinergic medication and sacral neuromodulation in the treatment of refractory overactive bladder; Female Pelvic Med Reconstr Surg; 2011; 97-99; 17;Abstract. |
Ghazwani, YQ, et al.; Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up; Neurourol Urodyn; 2011; 1271-1275; 30. |
Ghiselli, R, et al.; Nitric oxide synthase expression in rat anorectal tissue after sacral neuromodulation; J Surg Res; 2012; 29-33; 176. |
Giarenis, I, et al.; Management of refractory overactive bladder; Minerva Ginecol; 2013; 41-52; 65;Abstract. |
Giarenis, I, et al.; Managing urinary incontinence: what works?; Climacteric; 2014; 26-33; 17 Suppl 2;Abstract. |
Gibbons, SJ, et al.; Review article: carbon monoxide in gastrointestinal physiology and its potential in therapeutics; Aliment Pharmacol Ther; 2013; 689-702; 38. |
Gill, BC, et al.; Improved sexual and urinary function in women with sacral nerve stimulation; Neuromodulation; 2011; 436-443; discussion 443; 14. |
Gill, BC, et al.; Improvement of bowel dysfunction with sacral neuromodulation for refractory urge urinary incontinence; Int Urogynecol J; 2012; 735-741; 23. |
Gleason, JL, et al.; Sacral neuromodulation effects on periurethral sensation and urethral sphincter activity; Neurourol Urodyn; 2013; 476-479; 32. |
Glinski, RW, et al.; Refractory overactive bladder: Beyond oral anticholinergic therapy; Indian J Urol; 2007; 166-173; 23. |
Gonzalez-Chamorro, F, et al.; [Current status of neurostimulation and neuromodulation for vesicourethral dysfunction]; Arch Esp Urol; 1997; 687-694; 50;Abstract. |
Gonzalez-Chamorro, F, et al.; [Neurostimulation and neuromodulation in urinary incontinence]; Rev Med Univ Navarra; 2004; 75-84; 48;Abstract. |
Gormley, EA, et al.; Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment; J Urol; 2015; 1572-1580; 193. |
Gottwald, T, et al.; [Sex differences in neuromodulation of mucosal mast cells in the rat jejunum]; Langenbecks Arch Chir; 1997; 157-163; 382;Abstract. |
Govaert, B, et al.; Neuromodulation for functional bowel disorders; Best Pract Res Clin Gastroenterol; 2009; 545-553; 23. |
Govier, FE, et al.; Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study; J Urol; 2001; 1193-1198; 165. |
Green, BT, et al.; Neuromodulation of enteropathogen internalization in Peyer's patches from porcine jejunum; J Neuroimmunol; 2003; 74-82; 141. |
Griffin, KM, et al.; Sacral nerve stimulation increases activation of the primary somatosensory cortex by anal canal stimulation in an experimental model; Br J Surg; 2011; 1160-1169; 98. |
Grill, WM; Electrical activation of spinal neural circuits: application to motor-system neural prostheses; Neuromodulation; 2000; 97-106; 3. |
Groen, J, et al.; Chronic pudendal nerve neuromodulation in women with idiopathic refractory detrusor overactivity incontinence: results of a pilot study with a novel minimally invasive implantable mini-stimulator; Neurourol Urodyn; 2005; 226-230; 24. |
Groen, J, et al.; Computerized assessment of detrusor instability in patients treated with sacral neuromodulation; J Urol; 2001; 169-173; 165. |
Groen, J, et al.; Neuromodulation techniques in the treatment of the overactive bladder; BJU Int; 2001; 723-731; 87. |
Groen, J, et al.; Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding; J Urol; 2006; 1005-1009; discussion 1009; 175. |
Groen, LA, et al.; Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms: 15-year experience; J Urol; 2012; 1313-1317; 188. |
Groenendijk, PM, et al.; Five-Year Follow-up After Sacral Neuromodulation: Single Center Experience; Neuromodulation; 2007; 363-368; 10. |
Groenendijk, PM, et al.; Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence; BJU Int; 2008; 325-329; 101. |
Gross, T, et al.; Transcutaneous Electrical Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review; Eur Urol; 2016;Abstract. |
Grossi, U, et al.; Sacral neuromodulation for anorectal dysfunction secondary to congenital imperforate anus: report of two cases; Int J Colorectal Dis; 2014; 889-890; 29. |
Grunewald, V; Neuromodulation/neurostimulation; World J Urol; 1998; 299-300; 16. |
Guerci, B, et al.; Gastric electrical stimulation for the treatment of diabetic gastroparesis; Diabetes Metab; 2012; 393-402; 38. |
Gulur, DM, et al.; Management of overactive bladder; Nat Rev Urol; 2010; 572-582; 7. |
Gupta, P, et al.; Percutaneous tibial nerve stimulation and sacral neuromodulation: an update; Curr Urol Rep; 2015; 4; 16. |
Guys, JM, et al.; [Neurogenic bladder in children: basic principles in diagnosis and treatment]; Ann Urol (Paris); 2006; 15-27; 40;Abstract. |
Bernstein, AJ, et al.; Expanding indications for neuromodulation; Urol Clin North Am; 2005; 59-63; 32. |
Bertapelle, MP, et al.; Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System; World J Urol; 2015; 1109-1117; 33. |
Beusterien, K, et al.; Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder; Neurourol Urodyn; 2015;Abstract. |
Biemans, JM, et al.; Efficacy and effectiveness of percutaneous tibial nerve stimulation in the treatment of pelvic organ disorders: a systematic review; Neuromodulation; 2013; 25-33; discussion 33; 16. |
Bleier, JI, et al.; Surgical management of fecal incontinence; Gastroenterol Clin North Am; 2013; 815-836; 42. |
Blok, BF, et al.; Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators; BJU Int; 2006; 1238-1243; 98. |
Bolton, JF, et al.; Neuromodulation 10 years on: how widely should we use this technique in bladder dysfunction?; Curr Opin Urol; 2009; 375-379; 19. |
Bosch, JL, et al.; Neuromodulation: urodynamic effects of sacral (S3) spinal nerve stimulation in patients with detrusor instability or detrusor hyperflexia; Behav Brain Res; 1998; 141-150; 92. |
Bosch, JL, et al.; Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence: long-term results of a prospective longitudinal study; J Urol; 2000; 1219-1222; 163. |
Bosch, JL, et al.; What treatment should we use if drugs fail for OAB; and, what really works after drugs?; Neurourol Urodyn; 2010; 658-661; 29. |
Bosch, JL; An update on sacral neuromodulation: where do we stand with this in the management of lower urinary tract dysfunction in 2010?; BJU Int; 2010; 1432-1442; 106. |
Bosch, JL; Sacral neuromodulation in the treatment of the unstable bladder; Curr Opin Urol; 1998; 287-291; 8. |
Bosch, JL; Sacral neuromodulation: treatment success is not just a matter of optimal electrode position; BJU Int; 2000; 20-21; discussion 22-23; 85 Suppl 3. |
Bouchelouche, K, et al.; Recent developments in the management of interstitial cystitis; Curr Opin Urol; 2003; 309-313; 13. |
Bouguen, G, et al.; Effects of transcutaneous tibial nerve stimulation on anorectal physiology in fecal incontinence: a double-blind placebo-controlled cross-over evaluation; Neurogastroenterol Motil; 2014; 247-254; 26. |
Bower, WF, et al.; A pilot study of the home application of transcutaneous neuromodulation in children with urgency or urge incontinence; J Urol; 2001; 2420-2422; 166. |
Bower, WF, et al.; A review of non-invasive electro neuromodulation as an intervention for non-neurogenic bladder dysfunction in children; Neurourol Urodyn; 2004; 63-67; 23. |
Bower, WF, et al.; A urodynamic study of surface neuromodulation versus sham in detrusor instability and sensory urgency; J Urol; 1998; 2133-2136; 160. |
Braun, PM, et al.; [Chronic sacral bilateral neuromodulation. Using a minimal invasive implantation technique in patients with disorders of bladder function]; Urologe A; 2002; 44-47; 41. |
Braun, PM, et al.; Alterations of cortical electrical activity in patients with sacral neuromodulator; Eur Urol; 2002; 562-566; discussion 566-567; 41. |
Braun, PM, et al.; Stimulation signal modification in a porcine model for suppression of unstable detrusor contractions; Urology; 2003; 839-844; 61. |
Braun, PM, et al.; Tailored laminectomy: a new technique for neuromodulator implantation; J Urol; 1999; 1607-1609; 162. |
Brink, TS, et al.; A Chronic, Conscious Large Animal Platform to Quantify Therapeutic Effects of Sacral Neuromodulation on Bladder Function; J Urol; 2015; 252-258; 194. |
Bristow, SE, et al.; TENS: a treatment option for bladder dysfunction; Int Urogynecol J Pelvic Floor Dysfunct; 1996; 185-190; 7. |
Brooks, DR, et al.; The Caenorhabditis elegans orthologue of mammalian puromycin-sensitive aminopeptidase has roles in embryogenesis and reproduction; J Biol Chem; 2003; 42795-42801; 278. |
Brosa, M, et al.; Cost-effectiveness analysis of sacral neuromodulation (SNM) with Interstim for fecal incontinence patients in Spain; Curr Med Res Opin; 2008; 907-918; 24. |
Bross, S, et al.; [Sacral neuromodulation in patients with nonobstructive, chronic urinary retention: relevance of the carbachol test and influence of associated nerve lession]; Aktuelle Urol; 2003; 157-161; 34;Abstract. |
Bross, S, et al.; The role of the carbachol test and concomitant diseases in patients with nonobstructive urinary retention undergoing sacral neuromodulation; World J Urol; 2003; 346-349; 20. |
Brouwer, R, et al.; Sacral nerve neuromodulation is effective treatment for fecal incontinence in the presence of a sphincter defect, pudendal neuropathy, or previous sphincter repair; Dis Colon Rectum; 2010; 273-278; 53. |
Brown, DR, et al.; Delta-opioid receptor mRNA expression and immunohistochemical localization in porcine ileum; Dig Dis Sci; 1998; 1402-1410; 43. |
Brown, ET, et al.; New evidence in the treatment of overactive bladder; Curr Opin Obstet Gynecol; 2015; 366-372; 27. |
Brown, SR, et al.; Surgery for faecal incontinence in adults; Cochrane Database Syst Rev; 2013; Cd001757; 7. |
Buback, D; The use of neuromodulation for treatment of urinary incontinence; Aorn j; 2001; 176-178, 181-177, 189-190; quiz 191-176; 73;Abstract. |
Bugbee, M, et al.; An implant for chronic selective stimulation of nerves; Med Eng Phys; 2001; 29-36; 23. |
Buhmann, H, et al.; [Update on fecal incontinence]; Praxis (Bern 1994); 2014; 1313-1321; 103. |
Burks, FN, et al.; Neuromodulation and the neurogenic bladder; Urol Clin North Am; 2010; 559-565; 37. |
Burks, FN, et al.; Neuromodulation versus medication for overactive bladder: the case for early intervention; Curr Urol Rep; 2009; 342-346; 10. |
Burnstock, G, et al.; P2X receptors in health and disease; Adv Pharmacol; 2011; 333-372; 61;Abstract. |
Burnstock, G; Innervation of bladder and bowel; Ciba Found Symp; 1990; 2-18; discussion 18-26; 151;Abstract. |
Burnstock, G; Introduction and perspective, historical note; Front Cell Neurosci; 2013; 227; 7. |
Burnstock, G; Introductory overview of purinergic signalling; Front Biosci (Elite Ed); 2011; 896-900; 3;Abstract. |
Burnstock, G; Purinergic cotransmission; F1000 Biol Rep; 2009; 46; 1. |
Burnstock, G; Purinergic signalling in the gastrointestinal tract and related organs in health and disease; Purinergic Signal; 2014; 18323; 10. |
Burnstock, G; Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future; Bioessays; 2012; 218-225; 34. |
Burnstock, G; Purinergic signalling: past, present and future; Braz J Med Biol Res; 2009; 42437; 42. |
Burnstock, G; The journey to establish purinergic signalling in the gut; Neurogastroenterol Motil; 2008; 42601; 20 Suppl 1. |
Cadish, LA, et al.; Stimulation latency and comparison of cycling regimens in women using sacral neuromodulation; Neurourol Urodyn; 2016;Abstract. |
Cameron, AP, et al.; Battery explantation after sacral neuromodulation in the Medicare population; Neurourol Urodyn; 2013; 238-241; 32. |
Campbell, JD, et al.; Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence; BMC Urol; 2009; 18; 9. |
Campin, L, et al.; [Urinary functional disorders bound to deep endometriosis and to its treatment: review of the literature]; J Gynecol Obstet Biol Reprod (Paris); 2014; 431-442; 43;Abstract. |
Sherman, ND, et al.; Sacrel neuromodulation for the treatment of refractory urinary urge incontinence after stress incontinence surgery; Am J Obstet Gynecol, 2005; 2083-2087,193. |
Sherman, ND, et al.; The current use of neuromodulation for bladder dysfuntion: Minerva Ginecol; 2000; 283-293; 58:Abstract. |
Shi, P. et al.; Bladder response to acute sacral neuromodulation while treating rats in different phases of complete spinal cord injury: a preliminary study; Int Braz J Urol; 2015; 1194-1201; 41. |
Shi, P, et al.: Effects of acute sacral neuromodulation on bladder reflex in complete spinal ori injury rats; Neuromodulation: 2013; 583-589; discussion 589; 16. |
Shvarts, PG, et al.; [The modern methods of the electrical stimulation for the management of neurogenic disturbances of urination]; Vopr Kurortol Fizioter Lech Fiz Kult; 2015; 18-21; 92. |
Siegel, S, et al.; Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medial therapy at 6-months in subjects with mild syptoms of overactive bladder; Neurourol Urodyn: 2015; 224-230; 34. |
Sievert, KD, et al.; [Unconventional treatment procedures of the bladder in paraplegia and myelomeningocele]; Urologe A; 2012; 1692-1696; 51. |
Sievert, KD, et al.; Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury; Ann Neurol; 2010; 74-84; 67. |
Sievert, KD; Neuromodulation; Neurourol Urodyn; 2005; 310; 24. |
Signorello, D, et al.; Impact of sacral neuromodulation on female sexual function and his correlation with clinical outcome and quality of life indexes: a monocentric experience; J Sex Med; 2011; 1147-1155; 8. |
Sillen, U, et al.; Effects of transcutaneous neuromodulation (TENS) on overactive bladder symptoms in children: a randomized controlled trial; J Pediatr Urol; 2014; 1100-1105; 10. |
Silveri, M, et al.; Voiding dysfunction in x-linked adrenoleukodystrophy: symptom score and urodynamic findings; J Urol; 2004; 2651-2653; 171. |
Sivalingam, N, et al.; Concepts in the management of the overactive bladder in women; Med J Malaysia; 2012; 137-141; quiz 142; 67. |
Skobejko-Wlodarska, L; [Non-neurogenic lower urinary tract dysfuntion]; Pol Merkur Lekarski; 2008; 131-137; 24 Suppl 4;Abstract. |
Smaldone, MC, et al.; Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neurotoxin: Nat Clin Pract Urol; 2008; 120-121; 5. |
Smith, AL, et al.; Contemporary management of overactive bladder; Postgrad Med; 2012; 104-116; 124;Abstract. |
Smits, MA, et al.; [Neuromodulation as a treatment for overactive bladder syndrome]; Ned Tijdschr Geneeskd; 2012; A4135; 156;Abstract. |
Smits, MA, et al.; Sacral neuromodulation in patients with idiopathic overactive bladder after intial botulinum toxin therapy: J Urol; 2013; 2148-2158; 190. |
Snellings, AE, et al.; Effects of stimulation site and stimulation parameters on bladder inhibition by electrical nerve stimulation; BJU Int; 2012; 136-143; 110. |
South, MM, et al.; Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation; Int Urogynecol J Pelvic Floor Dysfunct: 2007; 1395-1398; 18. |
Speer, LM, et al.; Chronic Pelvic Pain in Women; Am Fam Physician, 2016; 380-387; 93. |
Spinelli, M, et al.; A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: description of the method and preliminary data; Neurourol Urodyn; 2005; 305-309; 24. |
Spinelli, M, et al.; Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety; Eur Urol; 2008; 1287-1296; 54. |
Spinelli, M, et al.; New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience; J Urol; 2003; 1905-1907; 170. |
Srivastava, D; Efficacy of sacral neuromodulation in treating chronic pain related to painful bladder syndrome/interstitial cystitis in adults; J Anaesthesiol Clin Pharmacol; 2012; 428-435; 28. |
Starkman, JS, et al.; Management of refractory urinary urge incontienence following urogynecological surgery with sacral neuromodulation; Neurourol Urodyn; 2007; 29-35; discussion 36; 26. |
Starkman, JS, et al.; Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 277-282; 19. |
Starkman, JS, et al.; Surgical options for drug-refractory overactive bladder patients; Rev Urol: 2010; e97-e110; 12. |
Starkman, JS, et al.; The evolution of obstruction induced overactive bladder symptoms following urethrolysis for female bladder outlet obstruction; J Urol; 2008; 1018-1023; 179. |
Steanu, ID, et al.; The Place of the Ice Water Test (IWT) in the Evaluation of the Patients with Traumatic Spinal Cord Injury, Maedica (Buchar); 2012; 125-130; 7. |
Stephany, HA, et al.; Prospective evaluation of sacral nerve modulation in children with validated questionnaires; J Urol; 2013; 1516-1522; 190. |
Stoffel, JT: Contemporary management of the neurogenic bladder for multiple sclerosis patients; Urol Clin North Am; 2010; 547-557; 37. |
Su, X, et al.; Comparison of neural targets for neuromodulation of bladder micturition reflex in the rat; Am J Physiol Renal Physiol; 2012; F1196-1206; 303. |
Su, X, et al.; Differentiation and interaction of tibial versus spinal nerve stimulation for micturition control in the rat; Neurourol Urodyn; 2015; 92-97; 34. |
Su, X, et al.; Neuromodulation attenuates bladder hyperactivity in a rat cystitis model; BMC Urol; 2013; 70; 13. |
Su, X, et al.; Neuromodulation in a rat model of the bladder micturition reflex; Am J Physiol Renal Physiol. 2012; F477-486; 302. |
Su, X, et al.; Optimization of Neuromodulation for Bladder Control in a Rat Cystitis Model; Neuromodulation; 2016; 101-107; 19. |
Su, X, et at.; Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex; BMC Urol; 2015; 50; 15. |
Su, X, et al.; Quantification of effectiveness of bilateral and unilateral neuromodulation in the rat bladder rhythmic contraction model; BMC Urol; 2013; 34; 13. |
Su, X, et al.; Role of the endogenous opioid systme in modulation of urinary bladder activity by spinal nerve stimulation; Am J Physiol Renal Physiol; 2013; F52-60; 305. |
Sullivan, J. et al.; Overactive detrusor; Curr Opin Urol; 199; 291-296; 9. |
Sullivan, J, et al.; The overactive bladder: neuropharmacological basis of clinical management; Curr Opin Obstet Gynecol; 1999; 477-483; 11. |
Sun, Y, et al.; Effects of neural blocking agents on motor activity and secretion in the proximal and distal rat colon; evidence of marked segmental differences in nicotinic receptor activity; Scand J Gastroenterol; 2000; 380-388; 35. |
Suskind, AM, et al.; Physician Use of Sacral Neuromodulation Among Medicare Beneficiaries With Overactive Bladder and Urinary Retention; Urology; 2015; 30-34; 86. |
Suskind, AM, et al.; Understanding the dissemination of sacral neuromodulation; Surg Innov; 2013; 625-630; 20. |
Sutherland, RS, et al.; Vesicourethral function in mice with genetic disruption of neuronal nitric oxide synthase; J Urol; 1997; 1109-1116; 157. |
Svensson, L, et al.; Neuromodulation of experimental Shigella infection reduces damage to the gut mucosa; Microbes Infect; 2004; 256-264; 6. |
Swinn, MJ, et al.; The cause and natural history of isolated urinary retention in young women; J Urol; 2002; 151-156; 167. |
Tai, C, et al.; Bladder inhibition by intermittent pudendal nerve stimulation in cat using transdermal amplitude-modulated signal (TAMS); Neurourol Urodyn; 2012; 1181-1184; 31. |
Tai, C, et al.; Inhibition of bladder overactivity by stimulation of feline pudendal nerve using transdermal amplitude-modulation signal (TAMS); BJU Int; 2012; 782-787; 109. |
Canbaz Kabay, S, et al.; Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results; Neurourol Urodyn; 2015; Abstract. |
Cardarelli, S, et al.; Efficacy of sacral neuromodulation on urological diseases: a multicentric research project; Urologia; 2012; 90-96; 79. |
Cardot, V, et al.; [Guidelines for the treatment of urinary incontinence in women with refractory idiopathic vesical hyperactivity using sacral neuromodulation]; Prog Urol; 2010; S161-169; 20 Suppl 2;Abstract. |
Carey, HV, et al.; Neuromodulation of intestinal transport in the suckling mouse; Am J Physiol; 1989; R481-486; 256; Abstract. |
Carey, M, et al.; Sacral nerve root stimulation for lower urinary tract dysfunction: overcoming the problem of lead migration; BJU Int; 2001; 15-18; 87. |
Carlson, JJ, et al.; Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States; Clin Ther; 2013; 414-424; 35. |
Carlucci, L, et al.; Functional variability of sacral roots in bladder control; J Neurosurg Spine; 2014; 961-965; 21. |
Carr, MC; Conservative nonsurgical management of spina bifida; Curr Urol Rep; 2010; 109-113; 11. |
Carrington, EV, et al.; A systematic review of sacral nerve stimulation mechanisms in the treatment of fecal Incontinence and constipation; Neurogastroenterol Motil; 2014; 1222-1237; 26. |
Chaabane, W, et al.; Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study; Neurourol Urodyn; 2011; 547-550; 30. |
Chan, DK, et al.; Effective treatment of dyssynergic defecation using sacral neuromodulation in a patient with cerebral palsy; Female Pelvic Med Reconstr Surg; 2015; e27-29; 21;Abstract. |
Chancellor, MB, et al.; Principles of Sacral Nerve Stimulation (SNS) for the Treatment of Bladder and Urethral Sphincter Dysfunctions; Neuromodulation; 2000; 16-26; 3. |
Chandra, A, et al.; Neuromodulation of perineally transposed antropylorus with pudendal nerve anastomosis following total anorectal reconstruction in humans; Neurogastroenterol Motil; 2014; 1342-1348; 26. |
Chapple, C, et al.; The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?; BJU Int; 2009; 1188-1190; 104. |
Chapple, CR, et al.; Surgery for detrusor overactivity; World J Urol; 1998; 268-273; 16. |
Chartier-Kastler, E, et al.; [Sacral neuromodulation with InterStim system: Results from the French national register]; Prog Urol; 2011; 209-217; 21;Abstract. |
Chartier-Kastler, E, et al.; [Update on the second line management of idiopathic overactive bladder]; Prog Urol; 2009; 530-537; 19;Abstract. |
Chartier-Kastler, E; Sacral neuromodulation for treating the symptoms of overactive bladder syndrome and non-obstructive urinary retention: >10 years of clinical experience; BJU Int; 2008; 417-423; 101. |
Chatoor, D, et al.; Constipation and evacuation disorders; Best Pract Res Clin Gastroenterol; 2009; 517-530; 23. |
Chen, G, et al.; Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease; Spinal Cord; 2014;Abstract. |
Chen, G, et al.; The inhibitory effects of pudendal nerve stimulation on bladder overactivity in spinal cord injury dogs: is early stimulation necessary?; Neuromodulation; 2012; 232-237; discussion 237; 15. |
Chen, ML, et al.; Electrical stimulation of somatic afferent nerves in the foot increases bladder capacity in healthy human subjects; J Urol; 2014; 1009-1013; 191. |
Chen, SC, et al.; Pudendal neuromodulation improves voiding efficiency in diabetic rats; Neurourol Urodyn; 2013; 293-300; 32. |
Chiarioni, G, et al.; Neuromodulation for fecal incontinence: an effective surgical intervention; World J Gastroenterol; 2013; 7048-7054; 19. |
Choudhary, M, et al.; Inhibitory effects of tibial nerve stimulation on bladder neurophysiology in rats; Springerplus; 2016; 35; 5. |
Colaco, M, et al.; Current guidelines in the management of interstitial cystitis; Transl Androl Urol; 2015; 677-683; 4. |
Collins, SM; Is the irritable gut an inflamed gut?; Scand J Gastroenterol Suppl; 1992; 102-105; 192;Abstract. |
Comiter, CV; Conscious Neuromodulation of the Bladder before Clinical Use; J Urol; 2015; 16-17; 194. |
Comiter, CV; Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study; J Urol; 2003; 1369-1373; 169. |
Corcos, J, et al.; Canadian Urological Association guidelines on urinary incontinence; Can J Urol; 2006; 3127-3138; 13;Abstract. |
Cornu, JN; Actual treatment of overactive bladder and urge urinary incontinence; Minerva Urol Nefrol; 2013; 21-35; 65;Abstract. |
Costa, JA, et al.; Spinal cord neuromodulation for voiding dysfunction; Clin Obstet Gynecol; 2000; 676-688; 43. |
Craggs, M, et al.; Neuromodulation of the lower urinary tract; Exp Physiol; 1999; 149-160; 84. |
Craggs, MD; Objective measurement of bladder sensation: use of a new patient-activated device and response to neuromodulation; BJU Int; 2005; 29-36; 96 Suppl 1. |
Crock, LW, et al.; Central amygdala metabotropic glutamate receptor 5 in the modulation of visceral pain; J Neurosci; 2012; 14217-14226; 32. |
Dahms, SE, et al.; Sacral neurostimulation and neuromodulation in urological practice; Curr Opin Urol; 2000; 329-335; 10. |
Daneshgari, F, et al.; Future directions in pelvic neuromodulation; Urol Clin North Am; 2005; 113-115, viii; 32. |
Daneshgari, F; Applications of neuromodulation of the lower urinary tract in female urology; Int Braz J Urol; 2006; 262-272; 32. |
Daniels, DH, et al.; Sacral neuromodulation in diabetic patients: success and complications in the treatment of voiding dysfunction; Neurourol Urodyn; 2010; 578-581; 29. |
Dasgupta, R, et al.; Changes in brain activity following sacral neuromodulation for urinary retention; J Urol; 2005; 2268-2272; 174. |
Dasgupta, R, et al.; The management of female voiding dysfunction: Fowler's syndrome—a contemporary update; Curr Opin Urol; 2003; 293-299; 13. |
Davis, T, et al.; Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: Lack of anticholinergic efficacy versus intolerability; Can Urol Assoc J; 2013; 176-178; 7. |
De Boer, TA, et al.; [Male urinary incontinence]; Ned Tijdschr Geneeskd; 2008; 797-802; 152;Abstract. |
De Gennaro, M, et al.; Current state of nerve stimulation technique for lower urinary tract dysfunction in children; J Urol; 2011; 1571-1577; 185. |
De Gennaro, M, et al.; Percutaneous tibial nerve neuromodulation is well tolerated in children and effective for treating refractory vesical dysfunction; J Urol; 2004; 1911-1913; 171. |
De Groat, WC, et al.; Impact of Bioelectronic Medicine on the Neural Regulation of Pelvic Visceral Function; Bioelectron Med; 2015; 25-36; 2015. |
De Seze, M, et al.; [Peripheral electrical stimulation in neurogenic bladder]; Ann Readapt Med Phys; 2008; 473-478; 51;Abstract. |
Deffieux, X, et al.; [Voiding dysfunction after surgical resection of deeply infiltrating endometriosis: pathophysiology and management]; Gynecol Obstet Fertil; 2007; S8-13; 35 Suppl 1;Abstract. |
Del Popolo, G, et al.; [Standard pharmacological treatment and new therapies for overactive bladder]; Urologia; 2012; 42534; 79. |
Denzinger, S, et al.; Does sacral neuromodulation lead to relevant reduction in the need for intermittent catheterization? A single-center experience on patients with chronic urinary retention; Neuromodulation; 2012; 586-591; discussion 591; 15. |
Guys. JM, et al.; Sacral neuromodutation for neurogenic bladder dysfunction in children; J Urol; 2004; 1673-1676; 172. |
Haddad, M, et al,; Sacral neuromodulation in children with urinary and fecal incontinence: a multicenter, open label, randomized, crossover study, J Urol: 2010; 696-701; 184. |
Hamann, MF, et al.; [Urinary incontinence in men and women. Diagnostics and conservative therapy]; Urolege A; 2014; 1073-1084; quiz 1085-1076: 53. |
Hartmann, KE, at al.; Treatment of overactive bladder in women; Evid Rep Technol Assess (Full Rep): 2009; 1-120. v:. |
Hasan, ST, et al.; Neuromodulation in bladder dysfunction; Curr Opin Obstet Gynecol; 1998: 395-399; 10. |
Hasan, ST, et al.; Surface localization of sacral foramina for neuromodulation of bladder function, An anatomical study; Eur Urol: 1996; 90-98; 29;Abstract. |
Hasan, ST, et al.; Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability; J Urol; 1996; 2005-2011; 155. |
Hashim, H, et al.; Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations; Drugs; 2004; 1643-1656; 64. |
Hashim, H, et al.; Novel uses for antidiuresis; Int J Clin Prat Suppl; 2007; 32-36; ;Abstract. |
Hashim. H, et al.; Patient preferences for treating refractory overactive bladder in the UK; Int Urol Nephrol; 2015; 1619-1627: 47. |
Hassouna, M, et al,; Dog as an animal model for neurostimulation; Neurourol Urodyn; 1994; 159-167; 13. |
Hassouna, M. et al.; Update on sacral neuromodulation; indications and outcomes; Curr Urol Rep; 2003; 391-398; 4. |
Hassouna, M; Sacral neuromodulation for overactive bladder: Is it worth It?: Can Urol Assoc J; 2013: E454; 7. |
Hassouna, MM, et al.; Economic evaluation of sacral neuromodutation in overactive bladder: A Canadian perspective; Can Urol Assoc J; 2015; 242-247; 9. |
Hedlund, H. et al.; Sacral neuromodulation in Norway: clinical experience of the first three years; Scand J Urol Nephrol Suppl; 2002; 87-95; ;Abstract. |
Heinze, K, et al.; [Neuromodulation—new techniques]; Urologe A; 2015; 373-377; 54. |
Hellstrom, PA, et al.; Sacral nerve stimulation lead implantation using the O-arm; BMC Urol; 2013; 48: 13. |
Herbison. GP, et al.; Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults; Cochrane Database Syst Rev; 2009; Cd004202. |
Hersh, L, et al.; Clinical management of urinary incontinence in women: Am Fam Physician; 2013; 634-640, 87. |
Hijaz, A, et al.; Complications and troubleshooting of two-stage sacral neuromodulation therapy: a single-institution experience; Urology; 2006; 533-537; 68. |
Hill, AJ, et al.; Resolution of Chronic Vulvar Pruritus With Replacement of a Neuromodulation Device; J Minim Invasive Gynecol; 2015: 889-891; 22. |
Hindley, RG, et al.; The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate; BJU Int; 2001; 217-220; 88. |
Hoag, N, et al.; Underactive Bladder: Clinical Features, Urodynamic Parameters, and Treatment; Int Neurourol J; 2015; 185-189; 19. |
Hoch, M, et al.; [Chemical destruction of sacral nerve roots by alcohol injection for the treatment of overactive bladder]; Prog Urol; 2006; 584-587; 16;Abstract. |
Hoda, MR, et al.; [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine?]; Urologe A; 2010; 1254-1259: 49. |
Hoebeke, P. et al.; Transcutaneous neuromodulation for the urge syndrome in children: a pilot study; J Urol; 2001; 2416-2419; 166. |
Hohenfellner, M, et el.; [Sacral neuromodulation of the urinary bladder]: Urologe A; 2000: 55-63; 39. |
Hohenfellner, M, et al.; Bilateral chronic sacral neuromodutation for treatment of low urinary tract dysfunction; J Urol; 1998; 821-824; 160. |
Hohenfellner, M, et al.; Chronic sacral neuromodulation for treatment of neurogenic bladder dysfunction: long-term results with unilateral implants; Urology; 2001; 887-892: 58. |
Hohenfellner, M. et al.; Sacral neuromodulation for treatment of lower urinary tract dysfunction: BJU Int: 2000; 10-19; discussion 22-13, 85 Suppl 3. |
Hoque, T, et al.; Validation of internal controls for gene expression analysis in the intestine of rats infected with Hymenolepis diminuta; Parasitol Int; 2007; 325-329; 56. |
Horrocks, EJ, et al.; Double-blind randomised controlled trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in the treatment of faecal incontinence: CONtrol of Faecal Incontinence using Distal NeuromodulaTion (the CONFIDeNT trial); Health Technol Assess; 2015; 1-164; 19. |
Hotouras, A. et al.; Prospective clinical audit of two neuromodulatory treatments for fecal incontinence: sacral nerve stimulation (SNS) and percutaneous tibial nerve stimulation (PTNS); Surg Today: 2014: 2124-2130; 44. |
Hoyle, CH, et al.; Ethylcholine mustard aziridinium on (AF64A) impairs cholinergic neuromuscular transmission in the guinea-pig ileum and urinary bladder, and cholinergic neuromodulation in the enteric nervous system of the guinea-pig distal colon; Gen Pharmacol; 1986; 543-548; 17. |
Hubsher, CP, et al.; Sacral nerve stimulation for neuromodulation of the lower urinary tract; Can J Urol; 2012; 6480-6484; 19. |
Hull, T, et al., Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence; Dis Colon Rectum; 2013; 234-245; 56. |
Hull, TL; Sacral neuromodulation stimulation in fecal incontinence; Int Urogynecol J; 2010: 1565-1568; 21. |
Humphreys, MR, et al.; Preliminary results of sacral neuromodulation in 23 children: J Urol; 2006; 2227-2231; 176. |
Hyun, SJ, et al.; Comparative analysis between thoracic spinal cord and sacral neuromodulation in a rat spinal cord injury model; a preliminary report of a rat spinal cord stimulation model; Korean J Spine; 2013; 14-18; 10. |
Iarumov, N, et al.; [Anal incontinence—new methods of surgical treatment using artificial bowel sphincter and sacral nerve stimulation]; Khirurgiia (Sofiia): 2007; 40-45; ;Abstract. |
Indar, A, et al.; A dual benefit of sacral neuromodulation; Surg Innov; 2008; 219-222: 15. |
Indinnimeo, M. et al.; Sacral neuromodulation for the treatment of fecal incontinence: analysis of cost-effectiveness; Dis Colon Rectum; 2010; 1661-1669, 53. |
Ingber, MS, et al.; Neuromodulation and female sexual function: does treatment for refractory voiding symptoms have an added benefit?; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 1055-1059: 20. |
Iqbal, F, et al.; Bilateral transcutaneous tibial nerve stimulation for chronic constipation; Colorectal Dis; 2016; 173-178; 18. |
Ishigooka, M, et al.; Sacral nerve stimulation and diurnal urine volume; Eur Urol; 1999; 421-426; 36;Abstract. |
Jacobs, SA, et al.; Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet; Neurourol Urodyn; 2014; 488-492; 33. |
Jadav, AM, et al.; Does sacral nerve stimulation improve global pelvic function in women?; Colorectal Dis; 2013; 848-857; 15. |
Jarrett, ME; Neuromodulation for constipation and fecal incontinence; Urol Clin North Am; 2005; 79-87; 32. |
Jarvis; JC, et al.; Functionai electrical stimulation for control of internal organ function; Neuromodulation; 2001; 155-164; 4. |
Jesus, LE, et al:, Psychosocial and respiratory disease related to severe bladder dysfunction and non-monosymptornatic enuresis; J Pediatr Urol; 2015;Abstract. |
Majerus, SJ, et al.; Wireless, Ultra-Low-Power Implantable Sensor for Chronic Bladder Pressure Monitoring: ACM J Emerg Technol Comput Syst; 2012;8. |
Mally, AD, et al.; Role of opioid and metabotropic glutamate 5 receptors in pudendal inhibition of bladder overactivity in cats; J Urol; 2013; 1574-1579; 189. |
Malossi, J, et al.; Sacral neuromodulation for the treatment of bladder dysfunction; Curr Urol Rep; 2002; 61-66; 3. |
Malouf, AJ, et al.; Short-term effets of sacral nerve stimulation for idiopathic slow transit constipation; World J Surg; 2002; 166-170; 26. |
Mamopoulos, A, et al., Active sacral neuromodulator during pregnancy: a unique case report; Am J Obstet Gynecol: 2014; e4-5; 211. |
Manriquez, V. et al.; Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial; Eur J Obstet Gynecol Reprod Biol; 2016; 42531; 196. |
Marcelissen, T, et al.; Is the screening method of sacral neuromodulation a prognostic factor for long-term success?; J Urol; 2011; 583-587; 185. |
Marcelissen, T, et al.; Sacral neuromodulation as a treatment for chornic pelvic pain; J Urol; 2011; 387-393; 186. |
Marcelissen, TA, et al.; Long-term results of sacral neuromodulation with the tined lead procedure; J Urol; 2010; 1997-2000; 184. |
Marcelissen, TA, et al.; Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment; BJU Int; 2011; 1834-1838; 108. |
Marcelissen, TA, et al.; The effect of pulse rate changes on the clinical outcome of sacral neuromodulation; J Urol; 2011; 1781-1785; 185. |
Marcelissen, TA, et al.; The use of bilaterai sacral nerve stimulation in patients with loss of unilateral treatment efficacy; J Urol; 2011; 976-980; 185. |
Marinkovic, SP, et al.; Neuremodutation for Overactive Bladder Symptoms in Women Utilizing Either Motor or Sensory/Motor Provocation With a Minimum Nine-Year Follow-Up; Neuromodulation; 2015; 517-521; discussion 521; 18. |
Martin Braun, P, et al.; [Continuous bilateral sacral neuromodulation as a minimally invasive implantation technique to patients with functional bladder changes]; Arch Esp Urol; 2003; 497-501; 56. |
Martinson, M. et al.; Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation; J Urol; 2013; 210-216; 189. |
Mason, MD, et al.; Prospective Evaluation of Sacral Neuromodulation in Children: Outcomes and Urodynamic Predictors of Success; J Urol; 2016. |
Matsuta Y, et al.; Contribution of opioid and metabotropic glutamate receptor mechanisms to inhibition of bladder overactivity by tibial nerve stimulation; Am J Physiol Regul Integr Comp Physiol; 2013; R126-133; 305. |
Matsuta, Y, et al.; Effect of methysergide on pudendal inhibition of micturition reflex in cats; Exp Neurol; 2013; 250-258; 247. |
Matsuta, Y, et al.; Poststimulation inhibition of the mictuntion reflex induced by tibial nerve stimulation in rats; Physiol Rep; 2014; e00205; 2. |
Mauroy, B, et al.; [Long-term results of interferential current stimulation in the treatment of bladder instability]; Prog Urol; 2001; 34-39; 11; Abstract. |
Mayer, R; Neuromodulation—who, what, when, where and why?; J Urol; 2010; 17-18; 183. |
Mayr, CA, et al.; Cost-effectiveness of novel therapies for overactive bladder; Expert Rev Pharmacoecon Outcomes Res; 2014; 527-535; 14. |
Mazo, EB, et al.; [Temporary sacral and tibial neuromodulation in treating patients with ovractive urinary bladder]; Zh Vopr Neirokhir Im N N.Burdenko; 2002; 17-21; ;Abstract. |
Mazo, EB, et al.; [Temporary sacral neuromodulation in patients with urge incontinence]; Urologiia: 2000; 42-46; ;Abstract. |
Mazo, EB, et al.; [The role of somatosensory evoked potentials in prognosis of efficacy of tibial neuromodulation in patients with hyperactive urinary bladder]; Urologiia; 2005; 49-52; ;Abstract. |
McAchran, SE, et al.; Sacral neuromodulation in the older woman; Clin Obstet Gynecol; 2007; 735-744; 50. |
McKertich, K; Urinary incontinence-procedural and surgical treatments for women; Aust Fam Physician, 2008; 122-131; 37. |
McNevin, MS, et al.; Outcomes associated with interstim therapy for medically refractory fecal incontinence; Am J Surg; 2014; 735-737; discussion 737-788; 207. |
Mehnert, U, et al.; [Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology, and treatment options]; Urologe A; 2012; 189-197; 51. |
Mehnert, U, et al.; The management of urinary incontinence in the male neurological patient; Curr Opin Urol; 2014; 586-592; 24. |
Meissnitzer, T, et al.; CT-Guided Lead Placement for Selective Sacral Neuromodulation to Treat Lower Urinary Tract Dysfunctions; AJR Am J Rosentgenol; 2015; 1139-1142; 205. |
Melenhorst, J, et al.; Sacral neuromodulation in patients with faecal incontinence: results of the first 100 permanent implantation; Colorectal Dis; 2007; 725-730; 9. |
Meurette, G. et al.; Sacral nerve stimulation enhances epithelial barrier of the rectum: results from a porcine model; Neurogastroenterol Motil; 2012; 267-273, e110; 24. |
Michelsen, HB, et al.; Rectal volume tolerability and anal pressures in patients with fecal incontinence treated with sacral nerve stimulation; Dis Colon Rectum; 2006; 1039-1044; 49. |
Miller, JJ, et al.; Diagnosis and treatment of overactive bladder; Minerva Ginecol; 2005; 501-520; 57;Abstract. |
Milne, JL; Behavioral therapies for overactive bladder: making sense of the evidence: J Wound Ostomy Continence Nurs; 2008; 93-101; quiz 102-103; 35;Abstract. |
Minardi, D, et al.; Activity and expression of nitric oxide synthase in rat bladder after saral neuromodulation; Int J Immunopathol Pharmacol; 2008; 129-135; 21;Abstract. |
Minardi, D, et al.; Lower urinary tract and bowel disorders and multiple sclerosis: role of sacral neuromodulation: a preliminary report; Neuromodulation; 2005; 176-181; 8. |
Miotla, P, et al.; [Sacral nerve stimulation in the treatment of the lower urinary tract function disorders]; Ginekol Pol; 2011; 851-856; 82. |
Mishra, NN; Clinical presentation and treatment of bladder pain syndrome/interstitial cystitis (BPS/IC) in India; Transl Androl Urol; 2015; 512-523; 4. |
Moon, KH, et al.; Prospective Trial of Sacral Neuromodulation for Refractory Overactive Bladder Syndrome in Korean Patients; Low Urin Tract Symptoms; 2014; 175-179; 6. |
Moutzouris, DA, et al.; Interstitial cystitis: an unsolved enigma: Clin J Am Soc Nephrol; 2009; 1844-1857; 4. |
Murphy, AM, et al.; Treatment of overactive bladder: what is on the horizon?; Int Urogynecol J; 2013; 42503; 24. |
Musco, S, et al.; Percutaneous Tibial Nerve Stimulation Improves Female Sexual Function in Women with Overactive Bladdere Syndrome: J Sex Med; 2016. |
N. Patidar et al.; Transcutaneous posterior tibial nerve stimulation in pediatric overactivebladdeer; A preliminary report; Journal of Pediatric Urology; 2015; 351.e1-351.e6; 11. |
Nakib, N, et al.; Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neuromodulation; Nat Clin Pract Urol; 2008; 118-119; 5. |
Nambiar, A, et al.; Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO); Neurourol Urodyn; 2014; S21-25; 33 Suppl 3. |
Natalin, R, et al.; Management of OAB in those over age 65; Curr Urol Rep; 2013; 379-385; 14, |
Ng, CK, et al.; Refractory overactive bladder in men: update on novel therapies; Curr Urol Rep; 2006; 456-461; 7. |
Nijman, RJ; Classification and treatment of functional incontinence in children; BJU Int; 2000; 37-42; discussion 45-36; 85 Suppl 3. |
Krivoborodov, GG, et al.; [Tibial neuromodulation in the treatment of neurogenic detrusor hyperactivity in patients with Parkinson's disease]; Urologiia; 2006; 42435; ;Abstract. |
Krolczyk, G, et al.; Effects of continuous microchip (MC) vagal neuromodulation on gastrointestinal function in rats; J Physiol Pharmacol; 2001; 705-715; 52. |
Kubota, M, et al.; Effects of neuromodulation with sacral magnetic stimulation for intractable bowel or bladder dysfunction in postoperative patients with anorectal malformation: a preliminary report; Pediatr Surg Int; 2011; 599-603; 27. |
Kumsar, S, et al.; Effects of sacral neuromodulation on isolated urinary bladder function in a rat model of spinal cord injury; Neuromodulation; 2015; 67-74; discussion 74-65; 18. |
Kuo, HC; Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction: Urology; 2007; 57-61; discussion 61-52; 69. |
Kuo, TL, et al.; Pelvic floor spasm as a cause of voiding dysfunction; Curr Opin Urol; 2015; 311-316; 25. |
Kurpad, R, et al.; The evaluation and management of refractory neurogenic overactive bladder: Curr Urol Rep; 2014; 444; 15. |
Kutzenberger, J: [Neurogenic urinary incontinence. Value of surgical management]; Urologe A; 2008; 699-706; 47. |
La, TH, et al.; Intermittent sacral neuromodulation for idiopathic urgency urinary incontinence in women; Neurourol Urodyn; 2015;Abstract. |
Laudano, MA, et al.; Disparities in the Use of Sacral Neuromodulation among Medicare Beneficiaries; J Urol; 2015; 449-453; 194. |
Laviana, A, et al.; Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome; Neurosurg Clin N Am; 2014; 33-46; 25. |
Lay, AH, et al.; The role of neuromodulation in patients with neurogenic overactive bladder; Curr Urol Rep; 2012; 343-347; 13. |
Lazzeri, M, et al.; The challenge of overactive bladder therapy; alternative to antimuscarinic agents; Int Braz J Urol; 2006; 620-630; 32. |
Le, NB, et al.; Expanding the Role of Neuromodulation for Overactive Bladder: New Indications and Alternatives to Delivery; Curr Bladder Dysfunct Rep; 2011; 25-30; 6. |
Leclers, F, et al.; [Cystomanometric study of bladder sensation during sacral neuromodulation test]; Prog Urol; 2005; 238-243; 15;Abstract. |
Lee, YY; What's New in the Toolbox for Constipation and Fecal Incontinence?; Front Med (Lausanne); 2014; 5; 1. |
Leicht, W, et al.; [Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity]; Urologe A; 2012; 348-351; 51. |
Leng, WW, et al.; How sacral nerve stimulation neuromodulation works; Urol Clin North Am; 2005; 42692; 32. |
Leong, FC, et al.; Neuromodulation for the treatment of urinary incontinence; Mo Med; 2007; 435-439; 104;Abstract. |
Leong, RK, et al.; Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder; BJU Int; 2011; 558-564; 108. |
Leong, RK, et al.; Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review; Urol Int; 2010; 245-253; 84. |
Leong, RK, et al.; PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy; Neurourol Urodyn; 2011; 1249-1252; 30. |
Leong, RK, et al.; Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey; J Urol; 2011; 588-592; 185. |
Levin, PJ, et al.; Psychosocial factors related to the use of InterStim(R) for the treatment of refractory overactive bladder; Female Pelvic Med Reconstr Surg; 2014; 272-275; 20;Abstract. |
Levin, PJ, et al.; The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review; Int Urogynecol J; 2012; 1591-1597; 23. |
Levy, RM; The evolving definitioin of neuromodulation; Neuromodulation; 2014; 207-210; 17. |
Lewis, JM, et al.; Non-traditional management of the neurogenic bladder; tissue engineering and neuromodulation; ScientificWorldJournal; 2007; 1230-1241; 7. |
Liao, KK, et al.; Effect of sacral neuromodulation on the spinal nociceptive reflex of patients with idiopathic overactive bladder; Neuromodulation; 2008; 50-55; 11. |
Liberman, D, et al.; Concerns regarding sacral neuromodulation as a treatment option for medical-refractory overactive bladder; Can Urol Assoc J; 2011; 285-287; 5. |
Lin, YT, et al.; Effects of pudendal neuromodulation on bladder function in chronic spinal cord-injured rats; J Formos Med Assoc; 2015. |
Linares Quevedo, AI, et al.; [Posterior sacral root neuromodulation in the treatment of chronic urinary dysfunction]; Actas Urol Esp; 2002; 250-260; 26;Abstract. |
Lippmann, QK, et al.; Successful use of sacral neuromodulation in a 12-year-old with cerebral palsy and neurogenic bladder; Neuromodulation; 2014; 396-398; 17. |
Lombardi, G. et al.; Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in patients with incomplete spinal cord injury; Spinal Cord; 2011; 629-636; 49. |
Lombardi, G, et al.; Clinical female sexual outcome after sacral neuromodulation implant for lower urinary tract symptom (LUTS); J Sex Med; 2008; 1411-1417; 5. |
Lombardi, G, et al.; Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms; Spinal Cord; 2009; 486-491; 47. |
Lombardi, G, et al.; Clinical outcome of sacral neuromodulation in incomplete spinal cord-injured patients suffering from neurogenic bowel dysfunctions; Spinal Cord; 2010; 154-159; 48. |
Lombardi, G, et al.; Intravesical electrostimulation versus sacral neuromodulation for incomplete spinal cord patients suffering from neurogenic non-obstructive urinary retention; Spinal Cord; 2013; 571-578; 51. |
Lombardi, G, et al.; Sacral neuromodulation and female sexuality; Int Urogynecol J; 2015; 1751-1757; 26. |
Lombardi, G, et al.; Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile function; J Sex Med; 2008; 2135-2140; 5. |
Lombardi, G, et al.; Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year-follow-up single-centre experience; Spinal Cord; 2014; 241-245; 52. |
Lopez-Delgado, A, et al.; Effect on anal pressure of percutaneous posterior tibial nerve stimulation for faecal incontinence; Colorectal Dis; 2014; 533-537; 16. |
Lowette, K, et al.; Role of corticosterone in the murine enteric nervous system during fasting: Am J Physiol Gastrointest Liver Physiol; 2014; G905-913; 307. |
Lyon, TD, et al.; Pudendal but not tibial nerve stimulation inhibits bladder contractions induced by stimulation of pontine micturition center in cats; Am J Physiol Regul Integr Comp Physiol; 2016; R366-374; 310. |
M. Matsushita et al.; Primary somatosensory evoked magnetic fields elicited by sacralsurface electrical stimulation; Neuroscience Letters; 2008; 77?80; 431. |
Madersbacher, H, et al.; What are the causes and consequences of bladder overdistension? ICI-RS 2011; Neurourol Urodyn; 2012; 317-321; 31. |
Madersbacher, H; Overactive bladder—a practical approach to evaluation and management; J Med Liban; 2004; 220-226; 52;Abstract. |
Maeda, Y, et al.; Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement; Colorectal Dis; 2015; O74-87; 17. |
Maher, CF, et al.; Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis; J Urol; 2001; 884-886; 165. |
Maher, RM, et al.; A novel externally applied neuromuscular stimulator for the treatment of stress urinary incontinence in women—a pilot study; Neuromodulation; 2013; 590-594; discussion 594; 16. |
Majerus, SJ, et al.; Low-power wireless micromanometer system for acute and chronic bladder-pressure monitoring; IEEE Trans Biomed Eng; 2011; 763-767; 58. |
Abdel Raheem, A, et al.; Voiding dysfunction in women: How to manage it correctly; Arab J Urol; 2013; 319-330; 11. |
Abraham, N, et al.; Urgency after a sling: review of the management; Curr Urol Rep; 2014; 400; 15. |
Abrams, P, et al.; The role of neuromodulation in the management of urinary urge incontinence; BJU Int; 2003; 355-359; 91. |
Abrams, P; The role of neuromodulation in the management of urinary urge incontinence; BJU Int; 2004; 1116; 93. |
Allahdin, S, et al.; An overview of treatment of overactive bladder syndrome in women; J Obstet Gynaecol; 2012; 217-221; 32. |
Alo, KM, et al.; Sacral nerve root stimulation for the treatment of urge incontinence and detrusor dysfunction utilizing a cephalocaudal intraspinal method of lead insertion: a case report; Neuromodulation; 2001; 53-58; 4. |
Alo, KM, et al.; Selective Nerve Root Stimulation (SNRS) for the Treatment of Intractable Pelvic Pain and Motor Dysfunction: A Case Report; Neuromodulation; 2001; 19-23; 4. |
Al-Shaiji, TF, et al.; Pelvic electrical neuromodulation for the treatment of overactive bladder symptoms; Adv Urol; 2011; 757454; 2011. |
Al-Zahrani, AA, et al.; Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center; J Urol; 2011; 981-986; 185. |
Amarenco, G, et al.; Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder; J Urol; 2003; 2210-2215; 169. |
Amend, B, et al.; [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A]; Urologe A; 2010; 245-252; 49. |
Amend, B, et al.; Prolonged percutaneous SNM testing does not cause infection-related explanation; BJU Int; 2013; 185-491; 111. |
Amoroso, L, et al.; Sacral-neuromodulation CT-guided; Radiol Med; 2005; 421-429; 109;Abstract. |
Amundsen, CL, et al.; Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?; Urology; 2005; 746-750; 66. |
Amundsen, CL, et al.; Sacral neuromodulation in an older, urge-incontinent population; Am J Obstet Gynecol; 2002; 1462-1465; discussion 1465; 187. |
Amundsen, Cl, et al.; The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial; Contemp Clin Trials; 2014; 272-283; 37. |
Anger, JT, et al.; The effect of sacral neuromodulation on anticholinergic use and expenditures in a privately insured population; Neuromodulation; 2014; 72-74; discussion 74; 17. |
Antolak, SJ, Jr., et al.; Therapeutic pudendal nerve blocks using corticosteroids cure pelvic pain after failure of sacral neuromodulation; Pain Med; 2009; 186-189; 10. |
Antolak, SJ, Jr.; Re: Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study; J Urol; 2003; 1956; author reply 1956; 170. |
Anton, PA; Stress and mind-body impact on the course of inflammatory bowel diseases; Semin Gastrointest Dis; 1999; 14-19; 10;Abstract. |
Aoun, F, et al.; [Lower urinary tract dysfunction following radical hysterectomy]; Prog Urol; 2015; 1184-1190; 25; Abstract. |
Apostolidis, A; Neuromodulation for intractable OAB; Neurourol Urodyn; 2011; 766-770; 30. |
Arlandis, S, et al.; Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder; Value Health; 2011; 219-228; 14. |
Arnold, J, et al.; Overactive bladder syndrome—management and treatment options; Aust Fam Physician; 2012; 878-883; 41. |
Arrabal-Polo, MA, et al.; Clinical efficacy in the treatment of overactive bladder refractory to anticholinergics by posterior tibial nerve stimulation; Korean J Urol; 2012; 483-486; 53. |
Atiemo, HO, et al.; Evaluation and management of refractory overactive bladder; Curr Urol Rep; 2006; 370-375; 7. |
Atnip, S, et al.; A unique approach to severe constipation; Urol Nurs; 2011; 348-350; 31. |
Badawi, JK, et al.; [Current diagnostics and therapy of the overactive bladder and urge incontinence]; Dtsch Med Wochenschr; 2005; 1503-1506; 130;Abstract. |
Badlani, GH; Update on lower urinary tract symptoms; ScientificWorldJournal; 2009; 499-500; 9. |
Baeten, CG; Status of sacral neuromodulation for refractory constipation; Colorectal Dis; 2011; 19-22; 13 Suppl 2. |
Balchandra, P, et al.; Women's perspective: intra-detrusor botox versus sacral neuromodulation for overactive plodder symptoms after unsuccessful anticholinergic treatment; Int Urogynecol J; 2014; 1059-1064; 25. |
Banakhar, M, et al.; Effect of sacral neuromodulation on female sexual function and quality of life: Are they correlated?; Can Urol Assoc J; 2014; E762-767; 8. |
Banakhar, M, et al.; Sacral Neuromodulation for Genitourinary Problems; Prog Neurol Surg; 2015; 192-199; 29; Abstract. |
Banakhar, MA, et al.; Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem; Ther Adv Urol; 2012; 179-185; 4. |
Bannowsky, A, et al.; [Sacral neuromodulation in treatment of functional disorders of the lower urinary tract. An overview of basic principles, indications, outcomes]; Urologe A; 2003; 1357-1365; 42. |
Bannowsky, A, et al.; Urodynamic changes and response rates in patients treated with permanent electrodes compared to conventional wire electrodes in the peripheral nerve evaluation test; World J Urol; 2008; 623-626; 26. |
Banyo, T; [The role of electrical neuromodulation in the therapy of chronic lower urinary tract dysfunction]; Ideggyogy Sz; 2003; 68-71; 56;Abstract. |
Barnett, G, et al.; Re: Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation: M. Martinson, S. MacDiarmid and E. Black J Urol 2013; 189: 210-216; J Urol; 2013; 1444-1445; 190. |
Baron, M, et al.; [Does urinary sacral neuromodulation improve bowel symptoms other than fecal incontinence: A systematic review]; Prog Urol; 2016;Abstract. |
Barroso U Jr et al.; Electrical nerve stimulation for overactive bladder in children;Nature Reviews Urology; 2011; 402-407; 8. |
Barroso, U, Jr., et al.; Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children; J Urol; 2013; 673-677; 190. |
Bartley, J, et al.; Neuromodulation for overactive bladder; Nat Rev Urol; 2013; 513-521; 10. |
Bartley, JM, et al.; Understanding clinic options for overactive bladder; Curr Urol Rep; 2013; 541-548; 14. |
Batla, A, et al.; Lower urinary tract dysfunction in patients with functional movement disorders; J Neurol Sci; 2016; 192-194; 361. |
Bayrak, O, et al.; Botulinum toxin injections for treating neurogenic detrusor overactivity; Turk J Urol; 2015; 221-227; 11. |
Bemelmans, BL, et al.; Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction; Eur Urol; 1999; 81-91; 36;Abstract. |
Beneton, C, et al.; [The medical treatment of overactive bladder]; Neurochirurgie; 2003; 369-376; 49;Abstract. |
Benson, JT, et al.; Pudendal neuralgia, a severe pain syndrome; Am J Obstet Gynecol; 2005; 1663-1668; 192. |
Benson, JT; New therapeutic options for urge incontinence; Curr Womens Health Rep; 2001; 61-66; 1;Abstract. |
Benson-Cooper, S, et al.; Introduction of sacral neuromodulation for the treatment of faecal incontinence; N Z Med J; 2013; 47-53; 126. |
Number | Date | Country | |
---|---|---|---|
20170312512 A1 | Nov 2017 | US |
Number | Date | Country | |
---|---|---|---|
61828981 | May 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14893946 | US | |
Child | 15650228 | US |